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ABSTRACT 
 
Colorectal cancer (CRC) is the most frequent malignancy of the gastrointestinal tract and 
therefore reflects a global health issue. Despite improved detection and treatment options the 
high mortality and morbidity rates of this disease emphasize the urgent need to unravel 
underlying mechanisms.  
Over the last decade extensive investigation allowed the identification of numerous key players 
involved in the onset and progression of CRC. Importantly, epigenetics is an emerging research 
area which has already contributed significantly to understanding this disease. Generally, 
epigenetic mechanisms can affect the gene expression profile without altering the underlying 
DNA sequences. One mediator involved in these processes is the Ubiquitin-Specific Protease 
22 (USP22) which is able to deubiquitinate the core histones H2A and H2B as well as other 
target proteins. Interestingly, the overexpression of USP22 in CRC patients was revealed by 
several studies and it was identified as a member of the so-called 11-gene “death-from-cancer” 
signature. This signature was correlated with poor prognosis and distant metastasis. However, 
the physiological function of USP22 in organ maintenance as well as its role in intestinal 
tumorigenesis remain to be elucidated. 
In the current project we investigated the effect of a global reduction and intestinal deletion of 
Usp22 in vivo. By generating a global Usp22 hypomorphic mouse line we could overcome the 
embryonic lethal effect of a complete loss of this gene. Using a lacZ reporter gene expressed 
under the control of the endogenous Usp22 locus, we detected ubiquitous Usp22 expression 
during embryonic development. Accordingly, a global reduction of Usp22 expression resulted 
in systemic effects in adult mice, i.e. reduced body size and weight. Moreover, while the gross 
organ morphology was only marginally affected in these animals, cell differentiation and lineage 
specification were influenced in the brain and, as we have observed earlier, the small intestine. 
 xxi 
 
The involvement of Usp22 in developmental and differentiation processes was confirmed in 
mouse embryonic fibroblasts by microarray-based gene expression analysis. 
Moreover, the function of Usp22 in tumorigenesis was explored in animals possessing an 
intestinal Usp22 loss and a truncation mutation in the tumor suppressor Adenomatous 
Polyposis Coli (APC). Surprisingly, Usp22 deletion combined with an APC mutation resulted in 
decreased survival rates, increased intestinal inflammation and tumor burden and importantly, 
led to the formation of invasive carcinomas with a mucinous phenotype. Our findings, that not 
only overexpression, as stated in the literature, but also downregulated USP22 expression can 
increase intestinal tumor burden were supported by in vitro and in silico analyses which 
revealed highly heterogeneous USP22 expression among CRC patients. Using global 
expression analyses we detected the involvement of USP22 in several cancer-related 
processes and identified the heat shock protein HSP90AB1 as an important USP22 target. 
Notably, we discovered that USP22 directly binds to the HSP90AB1 protein and prevents its 
proteasomal degradation. In addition, USP22 knockdown led to reduced HSP90AB1 
expression levels. As a consequence USP22 knockdown cells were more sensitive towards 
elevated temperatures. Intriguingly, we were able to induce synthetic lethality in CRC cells with 
low USP22 levels by treating them with an HSP90 inhibitor or the Bromo- and Extra-Terminal 
(BET) domain inhibitor JQ1. In summary, in this study we significantly contributed to the current 
knowledge about USP22 by demonstrating its relevance in organ maintenance and intestinal 
tumor formation in vivo as well as by describing how CRC cells with low USP22 levels can be 
therapeutically targeted in vitro.
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1. INTRODUCTION 
 
1.1 Epidemiology of colorectal cancer (CRC) 
Cancer is a disease characterized by abnormal cell growth and has emerged as a major public 
health problem worldwide. Generally, incidence and mortality rates have been reduced due to 
preventive vaccines, early diagnosis and improved treatments for some cancers (Tiwari and 
Roy, 2012, 2012). However, most recent studies indicate that in some countries cancer has 
replaced cardiovascular diseases as the leading cause of death (Townsend et al., 2015). 
Preventive and therapeutic measures generate an extensive economic load (Burns et al., 2016) 
and, more importantly, cancer diagnosis means a significant burden for affected individuals 
and their families. This emphasizes the urgent need to further improve our understanding 
regarding the progression, suitable detection methods and treatment options for this group of 
diseases.  
One example of successful research towards this goal is colorectal cancer (CRC) which is 
characterized by oncogenic growth inside the colon and rectum. Due to early diagnosis by 
colonoscopy and subsequent removal of pre-cancerous adenomas the mortality rate of CRC 
has decreased over the last decades (Bosetti et al., 2011; Vleugels et al., 2016). However, 
colorectal cancer remains a global health issue, being the third most commonly occurring 
cancer and the fourth most common cause of cancer-related deaths worldwide. In addition, the 
incidence is rising in developing countries (Favoriti et al., 2016). In a study from 2005, the 
development of incidence and mortality rates of CRC was compared among several countries 
over the last decades. While the mortality rate stagnated or slightly decreased in most 
countries, it has at least doubled in Japan, Hungary and Italy between 1955 and 2000. 
Concurrently, the authors described that the 5-year survival rates have improved since the mid 
70’s. The average 5-year survival rose from 30-40% to 45-50% in rectal cancer and from 
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approximately 40% to 50% in colon cancer (Boyle and Ferlay, 2005). The variation between 
CRC frequencies among countries can partially be explained by variations in the exposure to 
risk factors of this disease in different regions. 
 
1.2 Risk factors associated with CRC 
By studying dietary and lifestyle habits, family history, molecular backgrounds, comorbidities 
and further CRC patient details, several CRC-related risk factors were defined. For instance, 
the demographic change observed in our society reflects an established CRC risk factor since 
it has been be shown that increasing age is correlated with the development of malignancies 
(Hoyert and Xu, 2012; White et al., 2014). In fact, 50% of all diagnosed malignancies and 70% 
of cancer-related deaths can be observed in patients ≥65 years of age (Mazzola et al., 2012). 
However, there are several further aspects, preventable and unpreventable, associated with 
increased colorectal cancer risk. 
 
1.2.1 Diet and lifestyle 
According to the American Institute for Cancer Research, approximately 47% of colorectal 
cancer cases could have been prevented if individuals would adapt their diet, activity and 
weight management (Baena and Salinas, 2015; Bailie et al., 2016; Ferlay, 2016; Godos et al., 
2016). There are numerous reports on how this disease can be either promoted or prevented 
by the consumption of certain dietary factors; however, many study outcomes were 
inconclusive (Baena and Salinas, 2015). For instance, individuals consuming high rates of 
processed or red meat and alcohol have an increased colorectal cancer risk (Chan et al., 2011; 
Wang et al., 2015). Moreover, victuals containing high amounts of sugar were suggested to 
have negative effects (Galeone et al., 2012). In contrast, a fiber-rich diet, consumption of fruits, 
fish and milk were shown to confer a protective effect (Aune et al., 2012; Ben et al., 2014; Block 
et al., 1992; Yu et al., 2014). Furthermore, the composition of the bacterial community within 
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the intestine can be altered by dietary changes (David et al., 2014; Turnbaugh et al., 2009). 
Notably, dysbiosis, i.e. dysregulation of the gut microbiota is a phenomenon frequently 
observed in colorectal cancer patients (Wu et al., 2013).  
Importantly, regular physical activity decreased CRC risk by 24% while obesity increased it by 
19% (Baena and Salinas, 2015). Obesity is a risk factor gaining significance due to its 
increasing frequency, especially, since it is accompanied by numerous comorbidities. In fact, 
the incidence of obesity has increased by 28% in adults and 47% in children since 1980 (Ng 
et al., 2014). Moreover, it was shown that obese individuals frequently develop type 2 diabetes 
(Kearns et al., 2014) which in turn is also associated with CRC as demonstrated in a recent 
meta-analysis (Guraya, 2015). Consistently, treating diabetic patients with the anti-diabetic 
drug Metformin reduced colorectal cancer risk (Zhang et al., 2011). These findings reveal how 
not only our diet and its effect on the microbiota can directly modulate CRC risk but also 
morbidities possibly resulting from inadequate nutrition or deficiency in physical activity.  
 
1.2.2 Inflammatory bowel diseases (IBDs) 
Currently, approximately 0.4% of Europeans and North-Americans have a high risk of 
developing CRC due to inflammatory bowel diseases (IBDs) and incidence rates are expected 
to rise (Molodecky et al., 2012). Generally, these conditions are characterized by a chronic 
inflammation of the gastrointestinal tract mediated by genetic susceptibility, environmental 
factors and a deregulated immune response (Mesquita et al., 2008; Renz et al., 2011; Xavier 
and Podolsky, 2007). Two well-described IBD types are Crohn’s disease (CD) and ulcerative 
colitis (UC). However, besides these two major forms, there are further, rare disorders such as 
intestinal tuberculosis (ITB) and Behçet’s disease (BD) (Lee and Lee, 2016). The so-called 
hygiene hypothesis was proposed to be one of the explanations for the increasing prevalence 
of IBDs. The rationale of this assumption is that a low exposure towards microbes during early 
life leads to an augmented sensitivity of the immune system towards microorganisms and 
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therefore IBD (Saidel-Odes and Odes, 2014). Another hypothesis proposes the relevance of 
diet for the development of IBDs for instance due to a low fiber uptake (Shen and Wong, 2016). 
Moreover, in 2015 Liu and co-workers identified 38 loci which are associated with the 
susceptibility towards IBDs (Liu et al., 2015b). Symptoms of inflammatory bowel diseases can 
include (bloody) diarrhea, abdominal pain, passage of mucus and/or pus (Baumgart and 
Sandborn, 2007) and are often accompanied by psychological symptoms as anxiety or 
depression (Marrie et al., 2016). Upon indication, IBDs can be diagnosed via blood- and stool-
based tests, physical examination and imaging, as well as biopsy and endoscopy (Bernstein 
et al., 2010). Generally, IBDs have an early disease onset, i.e. 20-25% of cases are detected 
during childhood. Interestingly, pediatric IBDs were described to have particularly severe 
symptoms (Guariso et al., 2010; Ruemmele, 2010). During the course of the disease, patients 
frequently develop comorbidities such as anemia (Oldenburg et al., 2001), ocular 
manifestations (Felekis et al., 2009) as well as osteopenia and osteoporosis resulting in 
decreased bone mineral density (BMD) and therefore a highly increased fracture risk (Ali et al., 
2009; Bernstein et al., 2000). In a meta-analysis it was determined that the overall CRC 
prevalence in IBD patients is 1.7%. Accordingly, since disease duration correlates with the 
probability of CRC formation, for instance, the risk after >20 years of IBD was 5% (Lutgens, 
Maurice W M D et al., 2013). To reduce cancer risk, patients can be treated with anti-
inflammatory or immunosuppressive drugs and antibiotics. In addition, surgery may be required 
to remove damaged intestinal compartments (in CD patients) or even the entire colon and 
rectum (in UC patients), a proctocolectomy, resulting in the attachment of a pouch (Baumgart 
and Sandborn, 2007). 
 
1.2.3 Genetic susceptibility  
Nonetheless, not all CRCs can be attributed to a preexisting medical condition. In fact, it was 
reported that up to 30% of CRC cases develop due to genetic susceptibility. Approximately 5% 
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of patients are affected by an inherited mutation promoting tumorigenesis (Patel and Ahnen, 
2012). In the era of next generation sequencing (NGS) it would therefore be desirable to detect 
these genetic predispositions in order to identify individuals with a high CRC-risk to start 
treatment in time. It was already demonstrated that surveillance of individuals at high risk can 
decrease mortality rates (Jong et al., 2006). 
A well-known example for a genetic alteration is familial adenomatous polyposis (FAP), an 
autosomal dominant disorder, affecting 1-2:10,000 newborns. This condition is characterized 
by a heterozygous mutation of the tumor suppressor Adenomatous Polyposis Coli (APC) 
resulting in a truncated and therefore non-functional protein (Rozen et al., 2001; Rozen and 
Macrae, 2006). Under normal conditions, APC is a negative regulator of the Wnt signaling 
pathway, where it is a member of the destruction complex (Figure 1A). This complex consisting 
of APC, the kinase GSK-3β and AXIN phosphorylates β‐catenin to target it for ubiquitination 
and subsequent degradation. In the scenario of a non-functional APC protein or binding of a 
Wnt ligand to a Frizzled/LRP5/6 receptor, the destruction complex is destabilized (Figure 1B). 
Therefore, β‐catenin is no longer degraded and can translocate to the nucleus where it interacts 
with the transcription factors Lymphoid Enhancer Factor (LEF)/T-Cell Factor (TCF). By serving 
as a transcriptional coactivator, accumulated β‐catenin causes highly amplified cell proliferation 
rates (Giles et al., 2003; Reya and Clevers, 2005; Taipale and Beachy, 2001). As a 
consequence, hundreds to thousands of adenomas, including microadenomas, grow 
throughout the intestine of FAP patients (Eccles et al., 1997). In contrast, individuals affected 
by the attenuated form of FAP (AFAP) develop less than 100 tumors (Ibrahim et al., 2014). 
Notably, FAP is characterized by an early colorectal cancer onset, i.e. maximum 39 years in 
FAP and 55 years in AFAP (Novelli, 2015). 
Introduction 
6 
 
 
Figure 1: The canonical Wnt signaling pathway. (A) In the absence of a Wnt ligand, the 
destruction complex consisting of GSK-3β, AXIN and APC phosphorylates β-catenin. Thereby, 
β-catenin is targeted for ubiquitination and subsequent degradation by the proteasome. (B) 
Upon binding of a Wnt ligand to the Frizzled/LRP5/6 receptor, the destruction complex is 
destabilized. This destabilization is also observed if the tumor suppressor APC is non-
functional due to a truncation mutation. Consequently, β-catenin is no longer degraded and 
can accumulate and translocate to the nucleus. There it can interact with the transcription 
factors LEF/TCF to promote transcription of Wnt target genes. 
 
Another example for CRC in a familial context is the so-called Lynch syndrome which was 
described fifty years ago (Lynch, 1967) and accounts for approximately 3% of all CRC cases 
(Hampel et al., 2008). It is an autosomal dominant disease majorly caused by germline 
mutations in the mismatch repair genes MutL Homologue 1 (MLH1), MutS Homologue 2 
(MSH2) and 6 (MSH6) and Postmeiotic Segregation Increased 2 (PMS2) (Lynch et al., 2009).  
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It should be noted that Lynch syndrome is frequently referred to as hereditary non-polyposis 
colorectal cancer (HNPCC). However, to be diagnosed with Lynch syndrome one must 
possess mutations in mismatch repair (MMR) genes while HNPCC patients/families must fulfill 
Amsterdam criteria (AC) I or II. AC I reflects at least three CRC cases per family while AC II 
also takes the occurrence of extracolonic tumors into account, e.g. endometrial cancer (Novelli, 
2015; Vasen et al., 1999). In Lynch patients a relatively small number (<10) of polyps can be 
found, however, they frequently develop further malignancies such as brain, skin, ovarian and 
endometrial cancers (Novelli, 2015; Vasen et al., 1999). Further, but more rare examples for 
autosomal dominant conditions associated with an increased CRC risk are the Peutz-Jeghers 
syndrome (1:200,000) and Juvenile polyposis syndrome (1:100,000) (Shenoy, 2016).  
 
1.2.4 Genetic mutations 
Besides the presence of genetic predispositions, spontaneous mutations display a frequent 
phenomenon in the development and progression of colorectal cancer. In 1990 several genetic 
driver alterations were proposed by Eric Fearon and Bert Vogelstein to be involved in the 
adenoma to carcinoma sequence (Fearon and Vogelstein, 1990).  
The so-called Vogelgram revealed the significance of the Wnt/β-catenin pathway in the 
transition from normal epithelium to hyperproliferation and an early adenoma (Fearon and 
Vogelstein, 1990). In addition to the relevance of a functional APC protein in the case of FAP, 
APC mutations are the most frequent genetic alterations observed in sporadic colorectal cancer 
(Rozen et al., 2001; Rozen and Macrae, 2006). As mentioned before, the subsequent nuclear 
translocation of β-catenin results in increased cellular proliferation (Giles et al., 2003).  
According to the Vogelgram, the following transition from an early to intermediate and late 
adenoma is mediated by disturbed RAS signaling (Fearon and Vogelstein, 1990). There are 
three RAS (H, K and N) and three RAF (A, B and C) members. RAS is a small GTP-binding 
protein which is regulated by binding to GTP in exchange for GDP. When GTP is hydrolyzed, 
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RAS is no longer active. A RAS mutation at the position G12 prevents the activity of a GTPase 
to act on RAS-GTP to deactivate it and, therefore, it remains constitutively active, leading to 
sustained activation of RAF signaling (Chang et al., 2003; Hallberg et al., 1994). RAF members 
are responsible for phosphorylating and activating Mitogen-Activated Protein Kinase Kinases 
1 and 2 (MEK1/2) and Extracellular-Signal-Regulated Kinases 1 and 2 (ERK1/2) signal 
transduction to regulate among others MYC transcription. As a consequence, Mitogen-
Activated Protein Kinase (MAPK) signaling is induced in which serine/threonine kinases 
mediate signal transduction from the plasma membrane to the nucleus (Hallberg et al., 1994; 
Liebmann, 2001). Notably, RAS activating mutations or amplifications resulting in constitutively 
active RAS proteins occur frequently in CRC, i.e. approximately 40% for KRAS and 5% for 
NRAS (Fearon, 2011). Interestingly, RAS can activate Nuclear Factor Kappa B (NF-κB) 
signaling via its downstream factor RAC or PKB/AKT (Sulciner et al., 1996). NF-κB is a 
transcription factor exerting anti-apoptotic effects and promoting transformation (Mayo et al., 
1997). Moreover, NF-κB is associated with inflammatory processes, in general, as well as 
inflammation-induced gastrointestinal cancers (Merga et al., 2016). In addition to the 
stimulation of the MAPK and NF-κB pathways, RAS was shown to activate Phosphatidylinositol 
3-Kinase (PI3K) by directly interacting with the PI3K p110 catalytic subunit (Courtney et al., 
2010). Disturbed PI3K signaling was shown to be correlated with cell growth, metabolism and 
cancer progression (Engelman et al., 2006).  
The last transition in the Vogelgram, from late adenoma to carcinoma, is characterized by the 
loss of the tumor suppressor TP53. TP53 stabilization is regulated via ubiquitination by the E3 
ligase MDM2 resulting in its subsequent degradation. In turn, upon TP53 activation, it 
upregulates MDM2. Moreover, active TP53 induces mitochondrial (intrinsic) and death-
receptor-induced (extrinsic) apoptosis (Ryan et al., 2001). The corresponding gene, TP53, is 
mutated in approximately 50% of colorectal cancers and leads to a deregulation of the cell 
cycle and the prevention of apoptosis and therefore, tumor cell survival (Munteanu and 
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Mastalier, 2014). Though it was shown that only 6.6% of colorectal cancer lesions possess 
mutations in all three components, APC, KRAS and TP53 (Smith et al., 2002), the Vogelgram 
has largely contributed to our knowledge and was extended by numerous studies. For instance, 
in 2008 Issa suggested a new model in which tumor progression does not occur in a linear 
progress but rather in diverse distinct pathways. He divided them based on their pathological 
presentation, prognosis, localization of tumors and molecular markers (Issa, 2008). 
 
1.2.5 Epigenetic deregulation  
Epigenetic mechanisms represent an emerging research area with significant relevance in the 
field of tumorigenesis (Feinberg and Tycko, 2004). Generally, epigenetic mechanisms can 
affect gene expression without altering underlying DNA sequences, but rather by chromatin 
modifications. Eukaryotic chromatin is a highly compacted structure containing repeating 
structural subunits, the so-called nucleosomes. Each nucleosome is assembled of a histone 
octamer consisting of two copies of each histone (i.e. H2A, H2B, H3, and H4) wrapped around 
by 147 base pairs of DNA (Luger et al., 1997; Richmond and Davey, 2003). Each core histone 
possesses histone-fold domains and N-terminal histone-tails. While the fold domains serve for 
the interaction of the histones, the tails can be subjected to post-translational modifications 
(PTMs), potentially affecting gene expression. These modifications include for instance histone 
methylation (me), acetylation (ac), phosphorylation (P) and ubiquitination (ub). Histone PTMs 
can be carried out by enzymes called “writers”, recognized by “readers” and removed by 
“erasers” (Strahl and Allis, 2000; Torres and Fujimori, 2015). 
In 1983 Feinberg and Vogelstein described a global hypomethylation in human cancers 
(Feinberg and Vogelstein, 1983). Moreover, regions rich in CpG dinucleotides, namely the CpG 
islands, which are abundant in promoter regions, were found to be hypermethylated resulting 
in decreased transcriptional activity (Herman and Baylin, 2003). CpG hypermethylation 
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frequently affects and therefore represses tumor suppressor genes in various cancer types 
including CRC (Costello et al., 2000). 
A further relevant, yet poorly understood, epigenetic modification is the monoubiquitination of 
histone H2B at lysine 120 (H2Bub1). The process of H2B monoubiquitination can be initiated 
after the recognition of acetylated histone marks and/or transcription factors by BRD4 (Figure 
2) (Itzen et al., 2014). As a consequence, BRD4, a central member of the Bromo- and Extra-
Terminal (BET) domain protein family, recruits the Positive Transcriptional Elongation Factor b 
(P-TEFb) complex. P-TEFb consists of the Cyclin-Dependent Kinase 9 (CDK9) and Cyclin T1. 
P-TEF-b complex formation was shown to be facilitated by the Heat Shock Protein 90 (HSP90) 
(O'Keeffe et al., 2000). Subsequently, CDK9 phosphorylates the RNA Polymerase II (RNA Pol 
II) at serine 2 of its carboxyl-terminal heptapeptide repeat domain, thereby releasing promoter 
proximal pausing of several genes “poised” or “paused”  by RNA Pol II (Nechaev and Adelman, 
2011).  
The process of promoter proximal pausing was studied in detail in Drosophila melanogaster 
where it was demonstrated that in 15% of tissue-specific genes RNA Pol II is bound 
downstream of the promoter. Moreover, nearly half of the genes in human embryonic stem 
cells were occupied by an initiating form of RNA Pol II (Guenther et al., 2007). In an inducible 
manner, this paused state can be released to proceed transcription. As reviewed by Boettiger 
and colleagues, it was postulated that RNA Pol II pausing allows for rapid induction upon a 
stimulus and was referred to as a “loaded gun”. The possibility to regulate this mechanism in a 
tissue-specific manner implies its relevance during developmental processes (Boettiger et al., 
2011). Upon phosphorylation RNA Pol II interacts with WW Domain-Containing Adaptor with 
Coiled-Coil (WAC) protein which recruits the RNF20/RNF40 heterodimer (Zhang and Yu, 
2011). By exerting their E3 ligase activity the RING finger proteins RNF20/RNF40 
monoubiquitinate H2B at lysine 120 and thereby promote transcription (Zhu et al., 2005). It was 
proposed that monoubiquitinated H2B facilitates transcript elongation by interacting with the 
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Facilitates Chromatin Transcription (FACT) complex which promotes RNA Pol II activity 
(Orphanides et al., 1998; Pavri et al., 2006). Notably, the ubiquitin hydrolase Ubiquitin-Specific 
Protease 22 (USP22) is able to deubiquitinate H2B by functioning as a deubiquitinating enzyme 
(DUB) within the SAGA complex (Zhang et al., 2008b) as explained in detail in section 1.13.  
 
Figure 2: The interplay of H2Bub1 and epigenetic regulators. HSP90 facilitates the 
assembly of the P-TEFb complex consisting of CDK9 and Cyclin T1. Upon recognition of 
acetylated marks, BRD4 recruits the P-TEFb complex, enabling CDK9 to phosphorylate RNA 
Pol II at serine 2, thereby releasing promoter proximal pausing. RNA Pol II interacts with WAC 
which binds to the RNF20/RNF40 heterodimer monoubiquitinating the histone H2B. This 
ubiquitin molecule can be removed by the deubiquitinating enzyme USP22 which is part of the 
DUB module within the SAGA complex.    
 
Over the last years it has been demonstrated that the levels of several components involved 
in the monoubiquitination of H2B are perturbed in cancer. For instance, increased abundance 
of BRD4 (Jung et al., 2015) and CDK9 (Morales and Giordano, 2016) have been positively 
correlated with tumorigenesis. Interestingly, our group previously showed that H2Bub1 levels 
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are inversely correlated with malignancy during mammary tumor progression (Bedi et al., 2015; 
Prenzel et al., 2011) therefore potentially reflecting a tumor suppressive mark. In a recent 
study, 1,800 CRC samples were assessed for their H2Bub1 levels in a tissue microarray-based 
approach. Indeed, decreased H2Bub1 levels correlated with advanced tumor grade and stage 
(Qi et al., 2004). In addition, reduced Rnf20 expression in mice, and therefore decreased 
H2Bub1 levels, were associated with UC and CRC (Tarcic et al., 2016). Concerning the E3 
ligases RNF20/RNF40, further implications in cancer were described. For instance, RNF20 
appears to be required for mixed-lineage leukemia (MLL)-rearranged leukemia (Wang et al., 
2013), while deletion of both RNF20 and RNF40 suppresses breast cancer progression in vivo 
(Duan et al., 2016). Notably, USP22 was reported to be a member of the 11-gene “death-from-
cancer” gene expression signature which is strongly associated with distant metastasis, poor 
survival and high recurrence rates of human malignancies (Glinsky, 2005; Glinsky et al., 2005). 
The correlation of the overexpression of USP22 in several cancer types has been recently 
reviewed (Melo-Cardenas et al., 2016) and is described in more detail in section 1.13. In 
summary, besides well-known aspects such as lifestyle, IBDs and genetic mutations, 
epigenetic deregulations display substantial CRC risk factors. 
 
1.3 The composition of the intestinal system 
To understand how these risk factors can contribute to the transition of healthy intestinal 
epithelium to cancer lesions, it is of great importance to comprehend the intestinal anatomy 
and its cellular composition. During the last decade numerous studies have revealed the 
significance of the intestinal system to the human body. Its probably most well-known and best 
described functions are the digestion of food and the absorption of nutrients. After the uptake 
of food it is processed from the oral cavity and the pharynx into the upper gastrointestinal tract 
(GIT) consisting of esophagus and stomach (Figure 3A). From there the food reaches the lower 
GIT which is composed of the small and large intestine and extends to the anus (Ellis, 2006). 
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Figure 3: The human gastrointestinal tract and composition of the gastrointestinal wall. 
(A) After uptake, food migrates through the GIT consisting of the oral cavity, esophagus and 
the stomach. Afterwards, the food is further digested in the small intestine (duodenum, jejunum, 
ileum) and transferred to the large intestine via the ileocecal valve. The large intestine consists 
of the cecum, appendix, colon (ascending, transverse, descending, sigmoid) and the rectum. 
Finally, digestion is completed by defecation via the anus. (B) The intestinal lumen is 
surrounded by epithelial cells with the subjacent lamina propria mucosae. Below, the smooth 
muscle layer lamina muscularis mucosae and the tela submucosa can be found. Underlying 
the tunica muscularis, tela subserosa, and the outermost connective tissue layer, tunica 
serosa, are present. 
 
Generally, after receiving food from the stomach, the main function of the small intestine (SI) 
is to digest the food and absorb substances such as lipids, carbohydrates and vitamins into the 
bloodstream or lymphatic system. The SI is structurally subdivided into the duodenum which is 
continuous with the stomach, the jejunum, and the ileum. The uppermost 25 cm of the SI 
represent the duodenum which performs the major part of digestion with the help of chyme, 
digestive enzymes and bile contributed by stomach, pancreas and gall bladder, respectively. 
In the jejunum mainly fatty acids, sugars and amino acids are absorbed while in the ileum 
mainly absorption of bile acids, vitamins and further nutrients takes place. To increase the 
surface area, there are circular folds within the intestinal system. The large intestine is divided 
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into further structural subunits, namely the cecum, colon, rectum and the anal canal. The 
cecum is connected to the small intestine and is separated from the ileum by the ileocecal 
valve. The appendix is a blind, tube-formed structure attached to the cecum and plays a crucial 
role in mucosal immunity due to its high density of lymphocytes (Berry, 1900). The following 
structure is the colon which is divided into the ascending, transverse, descending and sigmoid 
colon. The main function of the colon is to absorb water from the food residues. The rectum is 
the final straight segment which is followed by the anal canal and the anus where the process 
of digestion is completed by defecation (Despopoulos and Silbernagl, 2003; Ellis, 2006; 
Rhoades and Tanner, 2003). Typically, the intestinal tissue possesses finger-like projections 
to further increase its surface. In the small intestine these evaginations are designated as villi 
with crypts at their bottom while the colon contains only invaginations (crypts). Generally, the 
lumen is surrounded by a monolayer of epithelial cells with an underlying layer of collagenous 
connective tissue, the lamina propria mucosae (Figure 3B). Below the smooth muscle layer 
lamina muscularis mucosae is present as well as the tela submucosa which contains nerves, 
blood and lymphatic vessels. The tunica muscularis is composed of longitudinal and circular 
muscle layers responsible for peristaltic movements of the intestine. Underlying, a layer of 
connective tissue, tela subserosa, and the outermost connective tissue layer, tunica serosa, 
can be found (Gartner and Hiatt, 2014; Young and Wheater, 2007).  
Interestingly, the intestinal epithelium is characterized by a rapid cell turnover with a renewal 
every 4-5 days and is therefore the most frequently self-renewing tissue in adults (van der Flier, 
Laurens G and Clevers, 2009). It consists of a monolayer of cells interconnected by tight 
junctions. Importantly, these tight junctions regulate the epithelial barrier function, i.e. 
permeability for solutes, ions, cells, etc. through intercellular space (Ichikawa-Tomikawa et al., 
2011). Epithelial cells are subdivided into four differentiated cell types (Figure 4). The majority 
of cells are enterocytes which are responsible for absorption. Goblet cells secrete mucins which 
are required to form a mucus layer in the intestine which confers a protective role to the organ.  
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Figure 4: Structure and cell types of the intestinal epithelium. The small intestine is 
subdivided into finger-like projections, villi, and crypts which are found at the bottom of villi. A 
monolayer of epithelial cells faces the luminal area of the intestinal tube. The epithelium mainly 
consists of enterocytes while Goblet and enteroendocrine cells are sporadically present. At the 
bottom of the crypts, Paneth and stem cells are located. In contrast, the colon consists only of 
crypts and no Paneth cells are present.  
 
Enteroendocrine cells secrete hormones which are amongst other functions relevant for 
digestion. In contrast to the other cell types, Paneth cells are exclusively present at the bottom 
of the crypts and secrete antimicrobial substances in addition to the fact that they are 
exclusively found in the small intestine but not the colon (Johansson et al., 2011; Roda et al., 
2010). Most importantly, the crypt bottoms harbor stem cells which give rise to the so-called 
transit-amplifying cells which migrate upwards into the villi to differentiate into the previously 
mentioned cell types (Barker et al., 2007; Barker et al., 2012; van der Flier, Laurens G et al., 
2009). The differentiation process is strongly regulated by active Wnt and Notch signaling 
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pathways which are also responsible for keeping the crypt compartment in an undifferentiated 
and proliferative state. Consistent with our knowledge about tumorigenesis, Barker and co-
workers demonstrated that loss of APC in intestinal stem cells causes uncontrolled proliferation 
and therefore development of adenomas (Barker et al., 2009). Interestingly, epigenetic 
mechanisms appear to be crucial for the maintenance of the intestinal epithelium. For instance, 
the loss of the maintenance DNA methyltransferase 1 (DNMT1) resulted in an almost twofold 
expansion of the crypt compartment in mice. This phenomenon was accompanied by increased 
expression of the stem cell markers Lgr5 and Olfm4 (Sheaffer et al., 2014). The fact that 
enhancer regions of these genes were strongly demethylated suggested a role of epigenetic 
regulation in differentiation and crypt maintenance in vivo (Lister et al., 2009).  
 
1.4 The intestinal microbiota 
To understand the complexity of physiological and pathological processes in the colon, it is 
relevant to know that the intestinal system should not be seen as an empty tube through which 
food is processed and in which tumors can develop. In fact, it displays a highly complex 
ecosystem with its own microenvironment, immune response and if malfunctioning, it can affect 
the entire body. In the process of digestion our body relies on numerous microorganisms, the 
so-called microbiota. Not only does the microbiota mainly comprise bacteria, but also fungi, 
viruses and protozoans can be found (Savage, 1977). One gram of dry ileal contents contains 
approximately 108 bacteria while the colon contains up to 1012 bacteria per gram (Smith, 1977). 
Notably, each human being possesses at least 160 species while in the entire experimental 
cohort analyzed by Qin and co-workers more than 1,000 different species were found (Qin et 
al., 2010). 
The most abundant phyla in the intestines gut are Firmicutes and Bacteriodetes (Human 
Microbiome Project Consortium, 2012), however, the composition of the gut microbiota is highly 
variable. For instance, the microbiota can vary among human populations, across age 
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(Yatsunenko et al., 2012), after antibiotic treatment (Panda et al., 2014) or due to dietary factors 
(David et al., 2014; Turnbaugh et al., 2009). As explained in detail in section 1.5, the microbiota 
can be seen as a component of the natural defense barrier of the intestine, however, at the 
same time it represents a potential danger in the case of dysbiosis. In dysbiosis, the microbial 
homeostasis is no longer maintained resulting in an increase of pathogenic and a decrease in 
beneficial microorganisms (Comito et al., 2014) and was described in colorectal cancer (Wu et 
al., 2013) and IBD patients. For instance, in IBD a high frequency of Bacteroides sp. was found 
(Rehman et al., 2010; Swidsinski et al., 2002) which produce sulfatases degrading the 
protective mucin layer resulting in impaired barrier function of the epithelium (Lucke et al., 
2006). Interestingly, the presence of microorganisms is indispensable for the development of 
factors of the immune response and even the gut morphology (Round and Mazmanian, 2009; 
Zeissig and Blumberg, 2013). 
 
1.5 The intestinal immune defense and ulcerative colitis 
In addition to the intestinal microbiota, our intestinal system is constantly confronted with 
potentially pathogenic food- and water-born agents. Hence, it must possess multiple defensive 
mechanisms which can involve physical, chemical, cellular or signaling processes. Inside the 
intestinal lumen the microbially-colonized mucus layer (Figure 5) protects the underlying 
epithelium in a dual way. First, the presence of microorganisms protects its host from bacterial 
overgrowth and infection with enteropathogenic bacteria via competition for nutrients and 
space (Frick and Autenrieth, 2013). Most of these bacteria possess a beneficial role in the 
organ function, for instance by their metabolic contributions (Hooper et al., 2002) but also by 
producing anti-microbial compounds in the presence of pathogens (Frick and Autenrieth, 
2013). Second, also the mucus layer prevents bacterial overgrowth and protects the epithelium 
from inflammation at the same time  (Petersson et al., 2011). Notably, mice deficient in Muc2, 
a main component for mucin formation, were prone to the development of colitis (van der Sluis 
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et al., 2006). A physical defense component is represented by the monolayer of intestinal 
epithelial cells (IECs) including tight junctions and microvilli to increase the surface area.  
 
Figure 5: The protective structures of the intestinal system. The mucus layer represents 
the first defensive component facing the intestinal lumen. Apart from its protective and lubricant 
function, it also harbors numerous microorganisms protecting the host from bacterial 
overgrowth. The epithelial monolayer represents a physical barrier which contains microvilli to 
increase surface area and tight junctions to regulate permeability. Below, free immune cells 
and mucosa-associated lymphoid tissues (MALTs) are responsible for the host’s immune 
response. 
 
As mentioned before, tight junctions regulate the paracellular barrier function via several 
transmembrane proteins (Ichikawa-Tomikawa et al., 2011). Another crucial feature of this cell 
layer is the presence of granule-containing Paneth cells which secrete anti-microbial 
substances such as defensins (Clevers and Bevins, 2013). Importantly, a certain degree of 
permeability is maintained in order to transport nutrients and fluids across this barrier. Below 
the physical barrier, mucosal immunity is regulated by free lymphocytes, dendritic cells, Natural 
killer T cells and macrophages which are in close proximity to IECs. Similar to the microbiota, 
Natural killer T cells can play a beneficial role by protecting the host from infections, however, 
deregulated activation can contribute to the pathogenesis of IBDs (Zeissig et al., 2007). 
Moreover, mucosal structures harbor mucosa-associated lymphoid tissues (MALTs) which in 
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the case of the intestine are known as gut-associated lymphoid tissue (GALT) such as Peyer’s 
patches (Mora and Andrian, 2008). Interestingly, in 1900 the significance of the appendix in 
our immune defense was recognized since lymphoid tissue is highly concentrated in this 
structure (Berry, 1900). In these lymphocyte accumulations, B cells can differentiate into 
Immunoglobulin A (IgA)-secreting cells (Mora and Andrian, 2008), an antibody of the innate 
immune system interfering with the invasion of bacteria into the IECs (Canny and McCormick, 
2008). In fact, IgA is the most abundant immunoglobulin isotype in the human body and 
approximately 80% of IgA-secreting cells are localized in the intestinal mucosa (Mora and 
Andrian, 2008). Moreover, a subset of immune cells is able to promote expression of pro-
inflammatory cytokines such as interleukin 6 (IL-6) and IL-8 but also of anti-inflammatory 
factors, e.g. IL-10 (Sommer and Backhed, 2013). As reviewed by Klampfer, cytokines and 
chemokines promote the proliferation and survival of tumor cells (Klampfer, 2011). 
In inflammatory bowel disease the intestinal barrier function was shown to be perturbed (Arslan 
et al., 2001; Hollander et al., 1986). Intestinal permeability can be affected by several factors 
such as misbalanced abundance of tight junction proteins (Barmeyer et al., 2015), damaged 
epithelium (Clayburgh et al., 2004) and increased abundance of inflammatory cytokines 
(Neurath, 2014). As recently discussed, it is challenging to determine the causal factor. Does 
barrier dysfunction cause inflammation? Or is it the other way around, or both, resulting in a 
vicious circle (Landy et al., 2016)? Once the permeability of the epithelial monolayer is 
disturbed luminal antigens and potentially pathogenic microorganisms can invade the mucosa 
triggering the innate and adaptive immune response (Rakoff-Nahoum and Bousvaros, 2010). 
Interestingly, while in ulcerative colitis only the mucosa is affected, inflammation in Crohn’s 
patients appears to be transmural, i.e. affecting all layers (Xavier and Podolsky, 2007).  
How inflammatory processes ultimately promote intestinal tumorigenesis, is a highly complex 
process and was explored several studies. For instance, the proinflammatory cytokine IL-1β 
produced by macrophages, was reported to be associated with the phosphorylation and 
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therefore inactivation of GSK-3β. Thereby, the Wnt signaling pathway was promoted by a NF-
κB-mediated activation of Phosphoinositide-Dependent Kinase-1 (PDK1) and the protein 
kinase PKB/AKT (Kaler et al., 2009). Notably, AKT can promote the nuclear translocation of β-
catenin and β-catenin/TCF transcriptional activity (Fang et al., 2007) which was associated 
with colorectal tumorigenesis (Taipale and Beachy, 2001). Similarly, it was demonstrated in 
vivo that PI3K activity is required for AKT-mediated activation of Wnt signaling (Lee et al., 
2010). Interestingly, it was observed that intestinal inflammation can cause mutations. For 
instance, macrophages and neutrophils, which are recruited during inflammatory processes, 
were shown to produce reactive oxygen and nitrogen species (RONS). In a mouse model for 
colitis, RONS were associated with the induction of DNA damage and mutations and an 
increased CRC risk (Meira et al., 2008). Notably, when analyzing non-cancerous colon regions 
isolated from UC patients, high TP53 mutation rates were identified (Hussain et al., 2000). 
Consistently, as reviewed by Rogler, TP53 mutations occur during the early phase in colitis-
associated colorectal cancer while this phenomenon can usually be observed in the late stages 
of sporadic CRC. Afterwards, dysplastic lesions accumulate further mutations, e.g. in KRAS or 
APC, which consequently lead to the formation of a carcinoma (Rogler, 2014). Notably, it was 
observed that the prognosis of ulcerative colitis-associated colorectal cancer is worse than in 
sporadic CRC (Jensen et al., 2006).  
 
1.6 Colorectal tumor progression 
Generally, the formation of colorectal cancer is a multistep process characterized by its slow 
progression. In the majority of patients, tumors develop after a minimum of ten years allowing 
for early detection if screenings are performed regularly (Smith et al., 2001). Usually, CRC is 
initiated by a hyperproliferation of the intestinal epithelium (Figure 6).  
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Figure 6: Tumor progression in colorectal cancer. Once mutated cells started 
hyperproliferating, they can form polyps. After accumulating mutations and proliferative 
properties pre-cancerous polyps followed by adenomas and adenocarcinomas occur. Finally, 
an invasive carcinoma can be formed which migrates through lamina propria and muscularis 
mucosae and can finally form metastases. 
 
Notably, tumors can have different cells of origin, e.g. stem-like, transient-amplifying, Goblet-
like and enterocytes (Sadanandam et al., 2013). If these hyperplastic properties are 
maintained, benign polyps of different sizes can be formed. Pre-cancerous polyps 
characterized by severe dysplasia can be developed as well as adenomas or 
adenocarcinomas. Finally, the cancer cells can gain migratory properties resulting in the 
formation of invasive adenocarcinoma (Janne and Mayer, 2000; Subramaniam et al., 2016). 
Tumors can invade through the lamina propria and muscularis mucosae into the proximity of 
the lymphatic system blood vessels (Fleming et al., 2012). Once cancer cells have reached the 
circulation, they can form lymphatic metastases or be transported to other organs. Liver 
metastases were detected in 10-25% of CRC patients who underwent surgery (Sheth and 
Clary, 2005). Importantly, the location of the primary tumor can be a determinant for the disease 
outcome. If the cancerous lesion is located in the rectal region, metastases form frequently in 
thorax, bone and nervous system. In contrast, in tumors located on the right side of the 
colorectum, metastases are more likely to form in the peritoneum and liver (Riihimaki et al., 
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2016). Generally, the right sided tumors were reported to be more aggressive and therefore 
correlated to poor prognosis (Hemminki et al., 2010). 
 
1.7 Colorectal cancer detection 
In order to improve prognosis and to prevent further tumor progression, early detection remains 
a critical aspect. Besides the previously mentioned colonoscopy there are further less invasive 
CRC screening approaches. Generally, two major types of screening methods, namely stool-
based and endoscopic/radiologic tests are available. The former include the guaiac-based 
fecal occult blood test (gFOBT), fecal immunochemical test (FIT), and fecal DNA testing. The 
latter include among others optical colonoscopy, capsule endoscopy and computed 
tomographic colonography (CTC) and magnetic resonance colonography (MRC) (El Zoghbi 
and Cummings, 2016; Kolligs, 2016). In gFOBT, the presence of occult blood can be detected 
after applying feces on a guaiac-coated test paper. After the addition of hydrogen peroxide, an 
oxidation reaction takes place resulting in the development of blue color in the presence of 
occult blood (Mandel et al., 1993; Young et al., 2015). In contrast, the FIT makes use of 
antibodies specifically recognizing the globin moiety of human hemoglobin (Mandel et al., 1993; 
Young et al., 2015). A recent meta-analysis describes a higher sensitivity of immunochemical 
approaches compared to gFOBT (Launois et al., 2014). The stool DNA test (Cologuard) is a 
relatively new technique which combines a FIT-based detection of human hemoglobin with a 
molecular screen for CRC-associated biomarkers (The Medical Letter, 2014).   
Colonoscopy is a standard endoscopic approach to directly visualize the intestinal structures 
and remove potential pre-cancerous polyps using a flexible endoscope. In case of colonoscopy 
contraindications or failure, capsule endoscopy can be performed (e.g. PillCam 2; Given 
Imaging Ltd., Israel). After capsule ingestion, a series of images is generated via two cameras 
which is subsequently evaluated by a gastroenterologist to detect diverticulosis, colitis, polyps 
or cancer lesions (Choi et al., 2016; Friedel et al., 2016). CTC is a radiographic method in 
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which a contrast medium is applied to patients in order to obtain images. Detection rates are 
similar to colonoscopy while CTC resulted in considerably less complications (Kim et al., 2007). 
Though MRC was shown to be less sensitive than conventional colonoscopy (Graser et al., 
2013) and CTC as recently reviewed (Kolligs, 2016), its advantage is the absence of radiation 
risk compared to CTC (Brenner, 2004).  
 
1.8 Classification of CRC subtypes 
Upon detection of colorectal cancer and the analysis of biopsies, the tumors can be classified 
based on, for instance, their histopathological and molecular features.  
 
1.8.1 Histopathological classification  
Due to the heterogeneity of colorectal cancer, e.g. the different stages and distinct pathological 
features, there are several histopathological classification criteria. For instance, based on their 
architecture, conventional adenomas can be classified as tubular, villous and tubulovillous 
lesions. Tubular adenomas are characterized by crypt-like dysplastic glands and a low (<25%) 
presence of finger-like projections, i.e. villus-like structures. In contrast, the rate of villous 
component is at least 75% in villous adenomas. Accordingly, tubulovillous adenomas show 
intermediate rates of villous components. Furthermore, serrated lesions are characterized by 
a serrated or sawtooth-like presentation of the epithelium (Fleming et al., 2012).  
The World Health Organization (WHO) has classified colorectal carcinomas into several 
subgroups such as adenocarcinomas, mucinous adenocarcinomas (MACs) and Signet ring 
cell adenocarcinomas. Conventional adenocarcinomas are characterized by the presence of 
glandular structures based on which the tumor can be graded. A high rate of glands (>95%) 
represents a well differentiated adenocarcinoma while a low rate (<50%) indicates a poorly 
differentiated adenocarcinoma. In contrast, cancer lesions are designated as mucinous 
adenocarcinomas when at least 50% of the tumor volume consists of extracellular mucin. When 
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the mucus content is less between 10% and 50%, tumors are described as adenocarcinomas 
with mucinous features/differentiation (Hamilton S.R., 2000). A meta-analysis revealed that 
MACs are majorly found in the right colon and are less frequent in male patients. Moreover, 
the authors described a poor prognosis for CRC patients with MACs (Verhulst et al., 2012). 
Mucinous adenocarcinomas are associated with microsatellite instability (MSI) and therefore 
often present in HNPCC or Lynch syndrome patients. Interestingly, MSI-MACs were described 
to be less aggressive than microsatellite stable (MSS) lesions (Leopoldo et al., 2008; Verhulst 
et al., 2012).  
Excessive mucus is also present in another type of adenocarcinoma, i.e. Signet ring cell 
adenocarcinoma. In affected cells large intracytoplasmic mucin vacuoles push the nuclei aside. 
At least 50% of tumor cells should possess Signet ring features to classify a cancer lesion as 
a Signet ring cell adenocarcinoma (Hamilton S.R., 2000). The presence of these tumors result 
in a worse overall outcome compared to conventional adenocarcinomas (Kang et al., 2005). 
There are further classifications such as medullary carcinomas which are extremely rare 
(Thirunavukarasu et al., 2010) with 5-8:10,000 CRC patients and associated with MSI (Hinoi 
et al., 2001). Finally, the staging according to the TNM classification of colorectal cancer does 
not only depend on the nature of the primary tumor (T), but also on the degree of invasion of 
regional lymph nodes (N) and distant metastasis (M). Each category has several subclasses, 
for instance, the size/spread of the primary tumor (T1-4), the number of affected lymph nodes 
(N0-2) and the presence of distant metastases (M0/1) (Akkoca et al., 2014). 
 
1.8.2 Molecular classification  
Besides the histopathological analysis, the molecular profile of the tumor biopsy is usually 
determined. Based on mutations in (proto-)oncogenes, tumor suppressors and further 
molecular alterations, a classification of the molecular basis of colorectal cancer into three 
pathways was proposed (Ahnen, 2011). In lesions characterized by the chromosomal instability 
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(CIN) pathway, large chromosome regions or entire chromosomes are depleted or 
translocated. This phenomenon results in the dysfunction of relevant tumor suppressor genes 
or proto-oncogenes (Coppede et al., 2014). The CIN pathway is among others associated with 
deregulated protein levels of APC, KRAS, and TP53 (Pancione et al., 2012). In contrast to CIN-
positive cancer lesions, tumors displaying microsatellite instability are characterized by 
changes in short base pair sequences. These deletions, insertions or substitutions of 
nucleotides lead to a significant genetic instability and frequently affect DNA mismatch repair 
genes. MSI can be detected in approximatively 15% of all colorectal tumors which commonly 
show a mucinous phenotype (Ahnen, 2011; Vilar and Gruber, 2010). Finally, the epigenetic 
pathway involves gene expression alterations not resulting from changes in the DNA sequence. 
Over the last years, major advances have been made in this rapidly evolving field helping 
researchers to unravel the role of epigenetic regulatory proteins in cancer (Ahnen, 2011; Mishra 
and Johnsen, 2014; Okugawa et al., 2015). For instance, the CpG island methylator phenotype 
(CIMP) subtype of CRC displays high rates of hypermethylated tumor suppressor genes which 
correlates with poor prognosis (Juo et al., 2014; Toyota et al., 1999). 
This molecular classification has been further refined in several studies. In 2015 an 
international consortium defined four consensus molecular subtypes (CMS) in which of MSI, 
CIN and CIMP can be accompanied by specific genetic mutations or processes such as 
immune or stromal infiltration. CMS1 combines MSI and CIMP with immune infiltration, while 
CMS2 includes copy number alterations and activation of MYC and Wnt signaling pathways. 
In contrast, CMS3 is associated with mixed MSI status, KRAS mutations and the deregulation 
of metabolic processes. Finally, in CMS4, copy number alterations, active Transforming growth 
factor-β (TGF-β) signaling, stromal infiltration and angiogenesis can be observed (Guinney et 
al., 2015).  
 
Introduction 
26 
 
1.9 Colorectal cancer treatment  
The diversity of CRC underlines the importance of tumor characterization to find the most 
suitable therapy option upon diagnosis. The major treatment options include surgery, radiation 
therapy, chemotherapy and targeted therapy (Cunningham et al., 2010). Generally, if the 
cancerous lesions are limited to only one location, total resection of the tumor including margins 
of at least 5 cm is performed. Additionally, at least 12 lymph nodes are typically removed for 
nodal staging. Total mesorectal excision (TME) for rectal and complete mesocolic excision 
(CME) for colon cancer describe the complete removal of the respective organ including the 
mesentery. Via additional excision of the mesentery, a membranous fold attaching 
colon/rectum to the abdominal wall, surgeons can ensure that cancerous mesentery-
associated lymph nodes will be removed as well. This procedure potentially reduces tumor 
recurrence after curative resection (Dimitriou and Griniatsos, 2015). 
If oncogenic growth is not restricted to one area due to venous or lymphatic invasion, 
radiotherapy combined with chemotherapy, i.e. chemoradiation, is the option of choice 
(Cunningham et al., 2010; Hafner and Debus, 2016). Notably, preoperative chemoradiation 
was associated with low recurrence rates and toxicity compared to postoperative treatment 
(Sauer et al., 2004). Notably, numerous studies revealed that CRC patients benefit more from 
combination therapies than from treatment with a single chemotherapeutic agent in terms of 
overall survival and tumor progression. For instance, the combinations of folinic acid and 
Oxaliplatin (FOLFOX) or folinic acid and Irinotecan (FOLFIRI) emerged as standard therapies 
(Aschele et al., 2011; Gramont et al., 1997; Landre et al., 2015; Mohiuddin et al., 2006). 
Notably, combining all three mentioned agents, folinic acid, Oxaliplatin and Irinotecan 
(FOLFOXIRI) resulted in better response as well as higher progression-free and overall survival 
compared to FOLFIRI (Falcone et al., 2007). 
Interestingly, targeted therapy, i.e. monoclonal antibodies, was shown to improve treatment 
efficacy when combined with standard regimens in metastatic colorectal cancer. Bevacizumab, 
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selectively targets the Vascular Endothelial Growth Factor (VEGF) and therefore impairs 
angiogenesis (Ohhara et al., 2016). For example, when administering Bevacizumab to patients 
receiving FOLFIRI, beneficial effects on the progression-free survival were noted (Fuchs et al., 
2007). Similar observations were made when combining Cetuximab targeting the Epidermal 
Growth Factor Receptor (EGFR) with standard therapies (Ohhara et al., 2016).  
Another promising approach is the induction of synthetic lethality. Synthetic lethality is based 
on the concept that the presence of a ‘first hit’ (e.g. genetic mutation) does not affect cell 
survival. In fact, certain mutation can rather result in a growth advantage for cancer cells. 
However, introduction of a ‘second hit’ (e.g. drug treatment or a second mutation) causes 
lethality in the mutated but not in normal, wild type cells (Kaelin, JR, 2005). One well-known 
example is the application of Poly(ADP-Ribose) Polymerase (PARP) inhibitors in patients with 
a mutation in BReast CAncer 1 or 2 (BRCA1 or BRCA2). BRCA1/2 contribute to DNA double-
strand break (DSB) repair (Yoshida and Miki, 2004) while PARP is necessary for the repair of 
single-strand breaks (SSBs) (Dantzer et al., 2000).The rationale behind this treatment is that 
once PARP is absent, SSBs develop to DSBs and since BRCA1/2 are not functional, these 
DSBs cannot be repaired. In other words, BRCA1/2 mutated cancer cells solely depend on 
PARP-mediated repair and once this mechanism is inhibited, lethality is induced. In contrast, 
healthy, BRCA1/2 wild type cells are not significantly affected by PARP inhibition since their 
DSB repair mechanism is still effective (Murata et al., 2016). 
In addition to conventional therapies and the induction of synthetic lethality, several epigenetic 
approaches are currently being tested in clinical trials or have already been FDA-approved. 
For instance, alterations in the methylation equilibrium can be targeted via DNA 
methyltransferase inhibitors, e.g. 5-aza-2′-deoxycytidine (Ghoshal et al., 2005). Histone 
methyltransferase inhibitors such as EPZ-6438 targeting Enhancer of Zeste Homolog 2 (EZH2) 
as well as histone demethylase inhibitors are also currently tested in clinical trials (Mair et al., 
2014). Furthermore, suberoylanilidehydroxamic acid (SAHA/Vorinostat), an inhibitor of histone 
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deacetylases (HDACs) was shown to be effective in T cell lymphomas by maintaining the levels 
of acetylated lysines and therefore normalizing gene expression patterns (Bose et al., 2014). 
Interestingly, in non-small cell lung cancer this epigenetic inhibitor improved the efficacy of the 
chemotherapeutic agents carboplatin and paclitaxel (Ramalingam et al., 2010). Another 
example is the combination of the HDAC inhibitor panobinostat with the proteasome inhibitor 
bortezomib in multiple myeloma patients (San-Miguel et al., 2014). Notably, the progression-
free survival was increased by additional treatment with dexamethasone (Richardson et al., 
2016). A further promising group of epigenetic drugs is represented by Bromo- and Extra-
Terminal domain inhibitors, e.g. JQ1 and I-BET151. As recently summarized by Ferri et al., 
there are several BET inhibitors being tested in clinical studies for malignant, inflammatory and 
cardiovascular diseases. Moreover, synergistic effects were observed when combining these 
inhibitors with HDAC or kinase inhibitors as well as conventional chemotherapeutic agents in 
vivo and in vitro (Ferri et al., 2016). A BET-associated candidate, CDK9 which is recruited by 
BRD4 in order to release promoter proximal pausing, is currently also under investigation as a 
suitable drug target (Bose et al., 2013). However, despite a successful tumor removal or 
chemo- and radiotherapy, disease recurrence and metastasis remain major challenges.  
 
1.10 Heterogeneity of colorectal cancer 
One of the challenges in investigating colorectal cancer and generating adequate therapy 
options is reflected by the heterogenic nature of this disease. In this section all aforementioned 
details about CRC are summarized. Generally, there are several risk factors associated with 
CRC formation (Figure 7). For instance, several morbidities were described such as type 2 
diabetes, obesity and, importantly, inflammatory bowel diseases. In addition, dietary and life 
style factors, e.g. alcohol consumption, smoking and the degree of physical activity were 
identified as risk factors. Individual parameters such as age and familial predisposition are 
correlated with colorectal cancer as well.  
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Once the cancer has formed from a certain cell of origin (e.g. stem-like, transient amplifying, 
Goblet-like, enterocyte) there are various parameters by which this disease can be 
characterized. Initially, it is relevant to determine whether the CRC is of sporadic, hereditary or 
inflammation-induced nature. The developing tumors can be affected by genetic or epigenetic 
alterations and based on these, the molecular subtype (CIN, MSI, CIMP) can be determined. 
These underlying molecular features can influence the tumor architecture which can be of 
serrated, tubular, villous or tubulovillous nature and either differentiated or undifferentiated.  
 
Figure 7: The heterogeneity of colorectal cancer. Several risk factors are associated with 
colorectal cancer. Once an individual is affected, there are distinct CRC subclasses and 
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categories defining the heterogeneity of this disease. These factors can determine therapy 
choice, prognosis, recurrence rate, and metastasis risk. 
 
Adenocarcinoma subclasses include among others conventional, mucinous or Signet cell 
adenocarcinomas. However, the pathological CRC staging does not only depend on the 
primary tumor but also on the presence of nodal and distant metastases. Besides the TNM 
staging, the tumor site can be a crucial determinant of the characteristics of the cancer lesion. 
All these factors contribute to the diversity of colorectal cancers and can potentially determine 
the outcome for the patient, especially recurrence and metastasis. Moreover, the type of 
therapy is determined based on tumor characteristics and spread. 
 
1.11 Murine models for ulcerative colitis and colorectal cancer  
Due to its clinical significance, the diverse underlying mechanisms of (inflammation-induced) 
colorectal cancer need to be elucidated. For research purposes a number of experimental 
animal models have been generated which closely resemble the human situation of 
inflammatory bowel disease and intestinal tumorigenesis. For instance, there are xenograft and 
allograft transplantations, genetic and chemically induced murine models (Robertis et al., 
2011). 
One commonly selected approach is xenograft in which human cancer cells are injected 
subcutaneously into immunodeficient mice which allows easy monitoring of tumor growth in 
vivo (Garofalo et al., 1993). In contrast, in allograft transplantations, also known as syngeneic 
models, murine cells are injected into mice. Thus, the same species is used in this approach 
(Voskoglou-Nomikos et al., 2003). Orthotopic transplantation, e.g. injection of human cancer 
cells into the cecum or rectum of mice, allows the interaction between the tumor and the 
microenvironment (Hoffman, 1999). 
One frequently applied genetic approach is to drive tumorigenesis in the intestine by inducing 
an APC mutation. Two commonly used models are APC multiple intestinal neoplasia (APCmin) 
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and APC1638N mice. Both models possess an APC truncation mutation resulting in a non-
functional APC protein which closely resembles the human situation, e.g. FAP (Fodde and 
Smits, 2001). In contrast to APCmin, where animals primarily display adenomas in the small 
intestine, the APC1638N mutant mouse model develops fewer tumors in the small intestine and 
more colorectal tumors. In addition, tumors in APC1638N mice are characterized by frequent 
progression to carcinomas and occasional metastasis (Fodde et al., 1994; Robanus-Maandag 
et al., 2010; Taketo and Edelmann, 2009).  
To investigate the function of a distinct gene in CRC formation, it can be conditionally deleted 
by making use of the Cre/loxP system. CreERT2 mice specifically express a Cre-recombinase 
as a fusion protein with a mutated Tamoxifen-inducible estrogen receptor ligand binding 
domain (ERT2). Upon the application of Tamoxifen the Cre-recombinase gets activated and 
can mediate the excision of a gene segment flanked by loxP-sites frequently resulting in a 
frameshift and therefore a non-functional gene (Feil et al., 2009). To ensure tissue specificity, 
the Cre-recombinase is usually expressed under the control of a tissue-specific promoter. For 
instance, the Villin promoter is mainly expressed in the small intestine and to a lesser extent in 
the large intestine (el Marjou et al., 2004) while the Caudal-Type Homeobox-2 (CDX2) 
promoter activity is restricted to the distal ileal, cecal, colonic and rectal epithelium (Feng et al., 
2013). In addition to genetic modifications, colorectal tumor formation can be triggered by the 
induction of colitis. Dextran sulfate sodium (DSS) is a chemical agent administered via the 
drinking water to induce colitis (Okayasu et al., 1990). Even though the exact underlying 
mechanisms remain unknown, it is widely accepted that DSS interferes with the epithelial 
barrier function and has a direct toxic effect on the epithelium. As a result, the mucosal 
permeability is increased allowing the entry of DSS, luminal antigens and intestinal 
microorganisms into the mucosa. Consistently, expression levels of proinflammatory cytokines 
are increased, tight junction protein levels perturbed, apoptosis rates elevated (Perse and 
Cerar, 2012), finally resulting in intestinal inflammation.  
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1.12 Ubiquitination and cancer 
Taken together, colorectal cancer reflects a highly complex and heterogeneous disorder with 
numerous associated risk factors and underlying (epi-)genetic alterations. Intensive 
investigations, especially using suitable animal models, are required to obtain further insights 
into CRC and its key players and, most importantly, to investigate new therapeutic strategies. 
As explained before, the ubiquitination status of the histone H2B was described as a predictive 
marker for tumor grade and stage (Qi et al., 2004). In addition, overexpression of USP22, a 
factor responsible for H2B deubiquitination, correlates with increased tumor burden. These 
examples indicate the relevance of maintaining the homeostasis of ubiquitin levels. In contrast 
to other PTMs, ubiquitination is characterized by conjugating its substrate with a relatively large 
(8.5 kDa) polypeptide molecule as a result of a three-step process (Figure 8). Generally, 
ubiquitin is activated in an ATP-dependent manner by the enzyme E1 and conjugated by E2. 
Subsequently it is covalently linked to a lysine residue of a substrate by an E3 ligase. 
Ubiquitination can predispose a substrate for proteasomal degradation, however, it is also 
involved in the regulation of enzyme activity, protein trafficking and the assembly of signaling 
complexes (Pickart, 2001). 
Importantly, this post-translational modification can be reversed by deubiquitinating enzymes 
which are therefore, together with E3 ligases, responsible for maintaining the homeostasis of 
cellular ubiquitin levels (Sowa et al., 2009). In humans, approximately 95 DUBs divided into 
five classes were discovered: JAB1/MPN/MOV34-Metalloprotease (JAMM) domain proteins, 
Machado-Joseph Domain (Josephin domain)-containing proteins (MJD), Ubiquitin C-Terminal 
Hydrolases (UCHs), Ubiquitin-Specific Proteases (USPs), and Otubain/Ovarian Tumor 
Domain-Containing Proteins (OTUs) (Nijman et al., 2005). Interestingly, various DUBs were 
described to influence gene expression by deubiquitinating histones, transcription factors or 
their interaction partners. In general, the removal of ubiquitin molecules stabilizes the substrate 
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by potentially preventing its degradation. Consequently, if tumor suppressors or oncogenes are 
affected by DUBs, the risk of developing malignancies can be modulated (McClurg and 
Robson, 2015).  
 
Figure 8: The E1-E2-E3 process of ubiquitination and its consequences. Ubiquitin is 
conjugated to a substrate in an E1-E2-E3 cascade in which ubiquitin is initially activated by the 
enzyme E1 in an ATP-dependent manner. Subsequently, ubiquitin is conjugated by E2 and 
attached to a substrate by an E3 ligase. This mark can result in the proteasomal degradation 
of the substrate, however, it can also play a role in regulating enzyme activity, protein trafficking 
and the assembly of signaling complexes. Deubiquitinating enzymes can remove the ubiquitin 
molecules and thereby stabilize the substrate by potentially preventing its degradation. 
 
To interfere with these mechanisms, it is either possible to prevent the degradation of 
ubiquitinated molecules, e.g. tumor suppressors, by targeting the proteasome activity or to 
inhibit the stabilization of oncoproteins by directly inhibiting DUBs. For instance, bortezomib 
was a FDA-approved drug to target the proteasome multiple myeloma and mantle cell 
lymphoma patients. However, similar to further proteasome inhibitors, bortezomib was 
associated with severe side effects since not only cancer cells were targeted by this drug (Liu 
et al., 2015a; Richardson et al., 2003). In contrast, inhibiting specific DUBs to prevent the 
stabilization of an oncogenic factor is a promising approach with less off-target effects to be 
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expected (Liu et al., 2015a). For instance, the Ubiquitin-Specific Protease 7 was reported to be 
overexpressed in several cancer types and to interfere with the activity of tumor suppressors 
such as TP53 by stabilizing MDM2 (Cummins et al., 2004; Li et al., 2004). It was successfully 
shown cancer cells in vitro that selective USP7 inhibitors were able to exert anti-tumor effects 
by activating TP53 levels (Colland et al., 2009; Fan et al., 2013; Reverdy et al., 2012). Similarly, 
inhibiting USP1 and USP14 which are frequently overexpressed in cancer as well, showed 
promising effects in in vitro approaches and in xenograft models (Dexheimer et al., 2010; Tian 
et al., 2014). In summary, deregulation of the ubiquitination/deubiquitination axis is associated 
with various human malignancies by frequently destabilizing tumor suppressors or stabilizing 
oncogenic factors. The inhibition of the proteasome or DUBs, such as USP1, 7 and 14, reflect 
promising therapeutic strategies. 
  
1.13 USP22 as a crucial player of CRC  
Due to its overexpression in cancer and its function as a DUB, the ubiquitin hydrolase Ubiquitin-
Specific Protease 22 represents a promising research subject. USP22 was described to be a 
member of the SAGA (Spt-Ada-Gcn5 Acetyltransferase) transcriptional cofactor complex 
(Zhang et al., 2008b). Generally, the 1.8-MDa SAGA complex was implicated in various 
mechanisms including chromatin remodeling and transcriptional regulation. These functions 
are exerted by its structural modules which are, for instance, involved in histone acetylation 
and deubiquitination (Baker and Grant, 2007; Gurskii et al., 2013). The relevance of SAGA in 
developmental processes was demonstrated when mutating or depleting Gcn5, Ada2 and 
Ada3, components of the histone deacetylase (HAT) module within the SAGA complex, 
induced lethality in Drosophila larvae (Carre et al., 2005; Qi et al., 2004). The ubiquitin 
hydrolase USP22 is, together with Ataxin 7 Like 3 (ATXN7L3) and Enhancer of Yellow 2 
Homolog (ENY2), a component of the deubiquitinating module (DUBm) within this complex. 
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Within this complex USP22 removes ubiquitin from the core histones H2B and H2A. While H2B 
monoubiquitination correlates to active gene expression, the monoubiquitination of H2A was 
associated to gene silencing (Zhang et al., 2008b; Zhang et al., 2008a). Like its yeast 
orthologue Ubp8, USP22 deubiquitination activity requires its USP domain (Samara et al., 
2010). Recently, it has been demonstrated that several functions of USP22 can be taken over 
by its homologs USP27X and USP51. For instance, USP22, USP27X and USP51 compete for 
interaction with ATXN7L3 and ENY2 in order to regulate H2Bub1 levels (Atanassov et al., 
2016). In addition, USP22 deubiquitinates several non-histone substrates and thereby 
stabilizes them by preventing their proteasomal degradation. For instance, a protein stabilized 
by USP22 is Telomeric Repeat Factor 1 (TRF1) which binds to telomere ends and thereby 
regulates telomere length. When USP22 was depleted in vitro, TRF1 levels were reduced and 
the number of telomere damage-associated foci increased (Atanassov et al., 2009). Moreover, 
the fact that complete loss of Usp22 resulted in early embryonic lethality in mice suggested the 
significance of Usp22 in developmental processes (Lin et al., 2012). In addition, Usp22 
expression was shown to be essential for pluripotent stem cells to differentiate into all three 
germ layers (Sussman et al., 2013). 
Glinsky (2005) defined USP22 as a member of the so-called 11-gene “death-from-cancer” gene 
expression signature which is characterized by a “stem cell-like” expression profile and was 
shown to be correlated with high recurrence rates, metastatic dissemination and poor survival 
rates (Glinsky, 2005; Wicha et al., 2006). After this finding, many further studies confirmed its 
relevance in cancer as recently reviewed (Melo-Cardenas et al., 2016). These reports were 
based on microarray data or immunohistochemical analyses using patient material and could 
reveal that increased USP22 abundance was correlated with poor prognosis (Ao et al., 2014; 
Ding et al., 2014; Hu et al., 2012; Lin et al., 2012; Liu et al., 2010; Liu et al., 2012; Xiao et al., 
2015). Moreover, it has been reported that increased USP22 expression was, among others, 
correlated with gastric carcinoma (Yang et al., 2011), pancreatic (Ning et al., 2014b; Ning et 
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al., 2014a) and colorectal cancer (Ao et al., 2015; Liu et al., 2010; Liu et al., 2011). Consistently, 
reduced levels of USP22 resulted in the accumulation of cancer cells in the G1 phase in vitro 
(Lin et al., 2015; Lv et al., 2011; Zhang et al., 2008a). Importantly, various key players involved 
in the development and progression of human malignancies are affected directly or indirectly 
by USP22. It was demonstrated that USP22 stabilizes Sirtuin 1 (SIRT1) which results in 
reduced transcription levels of the tumor suppressor TP53 (Li et al., 2014a; Lin et al., 2012). 
Moreover, in non-small cell lung cancer, USP22 interacts with MDM4, a protein highly similar 
to MDM2, leading to decreased TP53 activity and, therefore, elevated tumorigenesis (Ding et 
al., 2014). Besides destabilizing tumor suppressors, USP22 activity was shown to be essential 
for the transcription of target genes of the oncoprotein c-MYC. Accordingly, USP22 is required 
for c-MYC-mediated cell transformation (Zhang et al., 2008b). Furthermore, USP22 
deubiquitinates and stabilizes Nuclear Factor of Activated T cells 2 (NFATc2) which regulates 
transcription of interleukin 2, a mediator of T effector cell activation (Gao et al., 2014). This 
finding implicated a role of USP22 in controlling the immune response and therefore potentially 
in inflammatory processes. In addition, deubiquitinating H2B, and thus decreasing levels of the 
potential tumor suppressive mark H2Bub1, is a further mechanism implying the relevance of 
USP22 during tumorigenesis. Based on these studies and as discussed by Melo-Cardenas 
and colleagues USP22 represents an attractive therapeutic target (Melo-Cardenas et al., 
2016). Similar to USP7, an inhibitor could be generated interfering with USP22 activity and 
therefore preventing the stabilization of several oncoproteins.  
While the involvement of USP22 in cancer has been demonstrated several times, the function 
of USP22 in tumorigenesis in vivo using genetic mouse tumor models with a tissue-specific 
knockout of Usp22 has not been investigated so far. Thus, the exact mechanisms by which 
USP22 promotes tumorigenesis remain to be elucidated.  
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1.14 Implications of USP22 in intestinal cell differentiation (preliminary data) 
Prior to the current project, we investigated the role of USP22 in organ maintenance using 
Usp22 hypomorphic mice (Kosinsky, 2013). In this M.Sc. thesis a preliminary characterization 
of mice with heterozygous (Usp22lacZ/wt) and homozygous (Usp22lacZ/lacZ) reduction of Usp22 
compared to wild type (Usp22wt/wt) animals was performed. Embryonic stem cells 
(Usp22tm1a(KOMP)Wtsi C57Bl6) were obtained from the University of California-Davis Knockout 
Mouse Project Repository and mice were generated in cooperation with Prof. Dr. Ahmed 
Mansouri (Department of Molecular Cell Biology, Max-Planck Institute for Biophysical 
Chemistry, Göttingen, Germany). Based on the “knockout first” strategy these mice had a LacZ 
cassette and a neomycin resistance cassette inserted into the first intron of the Usp22 gene 
(Figure 9A). Due to the presence of an Engrailed2 splice acceptor site (EN2-SA-IRES) the 
LacZ reporter gene was expressed under the control of the endogenous Usp22 promoter and 
enabled the visualization of Usp22 gene activity. A reduction of Usp22 expression was 
achieved by stop codons and polyadenylation sequences downstream of the LacZ and 
neomycin resistance genes, while leaving the Usp22 gene intact. 
Notably, Usp22lacZ/lacZ animals were characterized by reduced body size and weight. Analyses 
were restricted to the small intestine in which we could not detect differences regarding 
proliferation and senescence rates. However, slightly increased apoptosis levels were shown. 
Moreover, the cellular composition of the small intestine was evaluated. In situ hybridization 
and immunohistochemical stainings were performed in order to visualize the different cell 
populations of the SI, i.e. Olfm4-positive stem cells, Goblet, enteroendocrine and Paneth cells. 
Interestingly, the number of stem cells was slightly increased in the small intestines of 
Usp22lacZ/lacZ animals. Consequently, we aimed to determine whether this alteration had an 
effect on the respective differentiated cell populations. Immunohistochemistry was performed 
using specific markers for Goblet (Mucin 2; MUC2), enteroendocrine (Chromogranin A; CGA) 
and Paneth (Lysozyme; LYZ) cells. Interestingly, reduced levels of Usp22 resulted in a nearly 
Introduction 
38 
 
twofold elevated abundance of MUC2-positive Goblet cells in villi (Figure 9B). Moreover, 
approximately 45-50% more enteroendocrine cells were counted in the crypts and villi in these 
mice. We also found an increased frequency of Paneth cells in Usp22lacZ/lacZ mice. Together, 
these findings suggested that USP22 is required for epithelial cell differentiation in villi and 
crypts. In addition, mouse embryonic fibroblasts (MEFs) were isolated and partially 
characterized. While apoptosis levels were slightly increased upon Usp22 loss, the cell cycle 
profile was not affected upon Usp22 loss (Kosinsky, 2013).  
For the current project we have generated bigger cohorts of Usp22-hypomorphic mice in order 
to analyze the effect of hypomorphic expression of Usp22 in more detail. In addition, for a 
higher validity and significance of data, not only the number of experimental animals was 
increased, but also some approaches presented in the M.Sc. thesis were repeated. Several 
results of this Ph.D. thesis supplemented by data from the M.Sc. thesis have recently been 
published (Kosinsky et al., 2015). 
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Figure 9: Reduced Usp22 levels lead to a differentiation shift in the small intestine. (A) 
The LacZ reporter gene is expressed downstream of the Usp22 promoter. Selection of 
embryonic stem cells was based on a neomycin-resistance cassette. Stop codons and poly-A 
sites mediated the reduced Usp22 expression. (B) In situ hybridization for the stem cell marker 
Olfm4 revealed an increased presence of stem cells in the small intestines of Usp22-
hypomorphic Usp22lacZ/lacZ mice. These mice were characterized by an increased abundancy 
of differentiated cells as shown by immunohistochemistry using specific markers, i.e. Goblet 
(MUC2), enteroendocrine (CGA) and Paneth (LYZ) cells (Kosinsky et al., 2015). Scale bar:  
100 µm.  
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1.15 Objectives of this study 
To contribute to the understanding of the molecular features underlying the complex and 
heterogeneous nature of CRC we aimed to elucidate the function of USP22 in tumor formation 
and progression. USP22, an ubiquitin hydrolase epigenetically modifying the histone H2B, is 
of particular interest since it appears to be involved in colorectal tumorigenesis. Notably, 
cancerous diseases characterized by a USP22 overexpression were correlated with poor 
prognosis and metastatic dissemination. Even though some USP22 targets were identified so 
far and several studies with USP22-related in vitro approaches have been published, the 
physiological significance and the role of USP22 in colorectal cancer remain largely unclear. 
This clearly demonstrates the need to investigate the role of USP22 under physiological 
conditions and during colorectal tumorigenesis including the underlying alterations in more 
detail both in vitro and in vivo with the help of a genetic animal model.  
For this purpose, we aimed to follow a dual approach by analyzing the consequences of a 
global reduction and an intestine-specific Usp22 deletion. In the Usp22-hypomorphic mouse 
model which was partially described in the aforementioned Master’s thesis, a global Usp22 
reduction was achieved. Here, we intended to focus on the expression patterns of Usp22 during 
different developmental stages of mouse embryos. Furthermore, by isolating mouse embryonic 
fibroblasts, we planned to investigate signaling pathways Usp22 is involved in via microarray 
analysis. In addition to the animals with the global reduction of Usp22 expression levels, we 
generated mice with an intestine-specific deletion of Usp22 combined with an APC mutation. 
Using these mice we sought to investigate the function of USP22 in intestinal cancer formation 
and progression in models for sporadic and inflammation-induced colorectal cancer. Based on 
the literature, we hypothesized that Usp22 loss would result in decreased tumor burden. To 
investigate the molecular structures underlying the phenotype observed in our mice, we 
planned to investigate human colorectal cell lines characteristics upon the loss of USP22. 
Besides analyses of proliferation patterns, morphology and migration potential, we sought to 
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identify the consequence of USP22 loss in human CRC cells on the global gene expression 
profile. Finally, it was our aim to identify therapeutic mechanisms to target colorectal cancer 
cells characterized by altered USP22 expression in vivo. Together, in the current project we 
sought to investigate the function of USP22 under physiological conditions and during CRC as 
well as to determine the potential of USP22 as a diagnostic marker and therapeutic target. 
 
Materials and Methods 
42 
 
2. MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Technical devices 
Table 1: Technical devices. 
Equipment Company 
2100 Bioanalyzer Agilent Technology, Santa Clara, USA 
Balance 440-35N Kern & Sohn GmbH, Balingen, Germany 
Biological Safety Cabinet “Safe 2020” Thermo Fisher Scientific, Waltham, USA 
Bioruptor® Plus sonication device  Diagenode, Liège, Belgium 
BioView UV-transilluminator UXDT-20SM-8R BioStep, Jahnsdorf, Germany 
Celigo® S Cell Imaging Cytometer Nexcelom Bioscience LLC, Lawrence, USA 
Centrifuge Heraeus Fresco21 Thermo Fisher Scientific, Waltham, USA 
Centrifuge 5417C Eppendorf AG, Hamburg, Germany 
Centrifuge 5417R Eppendorf AG, Hamburg, Germany 
Centrifuge HeraeusTM MegafugeTM 8R Thermo Fisher Scientific, Waltham, USA 
Centrifuge Mini Star silverline VWR, Radnor, USA 
CFX Connect Real-Time System Bio-Rad Laboratories, Hercules, USA 
CFX96™ Optical Reaction Module for Real-
Time PCR 
Bio-Rad Laboratories, Hercules, USA 
ChemiDocTM MP System Bio-Rad Laboratories, Hercules, USA 
CoolLED pE100 CoolLED Ldt., Andover, UK  
Cryotome CM1850 
Leica Mikrosysteme Vertrieb GmbH, 
Wetzlar, Germany 
Digital Caliper (0-150 mm) Zisaline GmbH, Bärnau, Germany 
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DLReadyTM Centro LB 960 Luminometer 
Berthold Technologies GmbH + Co. KG, 
Stadthagen, Germany 
DS-11+ spectrophotometer DeNovix, Inc., Wilmington, USA 
Freezer (-150°C) MDF-C2156VAN-PE 
Ewald Innovationstechnik GmbH, Bad 
Nenndorf, Germany 
Freezer (-20°C) Liebherr GmbH, Biberach, Germany 
Freezer (-80°C)  “New Brunswick™ Innova®” 
Eppendorf GmbH, Wesseling-Berzdorf, 
Germany 
Glass Hellendahl cuvettes for histology 
Omnilab-Laborzentrum GmbH & Co. KG, 
Bremen, Germany 
Glass slide racks with handle for histology 
Omnilab-Laborzentrum GmbH & Co. KG, 
Bremen, Germany 
Glass staining dish with cover for histology 
Omnilab-Laborzentrum GmbH & Co. KG, 
Bremen, Germany 
Heating block Thermo Mixer C Eppendorf AG, Hamburg, Germany 
Heating plate for slides Thermo Fisher Scientific, Waltham, USA 
Horizon® 58 Agarose Gel Electrophoresis 
Chamber     
Life TechnologiesTM, Gaithersburg, USA 
Humidified chamber for histology Weckert Labortechnik, Kitzingen, Germany 
Ice-machine B100 Ziegra, Isernhagen, Germany 
Incubator (CO2) for cell culture, Hera Cell 150i Thermo Fisher Scientific, Waltham, USA 
Incubator for histology 
Memmert GmbH & Co. KG, Schwabach, 
Germany 
Inverted Routine Microscope “Eclipse TS100”  Nikon Corporation, Tokyo, Japan 
Isotemp® water bath Thermo Fisher Scientific, Waltham, USA 
Liquid nitrogen tank LS4800 Worthington Industries, Theodore, USA 
Magnetic stirrer “IKA® RCT-basic” 
IKA®-Werke GmbH & Co. KG, Staufen im 
Breisgau, Germany 
Microcentrifuge C1413-VWR230 VWR, Radnor, USA 
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Microm EC350 embedding station Thermo Fisher Scientific, Waltham, USA 
Microscope Axio Scope.A1 with AxioCam MRc 
Carl Zeiss MicroImaging GmbH, Göttingen, 
Germany 
Microscope Axiovert 100    
Carl Zeiss MicroImaging GmbH, Göttingen, 
Germany 
Microscope camera UI-1240ML iDS, Obersulm, Germany 
Microtome Leica RM2235 Leica Biosystems, Nussloch, Germany 
Microwave R937 
Sharp Electronics Europe GmbH, Hamburg, 
Germany 
Mini Trans-Blot® Cell Bio-Rad Laboratories, Hercules, USA 
Mini-PROTEAN Tetra Cell Bio-Rad Laboratories, Hercules, USA 
Mr. Frosty® Cryo Freezing Container Thermo Fisher Scientific, Waltham, USA 
NanoDrop® ND-100 spectrophotometer PeqLab, Erlangen, Germany 
Neubauer counting chamber, Improved Brand GmbH & Co. KG, Wertheim, Germany 
Paraffin oven  Thermo Fisher Scientific, Waltham, USA 
PCR machine T100TM Thermal cycler  Bio-Rad Laboratories, Hercules, USA 
Personal Computer OPTIPLEX 7020 Dell, Round Rock, USA 
pH-meter “WTW-720” InoLab® Series WTW GmbH, Weilheim, Germany 
Pipette Aid® Portable XP Drummond Scientific Co., Broomall, USA 
Pipettes “Research” Series Eppendorf AG, Hamburg, Germany 
PowerLyzerTM 24 Homogenizer 
MO BIO Laboratories/QIAGEN, Carlsbad, 
USA 
PowerPacTM Basic Power Supply Bio-Rad Laboratories, Hercules, USA 
PowerPacTM HC Power Supply Bio-Rad Laboratories, Hercules, USA 
Precision balance TE124S Sartorius AG, Göttingen, Germany 
Protein electrophoresis Mini-PROTEAN® Tetra 
Handcast Systems 
Bio-Rad Laboratories, Hercules, USA 
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Qubit® 2.0 Fluorometer Invitrogen GmbH, Karlsruhe, Germany 
Refrigerator (4°C) Liebherr GmbH, Biberach, Germany 
Roller mixer  A. Hartenstein GmbH,Würzburg, Germany 
Scanner Epson V700 Photo Seiko Epson, Suwa, Japan 
Shaker “Rocky” 
Schütt Labortechnik GmbH, Göttingen, 
Germany 
Stainless feeding tubes (12 ga, 76 mm) 
Instech Laboratories, Inc., Plymouth 
Meeting, USA 
Test tube rotator 
Schütt Labortechnik GmbH, Göttingen, 
Germany 
Ultra pure water system “Aquintus” MembraPure GmbH, Hennigsdorf, Germany 
Vacuum pump BVC control 
Vacuubrand GmbH + Co KG, Wertheim, 
Germany 
Vortex Genie 2 
Electro Scientific Industries, Inc., Portland, 
USA 
Zwick device (145 660 Z020/TND) Zwick GmbH & Co. KG, Ulm, Germany 
 
2.1.2 Consumables 
Table 2: Consumables. 
Equipment Company 
8.0-µm track-etched membrane cell culture 
inserts 
BD Bioscience, Franklin Lakes, USA 
96-well Assay plate black Corning Life sciences, Tewksbury, USA 
96-well Multiplate® PCR plate, white Bio-Rad Laboratories, Hercules, USA 
AmershamTM ProtranTM 0.45 µM 
nitrocellulose transfer membrane  
GE Healthcare Europe GmbH, München, 
Germany 
CA-Membrane sterile filters (0.2 µm, 0.45 
µm) 
Sarstedt AG & Co., Nümbrecht, Germany 
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Cell culture dishes (10 cm, 14.5 cm) Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Cell culture plates (6-well, 12-well, 24-well) Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Cell scraper (16 cm, 25 cm) Sarstedt AG & Co., Nümbrecht, Germany 
Cellstar PP-tubes (15, 50 ml) Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Cover slips (24x40, 24x60 mm) Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Cryo TubeTM vials (1.8 ml)  Thermo Fisher Scientific, Waltham, USA 
Disposable Safety Scalpel FEATHER Safety Razor Co., Osaka, Japan 
EDTA 40n flat bottom test tubes KABE Labortechnik GmbH, Nümbrecht-
Elsenroth, Germany 
Embedding cassettes, for biopsies Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Gel blotting paper (Whatman) Sartorius AG, Göttingen, Germany 
Injekt-F Syringes (1 ml) B. Braun, Melsungen, Germany 
Low-profile disposable blades 819 Leica Biosystems, Nussloch, Germany 
Lysing Matrix Tubes with beads MP Biomedicals, Eschwege 
Microscope slides (75x26 mm) Thermo Scientific, Braunschweig, Germany 
Multiply PCR Microtube strip (8 x 0.2 ml) Sarstedt AG & Co., Nümbrecht, Germany 
OptiPlateTM-96 PerkinElmer, Waltham, USA 
Parafilm® “M” Pechiney Plastic Packaging, Chicago, USA 
PCR Single Cap SoftStrips 0.2 ml Biozym, Oldendorf, Germany 
Peel away cryo embedding molds (12x12 
mm) 
Electron Microscopy Sciences, Hatfield, USA 
Pipet tips (0.5-10 µl, 2-200 µl, 1000 µl) Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Pipets, serological (5 ml, 10 ml, 25 ml) Sarstedt AG & Co., Nümbrecht, Germany 
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Pipette filter tips Sarstedt AG & Co., Nümbrecht, Germany 
Reaction tubes (1.5 ml, 2 ml) Sarstedt AG & Co., Nümbrecht, Germany 
Sealing tape for qPCR plates Bio-Rad Laboratories, Hercules, USA 
Soft-Ject® Syringes (10 ml, 20 ml, 50 ml) Henke Sass Wolf GmbH, Tuttlingen 
SuperFrost® Plus slides (75x25 mm) Thermo Scientific, Braunschweig, Germany 
Syringe canula (0.6x25 mm, 0.3x12 mm) Dispomed Witt oHG, Gelnhausen, Germany 
Transfer pipettes (6 ml) Sarstedt AG & Co., Nümbrecht, Germany 
UV-Cuvette micro (8.5 mm) Brand GmbH, Wertheim, Germany 
 
2.1.3 Chemicals and reagents 
Table 3: Chemicals and reagents. 
Chemical Company 
0.9% NaCl solution B. Braun, Melsungen, Germany 
10x reaction buffer for M-MulV 
New England BioLabs GmbH, Frankfurt am Main, 
Germany 
3,3‘-Diaminobenzidin-
tetrahydrochloride (DAB) 
Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Acetic acid  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Adenosine 5‘-triphosphate (ATP) 
disodium salt hydrate 
Sigma-Aldrich Co., St. Louis, USA  
Agarose  GeneOn GmbH, Ludwigshafen am Rhein, Germany 
Albumin Fraction V (BSA)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ammonium persulfate (APS)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ammonium sulfate (NH4)2SO4  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Aprotinin Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Boric acid Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
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Bromophenol blue  Sigma-Aldrich Co., St. Louis, USA  
Butella Sunflower Oil 
Brökelmann + Co, Oelmühle GmbH + Co, Hamm, 
Germany 
Chloroform  Merck Millipore, Darmstadt, Germany 
Citric acid monohydrate Merck Millipore, Darmstadt, Germany 
Coelenterazine Promega, Madison, USA 
Coenzyme A (CoA) Sigma-Aldrich Co., St. Louis, USA  
Crystal violet  Merck Millipore, Darmstadt, Germany 
Deoxycholic acid (DOC) AppliChem GmbH, Darmstadt , Germany 
Deoxynucleotides (dNTPs) Jena Bioscience GmbH, Jena, Germany 
Dextrane Sulfate Sodium Salt, reagent 
grade 
MO Biomedicals, LLC, Illkirch, France 
Diethylpyrocarbonate (DEPC)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Dimethylformamide Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Dipotassium phosphate (K2HPO4) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
DL-Dithiothreitol (DTT), BioUltra, 
≥99.0% 
Sigma-Aldrich Co., St. Louis, USA  
Eosin Y solution, 1% in water Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ethanol Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ethylene diamine tetraacetic acid 
(EDTA)  
Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ethylene diamine tetraacetic acid 
disodium salt dihydrate (Na2EDTA) 
Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
ExtrAvidin-Peroxidase Sigma-Aldrich Co., St. Louis, USA  
Ethylene glycol tetraacetic acid (EGTA) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Formaldehyde solution 35%, DAB, for 
histology 
Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
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Gene RulerTM DNA-Ladder  Fermentas GmbH, St. Leon-Rot, Germany  
Glutaraldehyde, 25% EM Grade 
Aqueous 
Sigma-Aldrich Co., St. Louis, USA 
Glycerol  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Glycine  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
GlycylGlycine Sigma-Aldrich Co., St. Louis, USA  
Guaiac resin Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
HD Green® DNA stain Intas Science Imaging GmbH, Göttingen, Germany 
HEPES  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Hydrochloric acid (HCl)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Hydrogen peroxide solution (H2O2), 
30% 
Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Iodoacetamide  Sigma-Aldrich Co., St. Louis, USA  
Isopropanol  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Leupeptin Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Lipofectamine® 2000 Invitrogen GmbH, Karlsruhe , Germany 
Lipofectamine® RNAiMAX Invitrogen GmbH, Karlsruhe , Germany 
Magnesium chloride (MgCl2)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Magnesium sulfate (MgSO4) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Mayer‘s haematoxylin solution Merck Millipore, Darmstadt, Germany 
Methanol  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
N-ethylmaleimide (NEM)  Sigma-Aldrich Co., St. Louis, USA  
Nonidet® P 40 Substitute (NP-40) Sigma-Aldrich Co., St. Louis, USA  
Nuclear fast red-aluminum sulfate 
solution 0.1% 
Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
PageRulerTM Plus Prestained Protein 
Ladder 
Fermentas GmbH, St. Leon-Rot, Germany  
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Paraffin Rotiplast Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Paraformaldehyde (PFA) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Passive lysis buffer (5x) Promega, Madison, USA 
PBS tablets  GIBCO®, Invitrogen GmbH, Darmstadt, Germany 
Pefabloc SC Protease Inhibitor  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
pH solutions (pH 4.01, 7.01, 10.01) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ponceau S solution Sigma-Aldrich Co., St. Louis, USA  
Potassium chloride (KCl) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Potassium ferricyanide (III) 
(K2Fe(CN)6) 
Sigma-Aldrich Co., St. Louis, USA  
Potassium hexacyanoferrate (II) 
trihydrate (K4Fe(CN)6.3H2O) 
Sigma-Aldrich Co., St. Louis, USA  
Protein G sepharose beads 4 Fast 
Flow 
Amersham Biosciences, Uppsala, Sweden 
Roti-Mount Permanent mounting 
medium 
Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Rotiphorese® Gel 30  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Salmon sperm DNA  Stratagene, La Jolla, USA 
Powdered milk  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Sodium azide  Sigma-Aldrich Co., St. Louis, USA  
Sodium chloride (NaCl)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Sodium deoxycholate AppliChem GmbH, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Sodium hydroxide (NaOH)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
SYBR Green I  Roche Diagnostics GmbH, Mannheim , Germany 
Tamoxifen (>99%) Sigma-Aldrich Co., St. Louis, USA  
Temgesic® RB Pharmaceuticals Limited, Berkshire, UK 
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Tetramethylethylenediamine (TEMED) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Tissue-Tek O.C.TTM Compound Sakura Finetek USA, Inc., Torrance, USA 
Tris(hydroxymethyl)aminomethane Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Triton X-100  AppliChem GmbH, Darmstadt , Germany 
Tri-sodium citrate Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
TRIzol® Reagent  Invitrogen GmbH, Karlsruhe , Germany 
Tween-20  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Xylol (Isomere) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
X-β-Gal Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
α,α-Trehalose dihydrate  AppliChem GmbH, Darmstadt , Germany 
β-Glycerolphosphate (BGP)  Sigma-Aldrich Co., St. Louis, USA  
 
Table 4: Enzymes. 
Enzyme Company 
M-MuLV Reverse Transcriptase (25 U) 
New England BioLabs GmbH, Frankfurt am Main, 
Germany 
Proteinase K LifeTechnology, Carlsbad, USA 
RNase inhibitor 
New England BioLabs GmbH, Frankfurt am Main, 
Germany 
Taq-Polymerase (5 U/µl) Primetech, Minsk, Belarus 
 
Table 5: Inhibitors. 
Inhibitor Cat. no. Source 
JQ1 (C23H25ClN4O2S)  
Stefan Knapp, Goethe-University Frankfurt am Main, 
Germany 
Ganetespib S1159 Selleckchem 
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MG-132 S2619 Selleckchem 
 
 
2.1.4 Cell culture 
Table 6: Cell culture components. 
Component Company 
DMEM, high glucose, HEPES, no 
phenol red  
GIBCO®, Invitrogen GmbH, Darmstadt, Germany  
DMEM/F-12, HEPES, no phenol red GIBCO®, Invitrogen GmbH, Darmstadt, Germany  
Fetal Bovine Serum (FBS)  Thermo Scientific HyClone, Logan, USA  
Gibco® 0.05% Trypsin-EDTA GIBCO®, Invitrogen GmbH, Darmstadt, Germany  
McCoy's 5A (Modified) Medium GIBCO®, Invitrogen GmbH, Darmstadt, Germany  
Opti-MEM LifeTechnology, Carlsbad, USA 
Penicillin-Streptomycin Sigma-Aldrich Co., St. Louis, USA  
RPMI 1640 Medium, GlutaMAX™ 
Supplement 
GIBCO®, Invitrogen GmbH, Darmstadt, Germany  
Sodium pyruvate Sigma-Aldrich Co., St. Louis, USA  
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Table 7: Cell lines. 
Cell line Tumor type Medium Source 
COLO201 
Colorectal 
adenocarcinoma 
RPMI 
GlutaMAXTM 
Clinic for General, Visceral and 
Pediatric Surgery, UMG 
COLO320DM 
Colorectal 
adenocarcinoma 
RPMI 
GlutaMAXTM 
Clinic for General, Visceral and 
Pediatric Surgery, UMG 
DLD1 
Colorectal 
adenocarcinoma 
RPMI 
GlutaMAXTM 
Institute of Molecular Oncology, UMG 
HCT116 Colorectal carcinoma McCoy’s 5A Institute of Molecular Oncology, UMG 
HT-29 
Colorectal 
adenocarcinoma 
McCoy’s 5A 
Clinic for General, Visceral and 
Pediatric Surgery, UMG 
LS174T 
Colorectal 
adenocarcinoma 
DMEM/F-12 Institute of Molecular Oncology, UMG 
NCI-H508 
Colorectal 
adenocarcinoma 
RPMI 
GlutaMAXTM 
Clinic for General, Visceral and 
Pediatric Surgery, UMG 
RKO Colorectal carcinoma DMEM/F-12 Institute of Molecular Oncology, UMG 
SW48 
Colorectal 
adenocarcinoma 
DMEM/F-12 
Clinic for General, Visceral and 
Pediatric Surgery, UMG 
SW480 
Colorectal 
adenocarcinoma 
RPMI 
GlutaMAXTM 
Institute of Molecular Oncology, UMG 
SW837 
Rectal 
adenocarcinoma 
DMEM/F-12 
Clinic for General, Visceral and 
Pediatric Surgery, UMG 
T84 Colorectal carcinoma DMEM/F-12 
Clinic for General, Visceral and 
Pediatric Surgery, UMG 
 
 
2.1.5 Kits  
Table 8: Kits. 
Kit Company 
Agilent High Sensitivity DNA Kit Agilent Technology, Santa Clara, USA 
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Bioanalyzer DNA High sensitivity kit  Agilent Technologies, Santa Clara, USA  
Immobilon Western Blot HRP Substrate 
Luminol Reagent 
Merck Millipore, Darmstadt, Germany 
NEXTflex™ Rapid Illumina Directional 
RNA-Seq Library Prep Kit 
Bioo Scientific Corporation, Austin, USA 
PierceTM BCA Protein Assay Kit ThermoFisher Scientific, Rockford, USA 
Qubit dsDNA HS assay  Invitrogen GmbH, Karlsruhe , Germany 
SuperSignal® West Femto Maximum Thermo Fisher Scientific, Waltham, USA 
 
2.1.6 Oligonucleotides 
Table 9: Primers used to genotype experimental mice. 
Mouse 
line 
Gene 
Primer 
name 
Sequence (5'-3') Source 
Usp22lacZ Usp22 
LoxP F CCCAGCTTTCTTGTACAAAGTGGTT 
(Kosinsky et 
al., 2015) 
Wt F GTGCCCTGGTTGCCCAGTGAG 
LoxP/wt R CGGTTCAGGTGGATGCCGCA 
APC1638N Apc 
Apc-A3 CTAGCCCAGACTGCTTCAAAAT 
(Cremers et al., 
2016)  
Apc-C2 GGAAAAGTTTATAGGTGTCCCTTCT 
PN3 GCCAGCTCATTCCTCCACTC 
Usp22loxP Usp22 
Usp22 
6720F 
TGTGCCCTGGTTGCCCAGTGA 
This study 
Usp22 
14079R 
GCACCACCACAGCCGTCCTT 
Villin-
CreERT2 
Villin-
CreERT2 
Villin-
2kbseqS 
CAAGCCTGGCTCGACGGCC 
(Donovan et 
al., 2005) 
Villin-Cre198 CGCGAACATCTTCAGGTTCT 
 
  
Materials and Methods 
55 
 
Table 10: qRT-PCR primers for gene expression studies. 
Gene 
Primer 
name 
Sequence (5'-3') Organism Source 
18S rRNA 
h1SrRNA 
903F 
AACTGAGGCCATGATTAAGA Human 
(Upasana Bedi, 
2013) 
h18SrRNA 
1075R 
GGAACTACGACGGTATCTGA Human 
36B4 
m36B4F GATTGGCTACCCAACTGTTG Mouse 
(Mesange et al., 
2014) 
m36B4R CAGGGGCAGCAGCCACAAA Mouse 
HSP90AB1 
hHSP90AB1 
469F 
TTGACATCATCCCCAACCCTC Human 
This study 
hHSP90AB1 
641R 
ACCAAACTGCCCAATCATGGA Human 
USP22 
hUsp22 
2792F 
AGCCAAGGGTGTTGGTCGCG Human 
(Theresa Gorsler, 
2013) 
hUsp22 
2897R 
ACTGCCACCACGCCCGAAAG Human 
Usp22 
mUsp22 
189F 
GGAGCCTGAGGTCGAGGCCA Mouse 
This study 
mUsp22 
359R 
ACACAGGACTTTGCCTTGCGC Mouse 
 
Table 11: siRNAs used for transient gene silencing in vitro. 
Gene Sequence (5´- 3´) Cat. No. Company 
NT5 - D-001210-05 Dharmacon 
USP22 
GGAAGAAAGAUCACCUCGAA 
MU-006072-01-0010 Dharmacon 
CAAAGCAGCUCACUAUGAA 
GGAAGAUCACCAACGUAUGU 
CCUUUAGUCUCAAGAGCGA 
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2.1.7 Antibodies 
Table 12: Primary antibodies used for western blot, Co-IP and IHC. 
Antibody Host Cat. no. Source 
Western 
blot 
Co-IP IHC 
CTIP2 Rat ab18465 Abcam   1:100 
GAPDH Mouse ab8245 Abcam 1:1,000   
H2B Mouse ab52484 Abcam 1:20,000   
H2B Rabbit ab1790 Abcam   1:1,000 
H2Bub1 Mouse (Prenzel et al., 2011) 01:10  01:20 
HSP90AB1 (clone 4C10) Mouse TA500494 OriGene 1:5,000 2 µg  
IgG Mouse 
015-000-
003 
Dianova  2 µg  
SATB2 Rabbit 2819-1 Epitomics   1:100 
TBR2 Rabbit ab2283 Millipore   1:100 
USP22  Mouse sc 390585 Santa Cruz 1:1,000 4 µg  
 
 
Table 13: Secondary antibodies. 
Antibody Host Cat. no. Source 
Western 
blot 
IHC 
Anti-mouse IgG, biotinylated Sheep RPN1001 
GE 
Healthcare 
 1:1,000 
Anti-rabbit IgG, biotinylated Donkey RPN1004 
GE 
Healthcare 
 1:1,000 
goat-anti-mouse IgG-HRP goat sc-2005 Santa Cruz 1:10,000  
goat-anti-rabbit IgG-HRP goat sc-2004 Santa Cruz 1:10,000  
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2.1.8 Buffers 
2x qPCR mix  
75 mM Tris/HCl, 20 mM (NH4)2SO4, 0.01% Tween 20, 3 mM MgCl2, 0.2 mM dNTPs, 0.25% 
Triton X-100, 20 U/ml Taq polymerase, 1:80,000 SYBR Green I, 300 mM Trehalose, pH 8.8 
Citric acid buffer 
12 mM citric acid, 100 mM tri-sodium citrate, pH 6.0 
Crystal violet solution 
0.1% (w/v) crystal violet in 20% EtOH 
DNA extraction buffer 
10 mM Tris/HCl, 400 mM NaCl, 2 mM EDTA, 2% SDS, 10 µg/ml proteinase K 
DNA loading dye (6x)  
40% (w/v) sucrose, 10% (v/v) glycerol, 0.25% (w/v) bromophenol blue 
E1A buffer 
50 mM HEPES, 150 mM NaCl, 0.1% NP-40, pH 7.3 
Embryo fixation solution 
6.75 ml 37% formaldehyde, 2 ml 25% glutaraldehyde, 5 ml NP-40, 25 ml 10x PBS, filled up to 
250 ml with H2O, 110 mg DOC 
Firefly buffer 
25 mM glycylglycine, 15 mM K2HPO4, 4 mM EGTA, 15 mM MgSO4, 4 mM ATP, 1.25 mM 
DTT, 0.1 mM CoA, 80 µM luciferin, pH 8.0 
Laemmli buffer (6x) 
9.3% (w/v) DTT, 0.02% (w/v) bromophenol blue, 30% (v/v) glycerol, 10% (w/v) SDS, 0.35 M 
Tris, pH 6.8 
PBS 
137 mM NaCl, 4.29 mM Na2HPO4.2H2O, 2.68 mM KCl, 1.47 mM KH2PO4, pH 7.4  
Renilla buffer 
1.1 M NaCl, 2.2 mM Na2EDTA, 0.22 M K2HPO4, 1.5 mM NaN3, 0.5 mg/ml BSA, 1.5 µM 
Coelenterazine, pH 5.1  
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RIPA buffer 
1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate in PBS 
RNA loading dye 
0.1% (w/v) bromophenol blue, 49.9% DEPC water, 50% glycerol (w/v) 
SDS running buffer 
25 mM Tris, 86 mM glycine, 3.5 mM SDS 
SDS separating gel (10%) 
33%(v/v) acrylamide, 0.1% (w/v) APS, 0.1% (w/v) SDS, 375mM Tris/HCl, 0.04% (v/v) 
TEMED, pH 8.8 
SDS stacking gel 
5% (v/v) acrylamide, 0.1% (w/v) APS, 0.1% (w/v) SDS, 125.5 mM Tris/HCl, 0.1% (v/v) 
TEMED, pH 6.8 
TBE buffer 
45 mM Tris, 1 mM Na2EDTA, 45 mM boric acid 
Western blot transfer buffer 
10% (v/v) 10x western salts, 20% (v/v) methanol 
Western salts (10x) 
1.92 M glycine, 0.02% (w/v) SDS, 250 mM Tris/HCl, pH 8.3 
X-gal staining solution 
2.5% 250 mM K3Fe(CN)6, 2.5% 250 mM K4Fe(CN)6, 2% 100 mM MgCl2 in PBS  
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2.1.9 Software and tools 
Table 14: Software and tools. 
Software/Tool Source 
AxioCam MRc and AxioVision 4.8 Software Carl Zeiss  
Bio-Rad CFX Manager 3.1 Bio-Rad Laboratories, Hercules, USA 
cBioPortal 
http://www.cbioportal.org/  
(Cerami et al., 2012; Gao et al., 2013),  
CFX Manager Software 3.1 for qPCR cycler Bio-Rad 
FIJI (Schindelin et al., 2012) 
Galaxy http://usegalaxy.org/ 
GOTermFinder  
Princeton University, Lewis-Sigler Institute, 
http://go.princeton.edu/cgi-bin/GOTermFinder 
GraphPad Prism 
GraphPad Prism version 5 for Windows, 
GraphPad Software, Inc., San Diego, USA 
Image Lab Version 5.2 build 14 Bio-Rad Laboratories, Hercules, USA 
IST Online® MediSapiens Ltd., http://ist.medisapiens.com/ 
Microsoft Excel, Word, PowerPoint Microsoft, Redmond, USA 
Morpheus https://software.broadinstitute.org/morpheus/ 
OncomineTM 
https://www.oncomine.org/resource/login.html 
(Rhodes et al., 2004)  
Primer designing tool NCBI/Primer-BLAST  (Ye et al., 2012) 
REViGO http://revigo.irb.hr/ (Supek et al., 2011) 
Statistical software R 
R: A language and environment for statistical 
computing. R Foundation for Statistical 
Computing, 2013, https://www.r-project.org/ 
TestXpert software  Zwick GmbH & Co. KG, Ulm, Germany 
uEYE Cockpit 
IDS Imaging Development Systems GmbH, 
Obersulm, Germany 
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2.2 Methods 
2.2.1 Animal studies 
2.2.1.1 Generation of mice and genotyping 
C57BL/6 embryonic stem cells (ESCs) expressing the LacZ gene under the control of the 
endogenous Usp22 promoter were obtained from the University-Davis Knockout Mouse 
Project Repository (clone Usp22_D11). In Usp22lacZ mice stop codons and poly-A sites result 
in a reduced Usp22 expression as previously described (Kosinsky et al., 2015). By FLP-
mediated excision the lacZ and neomycin resistance locus were removed from the construct 
in order to generate Usp22loxP animals in which a conditional knockout of Usp22 was possible. 
Usp22loxP mice were crossed with Villin-CreERT2 and APC1638N animals to achieve an intestinal 
knockout and to promote tumorigenesis, respectively. Mice in this study were on the C57BL/6J 
background. 
 
2.2.1.2 Tamoxifen injection  
5% Tamoxifen (w/v) was dissolved in 100% EtOH. Right before intraperitoneal injection into 
mice, this solution was mixed 1:10 with sunflower oil. Mice were injected at an age of 4 weeks 
for five consecutive days with a total dose of 1 mg Tamoxifen per day.  Mice injected at an age 
of 14 weeks received 1.5 mg per day. 
 
2.2.1.3 DSS administration 
10 week-old mice were treated with the chemical agent dextran sulfate sodium (DSS) in order 
to trigger colitis and the subsequent formation of colorectal tumors. 2% DSS (w/v) was 
dissolved in drinking water and the solution was refreshed every two to three days. Since the 
treatment can be accompanied by diarrhea, intestinal bleedings and weight loss, the 
administration of DSS was segmented into two cycles. After four days of being treated with 
DSS, mice were put on a special diet using soft food and glucose for one week. During this 
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week the animals recovered and were treated with DSS for three days afterwards. At the end 
of the treatment the mice received soft food again for three weeks. Animals were injected with 
Temgesic® (buprenorphine) up to three times per day for a total duration of approximately 7 
days to prevent/treat abdominal pain starting on the last day of DSS treatment. The body weight 
of the mice and intestinal bleeding intensities were checked daily using the stool guaiac test.  
 
2.2.1.4 Stool guaiac test 
To assess the presence and intensity of intestinal bleedings caused by DSS treatment, the 
stool guaiac test was carried out. Guaiac resin was dissolved in 70% EtOH until the solution 
was saturated. A few drops were applied to a Whatman filter paper and left for drying at room 
temperature for at least 30 minutes. Feces were applied and distributed on the dried Guaiac 
solution. Upon H2O2 addition, blue staining was observed in the presence of blood which was 
scored according to its intensity from 3 to 0 with decreasing intensity or absence, respectively. 
 
2.2.1.5 Determination of disease activity index (DAI) 
To determine the severity of colitis the disease activity index (DAI) was calculated by scoring 
three aspects, i.e. weight loss, stool consistency and intestinal bleeding intensity. Weight loss: 
0-1% (0), 1-5% (1), 5-10% (2), 10-15% (3), >15% (4). Stool consistency: normal (0), soft (1), 
very soft (2), diarrhea (3). To evaluate intestinal bleeding intensity the stool guaiac test was 
performed. Scoring of the stool guaiac test was: no blue staining (0), weak, sporadic staining 
(1), medium (2) and strong blue staining (3), bloody anus (4). After adding the scores per aspect 
maximum score of 11 can be reached per day. Animals which had to be sacrificed due to 
severe symptoms received a score of 12.  
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2.2.1.6 Tissue isolation 
Mice were euthanized by CO2 and cervical dislocation. They were checked for the presence of 
metastases and further abnormalities such as intussusceptions. Intestines were flushed with 
PBS and cut open longitudinally. Tumors were counted and their location and size was 
measured. Some tumors were isolated and frozen. Subsequently intestines were rolled 
upwards resulting in their wrapping around themselves to form “Swiss rolls”. The distal third of 
the SI and the complete colon were fixed in 4% formaldehyde in PBS overnight for subsequent 
paraffin embedding. The proximal third of the SI was frozen at -20°C in Tissue-Tek O.C.TTM 
cryo embedding medium and the remaining third was snap-frozen in liquid nitrogen and stored 
at -80°C for subsequent protein or RNA isolation.  
 
2.2.1.7 Serum isolation 
After sacrificing animals, the heart was punctured and blood was isolated. It was stored at room 
temperature for 1 h and spun down at 1,000 rpm for 10 min. The serum was transferred to a 
new tube and if blood color varied among animals, the hematocrit/serum fractions were 
weighed and the ratio was calculated. Subsequently, the serum was stored at -20°C.  
 
2.2.1.8 Isolation of intestinal epithelial cells 
Intestines were flushed with PBS and cut longitudinally. 1-2 cm long fragments were prepared 
and vortexed in ice-cold PBS for 1 min. If the intestines were still dirty or covered by mucus, 
PBS was decanted, 4.5 mM DTT in PBS was added and after shaking at room temperature for 
10 min, tissues were transferred to fresh PBS. To separate the epithelium from the muscle 
layers, intestinal fragments were shaken in 20 ml 5 mM EDTA in PBS for 15 min. After vortexing 
for 2 min, the supernatant containing the epithelial cells was transferred into a clean 50 ml tube 
containing 20 ml 5 mM EDTA in PBS. These steps were repeated until the solution was clear 
and no villi were visible under the microscope. Supernatants were combined and spun down 
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at 1,000 rpm for 10 min. Pellets were washed with PBS and stored at -80°C for subsequent 
RNA and protein isolation. 
 
2.2.1.9 X-gal staining of embryos 
After heterozygous mating, Usp22lacZ embryos at E10.5 and E15.5 were collected and fixed in 
fixation solution on ice for 60 min. X-gal staining solution was pre-warmed to 37°C and X-gal 
solution (40 mg X-β-Gal/ml dimethylformamide) was added. After washing in PBS, embryos 
were incubated in staining solution protected from light for 24 h. Subsequently, they were 
embedded in Tissue-Tek O.C.TTM and cut on the sagittal plane. The frozen embryos were 
thawed in 0.1% PFA in PBS for approximately 10 min. Afterwards they were washed, 
dehydrated and prepared for paraffin embedding. 20 μm sections were counterstained using 
nuclear fast red-aluminum sulfate solution. 
 
2.2.1.10 Preparation of mouse embryonic fibroblasts (MEFs) 
After heterozygous mating the uterus of pregnant Usp22lacZ mice was removed at E13.5 and 
transferred into ice-cold PBS. Under sterile conditions the uterus and amnion were removed 
and embryos were washed in PBS. Liver, tail and limbs were removed and the head was lysed 
for genotyping. Tissues were homogenized in 5 ml 0.05% Trypsin-EDTA with a sterile scalpel. 
After incubating at 37°C for 5-10 min, the tissue was resuspended and incubated for further 5 
min. 5 ml DMEM was added and following inverting, tubes were centrifuged at 1,000 rpm for 7 
min. The pellet was resuspended in 5 ml warm DMEM supplemented with 10% FBS, 1% 
sodium pyruvate, 100 units/ml penicillin, and 100 µg/ml streptomycin and transferred into a 15 
cm dish containing 10 ml DMEM. Cells were incubated at 37°C, 5% CO2 until plates were 
confluent (24-72h).  
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2.2.1.11 Preparation of paraffin-embedded tissue 
After formaldehyde fixation, organs were washed using tap water and PBS and dehydrated in 
70% EtOH overnight. Dehydration proceeded using 80%, 90% and 100% EtOH with 1 h 
shaking for each. EtOH was exchanged with isopropanol and tissues were shaken overnight. 
Isopropanol was slowly exchanged with xylol by decreasing the isopropanol and increasing the 
xylol ratio. After shaking the organs in pure xylol, tissues were transferred to paraffin at 62°C 
for three days. Finally tissues were embedded in paraffin blocks which were used to prepare 5 
µm sections. 
 
2.2.1.12 H&E and Nissl staining 
Organ sections were de-paraffinized in xylol for 20 min and rehydrated by storing them in 
decreasing EtOH solutions (100%, 90%, 70%) each for 5 min. Slides were washed with water 
and nuclei were stained in Mayer’s hematoxylin solution for 1 min. Excess dye was removed 
by rinsing slides under running tap water for 5 min. Counterstaining was performed using Eosin 
for 5-10 min. Slides were washed and dehydrated in increasing concentrations of EtOH 
solutions. After incubation in xylol for 10 min, mounting medium and cover slips were added to 
slides. For morphological analyses 100-200 crypts/villi were assessed. For Nissl staining of 
brain material, sections were de-paraffinized, rehydrated and stained in 0.5% cresyl violet for 
10 min. For rehydration and mounting, the aforementioned steps were followed. Nissl staining 
was performed in cooperation with Dr. Nicole Hellbach and Prof. Dr. Tanja Vogel (Department 
of Molecular Embryology, Institute of Anatomy and Cell Biology, Faculty of Medicine, University 
of Freiburg, Germany).  
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2.2.1.13 Immunohistochemistry (IHC) 
Similar to H&E staining, sections were de-paraffinized and rehydrated. Antigen retrieval was 
performed by boiling slides in 10 mM citric acid buffer or 1 mM EDTA for 15 min. Sections were 
quenched for endogenous peroxidases with 5% H2O2 in PBS and blocked with 10% fetal bovine 
serum (FBS) in PBS. Primary antibodies were diluted in 10% FBS/PBS and incubated 
overnight at 4°C. Biotinylated secondary antibodies (1:200) and ExtrAvidin-Peroxidase 
(1:1,000) were added each for 1 h. Staining was developed using DAB and counterstaining 
was carried out using hematoxylin.  
 
2.2.1.14 Histo-score (H-score) 
The Histo-score (H-score) is based on the intactness of the intestinal epithelium and the rate 
of lymphocyte infiltration to determine inflammation intensity. The H-score is assigned in a 
range from 0 to 3 with an increasing disruption of crypt structure. In contrast to the normal and 
healthy intestinal epithelium (score 0), mild inflammation and therefore lymphocyte infiltration 
can cause crypts to be pushed apart from each other (1). While the presence of MALTs below 
the crypts are part of the normal immune defense, during colitis lymphocyte accumulations can 
destroy crypt structure (2). The highest score is assigned when the epithelial lining on top of 
the lymphocyte accumulation has been destroyed (3). The percentage of damaged tissue was 
multiplied by the respective score (0-3) and the sum was divided by the maximum H-score, 
which was 30. This method is based on a colitis-scoring technique established by Dr. med. 
Hanibal Bohnenberger (Institute for Pathology, UMG) and Garrit Meers (Institute for Cellular 
and Molecular Immunology, University of Göttingen Medical School) and has been modified 
accordingly for (colitis-induced) colorectal cancer sections. 
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2.2.1.15 Mechanical bone testing 
To determine bone biomechanical properties, femora were located on a Zwick device while a 
stamper moved towards the bone with 50 mm/min. Initially, a primary force of 1N was applied 
to fix the bone on the plate. Afterwards, measurements were performed with an accuracy of 
0.2-0.4% using 2-500 N. Data were recorded while the applied strength was linear and was 
aborted once the curve declined by 10 N. By means of the testXpert software the applied 
strength when the deformation was induced (yield load), during fracture (Fmax), before 
breaking the bone (failure load) and the bone stiffness were determined (Komrakova et al., 
2010). Analyses were performed in cooperation with Dr. med. Dominik Saul (Department of 
Trauma, Orthopedics and Reconstructive Surgery, UMG). 
 
2.2.2 Cell culture 
2.2.2.1 Cell culture and inhibitor treatment 
Human colorectal cancer cell lines were grown in phenol-red free Dulbecco's Modified Eagle's 
Medium (DMEM/F-12), RPMI or McCoy’s 5A medium supplemented with 10% fetal bovine 
serum, 100 units/ml penicillin and 100 μg/ml streptomycin at 37°C and 5% CO2. Inhibitors were 
dissolved in DMSO. Increasing concentrations of Ganetespib and JQ1 were added to the cells 
for 48 h. Cells were incubated with 20 µM of the proteasome inhibitor MG-132 for 4 h. As a 
negative control DMSO was added to the cells.  
 
2.2.2.2 siRNA transfection 
siRNA transfections were performed using Lipofectamine® RNAiMAX according to the 
manufacturer’s instructions. Briefly, 30 pmol siRNA was mixed with 500 μl of Opti-MEM and 5 
μl of Lipofectamine® RNAiMAX. After incubating the transfection mix at room temperature for 
20 min, it was added to a well of a 6-well plate containing 400,000 cells in 1.5 ml medium 
without antibiotics. For the determination of cells’ characteristics, cells were trypsinized 24 h 
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post transfection and subjected to a variety of assays. When isolating protein or RNA of siRNA-
treated cells, 24 h after transfection medium containing antibiotics was added and 48 h later 
cells were harvested. 
 
2.2.2.3 Proliferation assessment  
To assess proliferation rates, 2,000-5,000 cells were seeded per well of a 96-well plate after 
siRNA transfection. Proliferation during inhibitor treatment was assessed in 24-well plates. 
Confluence was measured every 24 h using a Celigo® Adherent Cell Cytometer for one week. 
Alternatively, 30,000-75,000 cells were seeded per well of a 12-well plate. After 48 h cells were 
washed with PBS and fixed with 4% PFA in PBS for 20 min. Upon a further washing step, cells 
were visualized by crystal violet staining for 20 minutes. Excess dye was removed by rinsing 
wells several times with water and plates were scanned. 
 
2.2.2.4 Migration assay 
Migration potential of cells was assessed using a trans-well migration assay as previously 
described (Prenzel et al., 2011). Briefly, 48 hours after transfection with siRNAs, 50,000 
HCT116 or 75,000 SW48 cells, respectively, were seeded into 8.0-μm PET track-etched 
membrane cell culture inserts. Cells were grown for another 48 hours 37°C and 5% CO2 before 
fixation with methanol for 10 minutes. Migrated cells were visualized by crystal violet staining 
for 20 minutes. Finally, inserts were rinsed with water, allowed to dry and scanned.  
 
2.2.2.5 Colony formation assay 
After trypsinization, 500 cells were transferred per well of a 6-well plate. Approximately 4-7 
days later when colonies were detected macroscopically, colonies were stained using crystal 
violet as explained before.   
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2.2.2.6 Soft agar colony formation assay 
This experiment was performed to assess the ability of cells to grow in an anchorage-
independent manner. Initially, a sterile stock agarose solution (3.2% in water) was prepared 
and autoclaved. It was then mixed with the respective growth medium and 1 ml was transferred 
per well of a 6-well plate to prepare a 0.8% base agarose layer. Subsequently, 150 µl of the 
3.2% pre-warmed (37-40°C) agarose solution was added to 11,500 cells in 1 ml of growth 
medium. 750 µl of this mixture was transferred immediately on top of the base agarose layer. 
Upon solidification, 1-2 ml of normal growth medium was added and cells were incubated at 
37°C for 10-20 days until colonies were visible macroscopically. Cells were fixed with 4% PFA 
in PBS for 20 min and subsequently stained with 0.005% crystal violet for 1 h. After carefully 
rinsing the wells with water, plates were scanned. 
 
2.2.2.7 CRISPR/Cas9-mediated knockout of USP22 
In order to achieve a permanent knockout of USP22 in HCT116 cells, 400,000 cells were 
seeded per well of a 6-well plate. Single guide RNAs (sgRNAs) targeting USP22 were designed 
by Dr. rer. nat. Florian Wegwitz (Department of General, Visceral and Pediatric Surgery, UMG) 
with the help of the E-CRISP algorithm from the German Cancer Research Center 
(http://www.e-crisp.org). The selected guide RNA sequences were then cloned into the 
pSpCas9(BB)-2A-GFP (PX458, Addgene) vector. 2.5 µg plasmid containing Cas9 and GFP 
sequences as well as a sgRNA were complexed with Lipofectamine® 2000 for 25 min at room 
temperature and added to the wells containing medium without antibiotics. After 24 h cells were 
washed with PBS and medium supplemented with antibiotics was added. 48 h after transfection 
the cells were sorted based on their fluorescence intensity via fluorescence activated cell 
sorting (FACS). FACS was performed by Sabrina Becker (Cell-sorting technology platform, 
Department of Haematology and Medical Oncology, UMG). Single highly fluorescent cells were 
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sorted into the wells of a 96 well plate. Cell clones were cultivated and propagated. The loss 
of USP22 was confirmed at the protein level by western blot.  
 
2.2.3 Molecular biology techniques 
2.2.3.1 DNA extraction from tail biopsies or cells 
Tail biopsies or cell pellets were lysed at 56°C in DNA extraction buffer overnight. To separate 
nucleic acids from other cellular contaminants, 100 µl 5M NaCl was added. Tubes were 
inverted and centrifuged at room temperature and maximum speed for 10 min. An equal 
volume of isopropanol was added to the supernatant in a new tube and after mixing samples 
they were spun down at 4°C to precipitate the DNA. The pellet was washed with 100 µl ice-
cold 70% EtOH and spun down. Following EtOH removal, DNA pellets were air-dried and 
dissolved in 50 µl H2O.  
 
2.2.3.2 Genotyping of experimental mice 
Genotyping of Usp22lacZ mice was performed by pre-heating PCR samples to 95°C for 3 min. 
The respective DNA fragments were amplified in 35 polymerization cycles with 95°C for 30 s, 
60°C for 30 s, 72°C for 1 min. Final elongation took place at 72°C for 10 min. For Usp22loxP 
mice, three separate PCR reactions were run in order to determine their Usp22, Apc and Villin-
CreERT2 status. For genotyping PCR samples were pre-heated to 95°C for 3 min. The respective 
DNA fragments were amplified in repeated polymerization cycles and it was allowed for a final 
elongation at 72°C for 10 min. The respective polymerization cycles for Usp22 were: 95°C for 
30 s, 67°C for 30 s, 72°C for 1 min (35 cycles); for APC1638N: 95°C for 30 s, 58°C for 30 s, 72°C 
for 1 min (40 cycles); and for Villin-CreERT2: 95°C for 15 s, 56°C for 15 s, 72°C for 30 s (35 
cycles).  
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2.2.3.3 RNA isolation 
Tissue or cell material was homogenized in TRIzol® and RNA was extracted according to the 
manufacturer’s manual. Briefly, mouse tissues were homogenized in 750 µl TRIzol® or cell 
pellets were resuspended in 500 µl TRIzol® and stored at -20°C overnight. 100 µl chloroform 
was added and samples were vortexed for 15 sec. Samples were spun down at 10,000 rpm 
and 4°C for 20 min and the aqueous phase was mixed with an equal volume of isopropanol. 
After storing samples at -20°C overnight, samples were spun down and the RNA pellet was 
washed in 80% EtOH in DEPC water. After a centrifugation step, the pellets were air-dried at 
room temperature and resuspended in 30 µl DEPC water. 
 
2.2.3.4 RNA gel electrophoresis 
To assess RNA integrity, RNA samples (250-500 ng) were mixed with RNA loading dye 1:10 
in a total volume of 10 µl. Samples were applied onto a 1% agarose gel prepared with TBE 
buffer and run at 100 V for 15 min. RNA integrity was assessed based on the intensity of 18S 
rRNA (approximately 2 kb) and 28S rRNA (approximately 5 kb; should be more intense than 
18S rRNA).  
 
2.2.3.5 cDNA synthesis 
In a total volume of 16 µl 1 μg of total RNA was mixed with DEPC water, 2 μl of 15 μM random 
primers, 4 μl dNTPs (each 2.5 mM) and incubated at 70°C for 5 min. After cooling the samples 
on ice 4 μl transcription master mix (2 μl 10x reaction buffer, 0.25 µl [10 U] RNase inhibitor, 
0.125 µl M-MuLV reverse transcriptase and 1.625 μl DEPC water) was added. cDNA synthesis 
was performed at 42°C for 1 h and terminated at 95°C for 5 min. Finally, samples were diluted 
with DEPC water to a total volume of 200 µl. 
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2.2.3.6 Quantitative Real-Time PCR (qPCR) 
To quantify gene expression levels 3 µl cDNA was added to a master mix containing 14 µl 2x 
qPCR mix, 6.5 µl H2O, and 1.5 µl primers. Samples were quantified based on a standard curve 
prepared from cDNA pools. Initially, cDNA was denatured at 95°C for 2 min. Afterwards, 
amplification took place in 40 polymerization cycles (95°C for 15 s, 60°C for 1 min) and SYBR 
Green I detection took place during a melting curve analysis from 60°C to 95°C with one read 
every 0.5°C. Human samples were normalized to the housekeeping gene 18S rRNA and 
murine samples to 36B4. 
 
2.2.3.7 Luciferase reporter assay 
In order to determine whether the knockdown of USP22 has an effect on Wnt signaling in vitro, 
a luciferase reporter assay was performed as previously described (Hossan et al., 2016). For 
this purpose, 45,000 SW480 and HCT116 cells were seeded per well in triplicates into 24-well 
plates. siRNA-transfections were carried out using Lipofectamine® RNAiMAX according to the 
manufacturer’s protocol. Two days after the knockdown, cells were transfected with Super-
TOP/FOP-FLASH (Veeman et al., 2003) plasmids encoding mutated or wild type TCF/LEF 
binding sites and a firefly- (Photinus pyralis) luciferase reporter construct. In addition, a Renilla-
reporter (Renilla reniformis) was used as a control. Plasmids were complexed with 
Lipofectamine® 2000 for 25 min at room temperature and added to the wells containing 
antibiotics-free medium. 24 h after transfection, cells were washed twice with ice-cold PBS and 
250 µl Passive Lysis Buffer was added per well. After shaking at room temperature for 15 min, 
plates were spun down at maximum speed for 1 min and 50 µl of the supernatant was 
transferred into 96-well Optiplates. All samples were pipetted in triplicates. The luminometer 
was equilibrated with firefly and Renilla buffer. First, chemiluminescence was measured after 
adding 100 µl firefly luciferase solution to the cell, afterwards the same volume of Renilla 
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reagent was measured. For analysis, the average value per triplicate was determined and the 
ratio of the firefly and Renilla signals was calculated to normalize all samples. 
 
2.2.4 Protein biochemistry 
2.2.4.1 Protein isolation 
To isolate proteins, cell pellets or snap-frozen intestines were lysed in ice-cold RIPA buffer 
containing 10 mM N-ethylmaleimide, 10 mM Pefabloc, 1 mM Aprotinin/Leupeptin, 0.1 mM 
Iodoacetamide and 10 mM β-Glycerolphosphate disodium salt hydrate on ice. Afterwards 
samples were sonicated for 10 min to shear genomic DNA.  
 
2.2.4.2 Bicinchoninic acid (BCA) assay 
To determine protein concentrations BCA assay was performed using the PierceTM BCA 
Protein Assay Kit. Solution A and B were mixed in a ratio of 50:1. Subsequently, 5 µl protein 
sample or BSA standard were added and incubated at 37°C for 30 min. Protein concentrations 
were determined spectrophotometrically based on a standard curve.  
 
2.2.4.3 SDS-PAGE and western blot 
To prepare the samples for SDS-PAGE, Laemmli buffer was diluted with the protein lysates in 
a ratio of 1:5 and boiled at 95°C for 5 min. Proteins were separated by SDS-PAGE at 100-200 
V and transferred onto a nitrocellulose membrane at 100 V for 90 min. In order to prevent 
unspecific binding of antibodies, membranes were blocked in 5% milk powder in TBS-T for 30-
60 min. Proteins were detected using specific primary antibodies and horseradish peroxidase-
conjugated secondary antibodies and subsequently visualized using the ChemiDocTM MP 
System. 
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2.2.4.4 Co-Immunoprecipitation (Co-IP) 
Co-IP was performed to detect the direct interaction between USP22 and HSP90. Protein G 
Sepharose (PGS) beads were equilibrated by washing them three times with H2O (spun down 
at 300 rpm, 1 min), and three times with E1A buffer containing protease inhibitors (10 mM N-
ethylmaleimide, 10 mM Pefabloc, 1 mM Aprotinin/Leupeptin, 0.1 mM Iodoacetamide and 10 
mM β-Glycerophosphate disodium salt hydrate). To prevent unspecific DNA binding, beads 
were resuspended in buffer containing salmon sperm DNA in a dilution of 1:10. Beads were 
incubated on a rotator at 4°C for 1 h. To isolate protein 500 µl E1A buffer was added per 10 
cm plate and HCT116 cells were scraped off. Samples were sonicated for 10 min. Next, beads 
were washed 5 times in E1A containing inhibitors and 1:5 of the beads was added to the protein 
sample to clear the lysate at 4°C overnight. The residual beads in E1A were divided into four 
portions to conjugate them with 2 µg of the respective antibodies: (1) USP22 antibody, (2) 
HSP90AB1 antibody, (3) non-specific IgG antibody as a background control and (4) only E1A 
buffer as a negative control. Lysate clearing and antibody binding was performed at 4°C 
overnight. Samples were spun down and the antibody-conjugated beads and the control were 
washed 5 times with E1A. The protein lysate was added in equal portions to the beads and 
one part was boiled in 6x Laemmli buffer as an input control. For protein binding to the 
antibodies samples were incubated further on a rotating device at 4°C overnight. Beads were 
washed 5x with E1A and an equal volume of 2x Laemmli buffer was added. Samples were 
boiled at 95°C for 5 min and stored at -20°C or directly used for western blot analysis. 
 
2.2.5 Next generation sequencing 
2.2.5.1 Microarray using mouse embryonic fibroblasts 
To generate global gene expression data RNA was isolated from MEFs obtained from four wild 
type and four Usp22lacZ/lacZ animals. Quality control of RNA samples as well as microarray 
analyses were performed by the Transcriptome Analysis Laboratory (TAL) Göttingen, 
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Germany. Briefly, the integrity of the input RNA was analyzed using an Agilent BioAnalyzer. 
200 ng of total RNA was reverse transcribed into cDNA which was labelled by a T7 RNA 
Polymerase incorporating cyanine 3-CTP, fluorescent nucleotide analogs. These Cy3-CTP-
labelled cRNA samples were fragmentized and hybridized to 4x44K microarray slides at 65°C 
for approximately 17 hours according to the manufacturer’s protocol. Arrays were washed with 
a 0.005% Triton X-102-containing buffer to reduce the presence of artifacts. Cy3-fluorescence 
of complementary bound probes on the microarray slides was detected and fluorescence 
intensities were quantified and compared amongst samples.  
 
2.2.5.2 mRNA Library Preparation 
Prior to preparing libraries for subsequent mRNA-seq analysis, integrity was confirmed using 
the Bioanalyzer system comparing the ratio of 18S and 28S rRNA fragments. Afterwards, 1 µg 
RNA was processed with the NEXTflex™ Rapid Illumina Directional RNA-Seq Library Prep Kit. 
Briefly, mRNA was purified by Poly(A) magnetic beads and fragmented. First and second 
strand cDNA synthesis was performed and single base overhangs were prepared and adapters 
were ligated to the cDNA. This product was amplified using specific barcode-containing primers 
allowing the subsequent identification of samples. Finally, DNA concentration was determined 
by Qubit® Fluorometer measurement. 16 samples were pooled to a final concentration of 2 nM. 
Sequencing was performed by the TAL using Illumina® HiSeq 2000 sequencers. 
 
2.2.5.3 mRNA-seq data processing 
FASTQ files obtained from the TAL were mapped to the human reference genome (assembly 
hg19) by Bowtie2 using default parameters. The number of reads per sample was determined 
using HTSeq. Subsequently, data were normalized and processed via DESeq2 on the 
statistical software R. Similarities between replicates have been determined using hierarchical 
clustering and PCA plots. For analysis of differentially expressed genes among siControl and 
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siUsp22 samples, following thresholds were defined: BaseMean ≥10, log2fold change ± 0.8, 
padj ≤ 0.05. Heatmaps were generated using R or Morpheus. Gene Ontology analysis was 
performed with the aforementioned threshold values using GOTermFinder and were 
subsequently visualized using REViGO. 
 
2.2.6 Statistical analyses 
All graphs in this study have been designed with GraphPad Prism version 5.04 (GraphPad 
Software, Inc.). P-values were determined using Student’s t-test (***p ≤ 0.001, **p ≤ 0.01, *p ≤ 
0.05.). 
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3. RESULTS 
 
3.1 USP22 is required for proper murine development and lineage specification 
While previous studies defined several deubiquitination and interaction partners of USP22, its 
general role in in vivo remained unclear. Initially, to unravel the general function of USP22 in 
mice, we aimed to determine its sites of expression and to investigate its relevance during 
organ maintenance. Consequently, to investigate both the expression pattern and function of 
Usp22 in vivo, we generated the so-called Usp22lacZ mice. This mouse line has been previously 
characterized in the aforementioned M.Sc. thesis (Kosinsky, 2013) and has recently been 
described by our group (Kosinsky et al., 2015). In the current project we increased the size of 
the experimental mouse cohort in order to confirm previous observations and to identify further 
Usp22-related cellular processes. To determine the expression levels of Usp22 and therefore 
determine the knockout efficiency, brain and small intestines (SIs) were isolated from 4 month-
old mice. Quantitative RT-PCR (qRT-PCR) analysis revealed a significant reduction of Usp22 
expression in both organs; however, approximately 3% of residual correctly spliced mRNA was 
still detectable in mutant animals compared to their wild type littermates (Figure 10A). 
Moreover, an incomplete reduction of USP22 protein levels was observed in western blot 
(Figure 10B). Interestingly, the homozygous expression of this hypomorphic Usp22lacZ allele 
led to a clear growth defect in adult animals at an age of four months; a phenotype which could 
be maintained even after several generations of breedings (Figure 10C). Accordingly, the body 
weight of Usp22lacZ/lacZ mice was significantly reduced as revealed after recording the weight of 
adult animals, as here indicated for males (Figure 10D). In contrast, in heterozygous animals 
the body size and weight were only marginally affected. These findings support our previous 
observations that Usp22-hypomorphic mice are viable but are affected by growth retardation. 
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Figure 10: Generation and phenotype of Usp22-hypomorphic mice. (A) The reduction of 
Usp22 on mRNA and (B) protein level was shown using small intestine and brain material. 
Mean ± SEM, Student's t-test, Usp22wt/wt: n=4; Usp22lacZ/wt: n=5; Usp22lacZ/lacZ: n=4. (C) 
Decreased Usp22 expression results in growth retardation and (D) lower body weight as shown 
for 4-month old male mice. Mean ± SEM, Student's t-test, Usp22wt/wt: n=5; Usp22lacZ/wt: n=9; 
Usp22lacZ/lacZ: n=6 (Kosinsky et al., 2015). 
  
In order to understand the function and the mechanism underlying the phenotype of Usp22-
hypomorphic mice, it is crucial to identify tissues and cell types in which Usp22 is expressed. 
For this purpose, we took advantage of the LacZ reporter gene under control of the 
endogenous Usp22 promoter to determine its spatio-temporal expression pattern during early 
and late stages of embryonic development. So far, the presence of Usp22 expression has only 
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been analyzed in whole tissue lysates or during very early stages of embryonic development, 
i.e. E10.5 and E12.5 (Lee et al., 2006). Beta-galactosidase enzymatic activity and therefore 
endogenous Usp22-promoter activity was visualized in whole mount stainings when the 
substrate X-gal was cleaved and thereby a blue staining was produced. At E10.5 Usp22lacZ/lacZ 
embryos showed strong color development in the skin and also blue staining was detected in 
the brain, spinal cord and intestines (Figure 11A). In order to obtain a better overview of the 
inner organs, we investigated Usp22 expression sites in later stages of development using 
E15.5 embryos. We detected strong staining of the skin in Usp22lacZ/wt and Usp22lacZ/lacZ 
animals, however, inner organs were not visible through the skin (Figure 11B). To overcome 
this problem embryos were cut sagittally and stained a second time for β-galactosidase activity 
(Figure 11C). Afterwards, paraffin sections were prepared and counterstained. Besides in the 
skin, strong staining was detected in connective and muscle tissue (Figure 11D, Table 15). In 
addition, the facial region including tongue, lips and nasal cavity as well as the brain (i.e. frontal 
lobe, cerebral cortex, subventricular zone and ganglionic eminences) were stained. Moreover, 
Usp22 promoter activity was visualized in the heart, lung, kidneys, penis, thymus, bladder, 
pancreas, thyroid and intestinal system. In summary, X-gal staining revealed ubiquitous Usp22 
expression suggesting its relevance during the development of embryonic tissues. 
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Figure 11: Ubiquitous expression of Usp22 in murine embryos. Using X-Gal staining β-
galactosidase activity, and therefore Usp22 expression, was detected in Usp22lacZ embryos at 
(A) E10.5 and (B) E15.5. At E10.5 strong staining of the skin, the spinal cord and inner organs 
was detected. (C) To observe staining intensity in the inner body regions at E15.5, embryos 
were cut sagittally and stained again. (D) Sections were prepared and ubiquitous Usp22 
expression was detected. Scale bar: 2,000 μm (Kosinsky et al., 2015). 
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Table 15: Usp22 levels visualized by X-gal staining in embryonic tissues at E15.5  
(Kosinsky et al., 2015).  
 
Organ Staining intensity Organ Staining intensity 
Front lobe +++ Thyroid ++ 
Cerebellum + Heart ++ 
Cerebral cortex ++ Thymus ++ 
Subventricular zone + Lung +++ 
Midbrain + Liver - 
Hindbrain + Intestinal system +++ 
Ganglionic eminences ++ Pancreas ++ 
Spinal cord + Kidneys +++ 
Nasal cavity +++ Bladder +++ 
Lips +++ Penis +++ 
Tongue +++   
 
As the previous results pointed at an involvement of Usp22 in embryo and tissue development, 
we next investigated the effect of Usp22 expression on organ maintenance in adult mice. For 
this purpose, the gross morphology of small intestines isolated from 4-month old animals was 
evaluated. Swiss rolls were prepared, fixed in formaldehyde and embedded in paraffin. After 
staining sections with H&E, we assessed proximal, intermediate and distal organ segments 
(Figure 12A). Generally, the number of crypts and villi was not affected by the reduction of 
Usp22 levels (data not shown). Moreover, we counted 22 to 24 cells per crypt in all mice by 
analyzing at least 50 crypts per animal (Figure 12B). In addition, we have measured villus 
length which is representative for the approximate cell numbers. In all genotypes, the average 
length per villus was between 264 μm and 266 μm (Figure 12C). In summary, low Usp22 
expression levels do not change the gross morphology of the small intestine. 
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Figure 12: Reduced Usp22 levels do not alter small intestine morphology. (A) Small 
intestine sections were stained with H&E to evaluate the gross organ morphology. Scale bar: 
100 µm. (B) The number of cells per crypt and the (C) villi length were not changed in Usp22-
hypomorphic mice. Mean ± SEM, Student's t-test, Usp22wt/wt: n=3; Usp22lacZ/wt: n=3; 
Usp22lacZ/lacZ: n=3 (Kosinsky et al., 2015).  
 
As described above, we have previously observed that the differentiation pattern in the small 
intestine is affected in Usp22lacZ/lacZ mice (Kosinsky, 2013; Kosinsky et al., 2015). We identified 
a slight increase in the Olfm4-positive stem cells and accordingly more differentiated cells, i.e. 
Goblet, Paneth and enteroendocrine cells. To test the effect of Usp22 loss in another organ 
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system, analyses of the brain were performed in cooperation with Dr. Nicole Hellbach and Prof. 
Dr. Tanja Vogel (Department of Molecular Embryology, Institute of Anatomy and Cell Biology, 
Faculty of Medicine, University of Freiburg, Germany).  
 
Figure 13: Usp22 affects cortical differentiation in the adult mouse brain. (A) Nissl and 
(B) H&E staining on sagittal brain sections revealed a less densely packed cortex in adult 
Usp22lacZ/lacZ mice. Scale bar: 500 µm. (C-E) By IHC progenitor and differentiation markers 
were visualized on coronal cortex sections. While the distribution of TBR2-positive intermediate 
precursor cells in the subventricular zone was unchanged, the density of deep-layer (CTIP2) 
and upper-layer (SATB2) neurons was decreased (Kosinsky et al., 2015). Scale bar: 100 μm. 
CP: cortical plate; SVZ: subventricular zone; V: ventricle.  
 
To evaluate the general brain morphology, H&E and Nissl stainings were performed. While the 
gross brain morphology was unaffected, the total organ size was reduced in Usp22lacZ/lacZ mice 
(Figure 13A, B). Moreover, the cell density in the cerebral cortex was lower in these animals. 
To investigate potential differentiation shifts, the number of progenitors and differentiated cells 
was observed in the subventricular zone as well as deep-layer and upper-layer neurons using 
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immunohistochemistry. Intermediate precursor cells (IPCs) were visualized by staining for T-
Box Transcription Factor 2 (TBR2) in the subventricular zone. We observed that the localization 
and number of IPCs was not significantly affected after the reduction of Usp22 levels (Figure 
13C). Next, differentiated early born deep-layer neurons and later born upper-layer neurons 
were detected by staining for C2H2-Type Zinc Finger Protein (CTIP2) and AT-Rich Sequence-
Binding Protein 2 (SATB2), respectively (Figure 13D, E). Interestingly, in Usp22lacZ/lacZ mice the 
density of CTIP2- and SATB2-positive cells was decreased. These results support our 
observations in the small intestine indicating that Usp22 affects lineage specification and 
differentiation in diverse organ systems. 
  
As reported previously, USP22 is able to deubiquitinate the histone H2B and thereby affect 
transcription (Zhang et al., 2008b). In addition, our group revealed the significance of H2Bub1 
in differentiation processes (Karpiuk et al., 2012). Thus we aimed to investigate whether 
H2Bub1 levels correlated with the differentiation shifts observed in adult mouse organs. For 
this purpose we stained small intestine sections for H2B and H2Bub1 using 
immunohistochemistry. Surprisingly, no difference in the number of positively stained cells, 
their staining intensity or localization was detected (Figure 14) suggesting that the effects of 
USP22 on differentiation are independent of its ability to deubiquitinate H2B. 
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Figure 14: H2B and H2Bub1 levels are not affected by reduced USP22 amounts in the 
small intestine. H2B and H2Bub1 levels have been visualized by immunohistochemistry on 
small intestine sections. Reduced USP22 levels did not result in altered staining intensities, 
numbers of positively stained cells or in changed localization of H2B/H2Bub1-positive cells 
(Kosinsky et al., 2015). Scale bar: 100 μm.  
 
To investigate the function of Usp22 in detail, we isolated mouse embryonic fibroblasts (MEFs) 
from eight individual embryos to perform subsequent gene expression analyses. RNA was 
isolated from four Usp22wt/wt and four Usp22lacZ/lacZ MEF samples and microarray-based 
profiling was carried out at the Transcriptome and Genome Analysis Laboratory (TAL), 
Göttingen, Germany. The variance between the four animals per genotype was assessed by 
hierarchical clustering and replicates were compared in a heatmap. As expected, the variance 
between the individual animals was rather high (Figure 15A). While Usp22lacZ/lacZ samples 
clustered together, there was a relatively high variation among wild type samples. Furthermore, 
we compared the variance in differentially regulated genes with high fold changes (log2fold 
change ± 0.8, padj <0.05) using the Morpheus tool. Despite the evident heterogeneity among 
the replicates, several differentially expressed genes were identified as depicted in the 
heatmap (Figure 15B). 
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Figure 15: Quality control of MEFs used for microarray analysis. (A) Hierarchical clustering 
of replicates reveals the heterogeneity of murine material. (B) Heatmap generating with the 
Morpheus tool displaying all replicates and their expression for genes with a high fold change 
(log2fold change ± 0.8, padj <0.05). Each row represents a single gene. Expression varies 
between replicates but the overall tendency was similar. The color code indicates the relative 
minimum (min) and maximum (max) expression value per gene. 
 
To investigate biological processes affected by the loss of Usp22 in MEFs, microarray data 
were subjected to gene ontology (GO) analysis, i.e. by GOTermFinder (Princeton University, 
Lewis-Sigler Institute) and the GO visualization tool REViGO (Supek et al., 2011). As expected, 
there was a significant enrichment in GO terms involved in developmental processes, 
proliferation and differentiation (Figure 16, Table 16). These findings support our in vivo data 
which revealed growth retardation in adult Usp22lacZ/lacZ mice and differentiation shifts in organs.  
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Figure 16: Gene Ontology analysis of genes affected by reduced Usp22 expression in 
MEFs. Summary of enriched GO terms after analyzing differential regulated genes (log2fold 
change ± 0.8, p-value <0.05) in Usp22lacZ/lacZ MEFs using the GO visualization tool REViGO. 
Analysis revealed association with development-, proliferation- and differentiation-associated 
processes.  
 
In summary, the Usp22lacZ mouse line enabled us to investigate the function of Usp22 in murine 
development and organ maintenance. Staining for β-galactosidase activity revealed ubiquitous 
Usp22 expression in the majority of murine embryonic tissues. As a consequence, reduced 
Usp22 levels result in systemic repercussions in adult mice, i.e. growth retardation and 
consistently reduced body weight. While the morphology of the small intestine and brain were 
only marginally changed, the cell differentiation pattern was altered in these organs. 
Interestingly, these phenomena seem to be independent of H2B monoubiquitination. Using 
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microarray-based gene expression and GO analyses in MEFs, we were able to confirm the 
involvement of Usp22 in developmental and differentiation processes. 
 
Table 16: GO terms enriched in Usp22lacZ/lacZ MEFs as revealed by GOTermFinder. 
Term ID Gene Ontology term 
Cluster 
frequency 
Corrected  
p-value 
FDR 
GO:0032502 Developmental process 36.9% 0.00000846 0 
GO:0044767 Single-organism developmental process 36.9% 0.0000038 0 
GO:0048856 Anatomical structure development 35.9% 0.000000982 0 
GO:0007275 Multicellular organism development 33.4% 0.000000453 0 
GO:0048731 System development 29.7% 0.00000471 0 
GO:0048869 Cellular developmental process 27.8% 0.00018 0 
GO:0030154 Cell differentiation 26.5% 0.0000724 0 
GO:0051239 
Regulation of multicellular organismal 
process 
20.4% 0.00011 0 
GO:0009653 Anatomical structure morphogenesis 20.1% 0.0000509 0 
GO:0048468 Cell development 16.0% 0.00361 0 
GO:0008283 Cell proliferation 14.3% 0.00699 0 
GO:0009888 Tissue development 13.8% 0.00905 0 
GO:0042127 Regulation of cell proliferation 12.5% 0.00334 0 
GO:0030182 Neuron differentiation 11.3% 0.00665 0 
GO:0060429 Epithelium development 11.1% 0.0001 0 
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3.2 The role of USP22 in colorectal tumorigenesis in vivo 
After investigating the function of USP22 in organ maintenance and differentiation, we aimed 
to elucidate the effect of USP22 loss on colorectal cancer formation and progression in vivo. 
This project was based on the hypothesis that an Usp22 loss lowers tumor burden since it was 
described that USP22 is overexpressed in CRC and further malignancies. For this purpose, 
we generated a mouse line which is based on the aforementioned Usp22lacZ animals. The 
‘knockout first’ allele contains FLP recombinase target (FRT) sequences which are recognized 
by flippase (FLP) recombinase. After crossing Usp22lacZ animals to transgenic FLP mice the 
lacZ sequence and neomycin-resistance cassette were excised leaving loxP-sites flanking 
exon 2 of the Usp22 gene (Figure 17A). Thereby the allele was converted to a conditional 
knockout allele based on the Cre/loxP system restoring Usp22 gene activity. These mice were 
crossed with Villin-CreERT2 mice in which the Cre-recombinase is fused to a mutated Tamoxifen-
inducible estrogen receptor ligand binding domain (ERT2) (el Marjou et al., 2004). By 
intraperitoneal Tamoxifen injections an Usp22 loss can be induced in the small intestine and 
to a lesser extent in the colon. In order to promote colorectal tumorigenesis mice were crossed 
with APC1638N mice. This mutation in the tumor suppressor results in a globally truncated APC 
protein as frequently observed in human colorectal cancers. Thus, for this project we analyzed 
six genotypes; APC+/+ or APC1638N/+ each with Usp22 wild type, heterozygous or knockout 
status (hereafter referred to as Usp22+/+, Usp22+/- or Usp22-/-; Table 17). To determine the 
genotypes, genomic DNA was isolated from tail biopsies. Finally, after using specific primers 
for conventional PCR, DNA fragment sizes were evaluated (Figure 17B; Usp22 wt: 322 bp, 
loxP: 470 bp; APC wt: 178 bp, 1638N: 347 bp; Villin positive: 220 bp). Initially, to determine the 
knockout efficiency, APC+/+ mice were injected with Tamoxifen at an age of 4 weeks for 5 
consecutive days and Usp22 mRNA levels were determined 4 weeks later. Using qRT-PCR 
we detected a decrease of Usp22 levels by approximately 96% in intestinal epithelial cells 
Results 
89 
 
(Figure 17C). A corresponding decrease on protein level was confirmed by western blot 
analysis (Figure 17D).  
 
Figure 17: Generation of mice with a conditional intestinal Usp22 knockout. (A) In Villin-
CreERT2 positive, APC1638N/+ mice the second exon of the Usp22 gene was flanked by loxP-
sequences. This allowed an intestine-specific and Tamoxifen-inducible deletion of Usp22. (B) 
By conventional PCR, genotypes were determined based on DNA fragment sizes (Usp22 wt: 
322 bp, loxP: 470 bp; APC wt: 178 bp, 1638N: 347 bp; Villin-CreERT2 positive: 220 bp). (C) 
Usp22 mRNA levels were reduced by 96% in Usp22-/- mice. Mean ± SEM, Student's t-test, 
n=5. (D) Accordingly USP22 protein levels were decreased after Tamoxifen treatment. (E) DSS 
treatment time points to cause inflammation-induced CRC. Colitis was induced either after 
(group 1; Tam-DSS) or prior to Usp22 knockout (group 2; DSS-Tam). Additionally, a group for 
sporadic CRC (group 3; Tam) without DSS treatment has been studied.   
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After demonstrating that the knockout efficiency was sufficient, we divided the mice into three 
experimental cohorts (Figure 17E). The first cohort (Tam-DSS) reflected the situation of colitis-
induced colorectal cancer. For this purpose, the knockout of Usp22 was induced and mice 
were treated with DSS to induce colitis afterwards. In the second experimental group (DSS-
Tam) colitis was induced as well, however, in contrast to the first group, DSS-treatment was 
performed prior to the loss of Usp22. The last cohort (Tam) was only treated with Tamoxifen 
and therefore represented a model for sporadic CRC formation. In the following sections these 
mouse cohorts and the corresponding experimental outcomes will be explained in detail.  
 
Table 17: Mouse numbers per experimental cohort used throughout the study to 
determine the function of USP22 in colorectal tumorigenesis. 
 
  APC+/+   APC1638N/+  
 Usp22+/+ Usp22+/- Usp22-/- Usp22+/+ Usp22+/- Usp22-/- 
Tam-DSS 8 10 13 16 13 9 
DSS-Tam 10 6 5 7 6 4 
Tam 15 14 8 9 8 7 
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3.2.1 Inflammation-induced CRC: Intestinal Usp22 deletion prior to colitis (Tam-DSS) 
3.2.1.1 Intestinal Usp22 loss shortens survival and increases intestinal tumor burden 
When starting this project we aimed to utilize a mouse model in which tumorigenesis was not 
promoted by an APC mutation alone, but also by colitis. For this purpose, experimental mice 
used to observe inflammation-induced CRC (treatment group 1: Tam-DSS) were injected with 
Tamoxifen at an age of 4 weeks to induce the intestine-specific Usp22 knockout. When the 
animals were 10 weeks old and could physically withstand the burden of colitis we started the 
DSS treatment. We initially administered 2% of the chemical agent DSS dissolved in drinking 
water for 7 days. However, we observed strong intestinal bleedings, severe diarrhea and 
subsequent death in several mice. Therefore, we decided to reduce the load by treating the 
animals with 2% DSS for 4 days, feed them with mush food supplemented with glucose for 7 
days and continue the DSS treatment for 3 further days. Thus, DSS treatment was terminated 
when the animals were 12 weeks old. The animal weight, stool consistency and the presence 
of occult blood was recorded daily from the first day of DSS supplementation until 1 week after 
terminating the treatment. Despite the reduced burden we observed increased weight loss 
(Figure 18A), intestinal bleedings (Figure 18B) and severe diarrhea (data not shown) in 
APC1638N/+, Usp22-/- animals. These parameters were scored to determine the disease activity 
index (DAI). In both groups, APC wild type and heterozygous, mice with Usp22 loss were 
characterized by the highest DAI (Figure 18C). Surprisingly, shortly after the DSS treatment 
APC1638N/+, Usp22-/- mice died at the age of approximately 12-20 weeks (Figure 18D). Their 
APC1638N/+, Usp22+/+ and Usp22+/- littermates were characterized by longer survival (Usp22+/+: 
25-54 weeks, Usp22+/-: 28-39 weeks). In contrast, life expectancy of APC+/+ animals was only 
marginally affected. We found blocked intestines due to intussusceptions or prolapses to be 
the primary causes of death in APC1638N/+, Usp22-/- mice. For further analyses the intestinal 
system was isolated. Notably, the colon length was significantly decreased in APC1638N/+, 
Usp22-/- mice (Figure 18E) indicating strong inflammatory processes (Nordgren et al., 1997). 
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Figure 18: Simultaneous loss of Usp22 and APC mutation lowers life expectancy and 
increases the DAI in Tam-DSS mice. After starting the DSS treatment health parameters 
were recorded daily. APC1638N/+, Usp22-/- mice showed (A) increased weight loss, (B) intestinal 
bleedings and (C) a high average DAI. (D) An APC truncation mutation lead to decreased 
survival. In comparison to Usp22 wild type and heterozygous animals, upon deletion of Usp22, 
life expectancy was significantly shortened animals. (E) After sacrifice these mice were 
characterized by significantly shorter colons. Mean ± SEM, Student's t-test, n-numbers 
indicated in Table 17. 
After sacrificing the mice we checked for metastases and physical abnormalities. While no 
metastases were detected, increased spleen size was observed in APC1638N/+ animals but did 
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not correlate with the Usp22 status (data not shown). The intestines were washed and 
measured. Moreover, tumor locations as well as tumor sizes were recorded. Due to the 
induction of colitis via DSS treatment, intestinal tumors were found in nearly all animals (Figure 
19A, B). In addition, as expected, the truncated APC protein correlated with promoted 
tumorigenesis. While APC+/+ mice had on average 0-7 tumors in the colon and 0-16 in the SI, 
APC1638N/+ mice showed the presence of approximately 0-33 tumors in the colon and 2-129 in 
the SI, respectively. To our surprise, the total number of intestinal tumors was especially 
elevated upon the loss of Usp22. In APC+/+ animals with Usp22 wild type or heterozygous 
status, the tumor number was slightly lower in the colon compared to Usp22-/- animals. In the 
SI the difference among the APC+/+ mice was not significant. In contrast, in the APC1638N/+ 
cohort Usp22-/- animals developed significantly more tumors in the colon and SI compared to 
their Usp22 wild type and heterozygous littermates. In fact, tumors were not only more frequent 
in APC1638N/+, Usp22-/- mice but also characterized by their increased size (Figure 19C, D). The 
ratio of tumors with a greater surface area than 2 mm2 was significantly increased in APC1638N/+, 
Usp22-/- animals. To summarize, in contrast to previously published reports which our 
hypothesis was based on, we observed that Usp22 loss did not only reduce survival but it also 
significantly increased tumor burden in inflammation-induced CRC. 
 
Results 
94 
 
 
Figure 19: Reduced Usp22 levels significantly elevate intestinal tumor burden. In (A) 
colon and (B) small intestine loss of Usp22 leads to increased tumor numbers in both, APC+/+ 
and APC1638N/+ mice. (C, D) Apart from tumor frequency, tumor size was elevated in Usp22-/- 
mice. Mean ± SEM, Student's t-test, n-numbers indicated in Table 17. 
 
Generally, the intestinal system is divided into several segments with distinct properties and 
structural features. Moreover, the activity of the Villin promoter decreases from the proximal to 
the distal intestinal region which can affect the sites of tumor formation as well. Thus, the 
relative tumor location within the intestinal system was determined. For this purpose, the small 
intestine and colon were always dissected in the same manner and the tumor distance from 
the left side and the bottom of the organ was determined. Per genotype the tumor locations of 
five animals with representative tumor numbers were depicted. As mentioned before, in APC+/+ 
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mice the tumor number is slightly elevated after the loss of Usp22, however, their distribution 
is similar to Usp22+/+ littermates (Figure 20). In contrast, in the presence of an APC mutation 
the deletion of Usp22 leads to an accumulation of tumors in the proximal region of the small 
intestine.  
 
Figure 20: Usp22 loss results in the accumulation of tumors in the proximal SI region. 
Relative tumor locations from five mice per genotype with representative tumor numbers were 
depicted. APC1638N/+, Usp22-/- mice were characterized by an accumulation of tumors in the 
proximal region of the small intestine. 
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After measuring tumor size and location, intestines were fixed in formaldehyde and embedded 
in paraffin. Swiss rolls were prepared to obtain an overview of all regions of the SI and colon. 
Afterwards, sections were stained with H&E to visualize organ structures. For morphological 
studies, we selected the distal third of the small intestine. Generally, the gross morphology of 
the SI did not vary among genotypes (Figure 21). In APC+/+ colons the organ structure was 
mainly unaffected. Conversely, due to a heterozygous APC mutation, the number of tumors 
was strongly increased and therefore the organ integrity destroyed.  
 
Figure 21: Morphological overview of small intestines and colons. Small intestine and 
colon sections were stained with H&E and images were prepared to get a morphological 
overview. Only marginal differences were detected in small intestines among genotypes. In 
colons of APC1638N/+ mice tumors disturb organ integrity. Scale bar: 1,000 µm.  
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3.2.1.2 Usp22 ablation is associated with inflammation and invasive carcinomas 
Based on these H&E sections we decided to analyze the morphology of the small intestine in 
more detail. For this purpose we selected healthy SI segments without the presence of MALTs, 
tumors, etc. (Figure 22A). First, we counted the number of crypts per 100 µm. In all mice 1-2 
crypts per 100 µm were detected, however, crypts of Usp22-/- mice were slightly narrower 
(Figure 22B). The number of cells per crypt (approximately 20 to 25) did not differ significantly 
among genotypes (Figure 22C). Similar to the number of crypts, the amount of villi present per 
100 µm was comparable but slightly decreased in Usp22-/- animals (Figure 22D). In contrast, 
the villi length, representative for the approximate number of cells per villus, did not vary 
significantly (Figure 22E).  
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Figure 22: Conditional intestinal loss of Usp22 does not affect small intestine 
morphology. (A) To evaluate small intestine morphology more in detail, H&E-stained sections 
were assessed. Scale bar: 100 µm. (B) There was no difference among genotypes when 
comparing the number of crypts per 100 µm and (C) cells per crypt. (D) The number of villi per 
100 µm as well as the (E) villi length was not changed. Mean ± SEM, Student's t-test, n-
numbers indicated in Table 17. 
  
Results 
99 
 
In addition, we observed the morphology of the colon in these mice (Figure 23A). It must be 
mentioned that the rate of intact colon segments was reduced in APC1638N/+ mice due to the 
high tumor frequency. However, at least 50 crypts from different organ regions were evaluated. 
On average two crypts were detected per 100 µm in all mice (Figure 23B). Moreover, the crypts 
were characterized by a depth of approximately 150 to 200 µm (Figure 23C). Taken together, 
the morphology and integrity of the small intestine as well as the colon was only marginally 
affected by the loss of Usp22. 
 
Figure 23: The morphology of healthy colon segments is not affected by reduced Usp22 
expression. (A) Colon morphology was evaluated on H&E-stained sections in intact organ 
regions. Scale bar: 100 µm. (B) In intact colon segments the number of crypts per 100 µm and 
(C) crypt length did not differ among genotypes. Mean ± SEM, Student's t-test, n-numbers 
indicated in Table 17. 
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Besides determining the tumor number/location and the morphology of healthy intestinal 
structures, tumors were also evaluated based on their aggressiveness. Generally, during 
progression tumors can accumulate mutations influencing their growth characteristics (Fearon 
and Vogelstein, 1990). Once a tumor spreads beyond the inner muscular lining of the colon, 
the muscularis mucosae, it becomes invasive. We assessed H&E-stained colon sections for 
this phenomenon and could indeed detect several occurrences (Figure 24A).  
 
Figure 24: Invasive carcinomas are exclusively present in Usp22-/- mice. (A) H&E-stained 
colon sections were assessed for the presence of invasive carcinomas which migrate though 
the muscularis mucosae as shown for Usp22-/- mice. (B) Invasive carcinomas were only found 
in Usp22-/- animals, in both APC+/+ and APC1638N/+ background. (C) Compared to the total tumor 
number in the colon the average abundance of invasive carcinomas was approximately 20% 
higher in Usp22-/- mice. Mean ± SEM, Student's t-test, n-numbers indicated in Table 17. 
 
Interestingly, invasive tumors were exclusively found in Usp22-/- animals (Figure 24B), 
independent of the APC status. In total, the number of invasive tumors was higher in the APC 
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mutated mice, however, when taking the total tumor number into account, the percentage of 
invasive tumors was similar in Usp22-/- animals with APC+/+ and APC1638N/+ status (Figure 24C). 
This finding clearly demonstrates that not only the tumor number is elevated after Usp22 loss 
but also their tumor aggressiveness is higher leading to a higher probability of metastasis. 
 
While analyzing H&E-stained colon sections we detected mucus accumulations in several 
animals. Generally, these mucus cysts were present below the lamina muscularis mucosae as 
encapsulated structures within the muscle layer (Figure 25A). Even extremely large cysts were 
always surrounded by muscle tissue (black arrowhead). Interestingly, besides these mucus 
cysts, in Usp22-/- mice carcinomas with a mucinous appearance were detected sporadically. In 
these lesions not only encapsulated cysts (yellow arrowhead) as shown in the first two images 
were present but also mucus accumulations surrounded by epithelial cells (red arrowhead). 
Notably, these mucus accumulations and tumors with a mucinous appearance were 
predominantly detected in Usp22 knockout animals (Figure 25B). Moreover, we noticed that 
Usp22-/- animals were characterized by a high frequency of MALTs (Figure 25C). As a crucial 
component of the mucosal immunity, mucosa-associated lymphoid tissues are routinely found 
in the intestine; however, their high abundance could result from an increased anti-
inflammatory response due to colitis. Colon sections were evaluated and an increased MALT 
frequency was detected in Usp22-/- mice while it could only be found sporadically in Usp22 wild 
type and heterozygous animals. This finding was independent from the APC status. These 
results reveal increased lymphocyte accumulation rates after the loss of Usp22 and 
interestingly, also a mucinous phenotype. 
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Figure 25: Mucinous presentation and elevated frequency of MALTs in Usp22-/- colons. 
(A) Mucus cysts of different sizes were found in several animals and were frequently 
surrounded by muscle tissue (black arrow). In Usp22-/- colons carcinomas with a mucinous 
appearance were present which contain cysts surrounded by muscle tissue (yellow arrow) or 
by epithelial cells (red arrow). Scale bar: 200 µm. (B) These mucus cysts were predominantly 
found in Usp22-/- mice. (C) To assess the presence of immune defense-associated lymphoid 
aggregates, MALTs have been counted in H&E-stained colon sections. An elevated 
abundance of MALTs was detected after the loss of Usp22. Mean ± SEM, Student's t-test, n-
numbers indicated in Table 17. 
 
Based on these findings, the inflammatory response upon DSS treatment was investigated in 
more detail. A well-accepted method to evaluate the inflammation based on H&E staining is 
the determination of the Histo-score (H-score). The scoring system is based on the intactness 
of the colonic epithelium and lymphocyte infiltration. It ranges from 0 to 3 (Figure 26A) 
considering normal epithelium (score 0), mild inflammation in which lymphocyte infiltration 
pushed crypts apart (1), lymphocytes accumulations interfering with crypt structure (2) and 
crypt integrity which is destroyed by lymphocytes and where the epithelial lining (black  
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Figure 26: High occurrence of inflammation-associated epithelial damage in Usp22-/- 
animals. (A) Inflammation-associated alterations of the epithelium were assessed on H&E-
stained colon sections. Analyses were based on the H-score ranging from 0 to 3 reflecting 
increasing degrees of epithelial damage. During severe inflammation the epithelial lining (black 
arrowhead) is destroyed. Scale bar: 100 µm. (B) The loss of Usp22 was associated with 
severely inflamed intestinal epithelium. Scale bar: 200 µm. (C) Usp22-/- animals were 
characterized by higher H-scores (D) caused by many segments with mild (1), medium (2) or 
severe (3) damage. Mean ± SEM, Student's t-test, n-numbers indicated in Table 17. 
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arrowhead) on top is absent (3). We calculated the H-score and found inflammation in the 
majority of mice due to the DSS treatment. In both groups, APC+/+ and APC1638N/+, there were 
only marginal differences between Usp22 wild type and heterozygous animals. Notably, in both 
these groups, Usp22-/- mice were characterized by a high proportion of epithelium showing 
medium to severe signs of inflammation (Figure 26B). Accordingly, we detected significantly 
elevated H-scores (Figure 26C) due to an increased rate of severely damaged tissue (Figure 
26D). In summary, even several weeks after ending the DSS treatment colons of Usp22 
knockout mice were partially inflamed in contrast to the Usp22 wildtype and heterozygous 
animals which showed overall less inflammation.  
 
Finally, we aimed to evaluate H2Bub1 levels in healthy colon epithelium and tumors. For this 
purpose, Tam-DSS colon sections were stained for H2Bub1 by immunohistochemistry. As 
expected, the finding was similar to our observations made in Usp22lacZ small intestine 
sections. We did not see any differences in H2Bub1 levels in normal colon crypts (Figure 27A). 
In contrast, H2Bub1 levels in colorectal tumors were highly heterogeneous. While cells were 
positively stained in some tumor regions, especially poorly differentiated areas were 
characterized by the absence of H2Bub1 (Figure 27B). Thus, our previous findings obtained 
from this cohort seem to be independent of H2Bub1 levels. 
To sum up, in the first cohort of experimental mice (Tam-DSS) we assessed the effect of Usp22 
on colitis and subsequent formation of intestinal tumors. Interestingly, shortly after finishing the 
DSS treatment, APC1638N/+, Usp22-/- animals died. To our surprise, wild type Usp22 expression 
attenuated tumor growth while tumor burden and the presence of invasive tumors were 
exacerbated by Usp22 knockout. Notably, in Usp22-/- mice severe inflammation was detected 
even several weeks after DSS treatment and the colon as well as some tumors were 
characterized by a mucinous phenotype. 
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Figure 27: H2Bub1 levels are independent of the Usp22 status but show intratumoral 
variations. (A) Immunohistochemistry was performed for H2Bub1 on healthy colon segments 
and the number of positive cells, their localization and staining intensity was independent of 
the Usp22 status. Scale bar: 100 µm. (B) The intratumoral H2Bub1 distribution was highly 
diverse. While in the healthy epithelium H2Bub1 was detected, its levels decreased in poorly 
differentiated tumor regions. Representative photo of an APC1638N/+; Usp22-/- colon tumor. Scale 
bar: 200 µm. 
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3.2.2 Inflammation-induced CRC: Colitis prior to intestinal Usp22 deletion (DSS-Tam) 
3.2.2.1 Inducing colitis prior to Usp22 loss reduces tumor and inflammation burden 
In the first mouse cohort (Tam-DSS) we induced the Usp22 knockout prior to DSS treatment 
to observe how inflammation and subsequent tumor formation were affected by the absence 
of Usp22. In a second cohort for inflammation-associated CRC (treatment group 2: DSS-Tam), 
colitis was induced at an age of 10 weeks followed by an Usp22 knockout after a short recovery 
period. In this group we avoided the possibility that mice react differently to DSS treatment due 
to their genetic background which in turn could have affected tumorigenesis. Health-related 
parameters were recorded weekly at the onset of DSS administration until three weeks after 
Tamoxifen injection. Surprisingly, body weight was only marginally affected by induction of 
colitis (Figure 28A) while mild intestinal bleedings were observed in all animals (Figure 28B). 
Diarrhea was rarely observed (data not shown) and the disease activity index was comparable 
among all genotypes (Figure 28C). Similar to our previous findings, APC1638N/+, Usp22-/- mice 
were characterized by decreased survival rates (Figure 28D). However, compared to 
APC1638N/+ mice with Usp22 wild type or heterozygous status, this finding was not statistically 
significant. After sacrificing the experimental animals, we could not detect any differences in 
the colon length (Figure 28E). 
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Figure 28: Usp22 loss after DSS treatment does not affect the DAI but decreases survival 
rates. (A) Body weight and (B) bleeding intensity were recorded regularly and did not differ 
among genotypes. (C) The average DAI was similar for all animals. (D) Survival rates were 
decreased for Usp22-/- mice independent of the APC status. (E) Colon length was similar in all 
mice. Mean ± SEM, Student's t-test, n-numbers indicated in Table 17. 
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Similar to our aforementioned approach in Tam-DSS mice, we counted and measured all 
intestinal cancer lesions. Consistent with our previous observations, we could detect elevated 
tumor burden in Usp22-/- animals (Figure 29A, B). While the effect was only minimal in the 
APC+/+ cohort, the tumor burden was obviously increased in APC1638N/+ mice with an Usp22 
loss. Furthermore, tumors found in APC1638N/+, Usp22-/- mice were bigger than the cancer 
lesions present in their littermates (Figure 29C, D). 
 
Figure 29: Elevated tumor frequency and size in DSS-Tam APC1638N/+, Usp22-/- mice. 
Tumors were counted in the (A) colon and (B) small intestine. There were only marginal effects 
among APC+/+ mice while the frequency of cancer lesions was increased in APC1638N/+, Usp22-
/- mice compared to the other APC1638N/+ animals. (C, D) The loss of Usp22 in an APC1638N/+ 
background resulted in the formation of intestinal tumors with enlarged sizes. Mean ± SEM, 
Student's t-test, n-numbers indicated in Table 17. 
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Finally, we compared the tumor location within the intestinal system. In the Tam-DSS mouse 
cohorts we could observe an accumulation of cancer lesions in the proximal and medial 
segment of the small intestine. In this cohort, even though the total tumor number was lower, 
a similar tendency was demonstrated (Figure 30). 
 
Figure 30: Tumors tend to accumulate in the proximal/medial SI segment of DSS-Tam 
animals. Relative tumor locations from five mice per genotype with representative tumor 
burden were visualized. There is a tendency that tumors accumulate in the proximal/medial 
region of the small intestine.  
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Furthermore, we assessed whether the inflammation burden of the DSS-Tam cohort is 
comparable to the Tam-DSS group. Colon sections were stained with H&E and a slight 
increase in lymphocyte infiltration was observed (Figure 31A). The corresponding H-scores 
were found to be increased in animals with an intestinal Usp22 deletion (Figure 31B) because 
of more damaged epithelial regions (Figure 31C).  
 
Figure 31: Usp22 ablation increases inflammation in DSS-Tam mice. (A) H&E-stained 
colon sections obtained from DSS-Tam mice were assessed for signs of inflammation. Usp22 
knockout mice showed increased epithelial damage and lymphocyte infiltration. Scale bar: 100 
µm. (B) Usp22-/- animals were characterized by increased H-scores because of (C) more 
severe inflammation. Mean ± SEM, Student's t-test, n-numbers indicated in Table 17. 
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Summing up, induction of colitis with DSS prior to Usp22 deletion led to a similar phenotype 
regarding survival, tumor number and location as in Tam-DSS mice. However, tumor and 
inflammation burden were less severe in DSS-Tam animals compared to Tam-DSS mice. 
These findings suggest that Usp22 loss prior to DSS treatment exacerbates symptoms of colitis 
and resulting tumor burden. 
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3.2.3 Intestinal Usp22 deletion in a model of sporadic CRC (Tam) 
3.2.3.1 Intestinal Usp22 deficiency promotes sporadic colorectal tumorigenesis 
Since we could observe extreme consequences in our murine models for inflammation-induced 
colorectal cancer, we aimed to observe the effects of Usp22 on sporadic CRC formation 
(treatment group 3: Tam). Animals were injected with Tamoxifen at an age of 4 weeks and no 
DSS was administered. Parameters to determine the disease activity index were recorded 
weekly. The maximum weight loss was determined from the time point of Tamoxifen injection 
till sacrificing the animals and was similar in all mice. Generally, the body weight fluctuated 
minimally (Figure 32A). Sporadic presence of occult blood was detected in all animals and did 
not differ among genotypes (Figure 32B). Consistently, the disease activity index was 
comparable among all groups (Figure 32C). In APC1638N/+, Usp22-/- only a slight increase in 
intestinal bleeding intensity and DAI was observed. Approximately 14-33 weeks after 
Tamoxifen injection APC1638N/+, Usp22-/- mice died. APC1638N/+ mice with Usp22 wild type (aged 
22-64 weeks) or heterozygous state (27-71 weeks) survived significantly longer (Figure 30D). 
In contrast, compared to the truncated APC protein, APC wild type status clearly prolonged 
overall survival. In the APC+/+ animals we observed that mice with depleted Usp22 had the 
shortest life expectancy. This observation seemed to be independent from the induction of 
colitis, though DSS treatment resulted in earlier lethality (Figures 18D and 28D). Similar to the 
DSS-treated cohort APC1638N/+, Usp22-/- mice were characterized by decreased colon lengths 
(Figure 32E). 
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Figure 32: Usp22 loss alone results in decreased survival. (A) Weight loss, (B) bleeding 
intensity or (C) average DAI were barely influenced by Usp22 loss alone. (D) Upon Tamoxifen 
injection accelerated lethality was observed in Usp22-/- mice. (E) Colon length appeared to be 
decreased in APC1638N/+, Usp22-/- animals. Mean ± SEM, Student's t-test, n-numbers indicated 
in Table 17. 
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After sacrificing the mice, we followed the same procedure as described before. Again no 
metastases were detected and APC1638N/+ mice were characterized by increased spleen sizes 
(data not shown). As expected, the absence of colitis resulted in decreased tumor burden while 
the truncated APC protein in APC1638N/+ animals correlated with promoted intestinal 
tumorigenesis (Figure 33A, B). On average APC+/+ animals had 0-1 tumors in the colon and 5-
8 in the SI, while 1-5 tumors were found in the colon and 15-85 in the SI of APC1638N/+ mice. 
The majority of APC+/+ animals with Usp22 wild type or heterozygous status was characterized 
by the absence of tumors in the colon while Usp22-/- animals possessed 0-2 cancer lesions. In 
the small intestine of APC wild types the loss of Usp22 did not show any effects regarding the 
tumor number. In APC1638N/+ background Usp22-/- animals were characterized by significantly 
more oncogenic growth in the colon and SI than Usp22+/+ mice. Remarkably, in APC1638N/+, 
Usp22-/- mice the tumor frequency in the small intestine was surprisingly high and comparable 
to the DSS-treated cohort. In the SIs of these animals 40-112 tumors were detected. Similar to 
the DSS-treated groups, the rate of tumors with a surface area higher than 2 mm2 was 
significantly increased in APC1638N/+, Usp22-/- animals (Figure 33C, D). Altogether these results 
demonstrate that the loss of Usp22 significantly increases sporadic CRC formation even 
without preceding colitis. 
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Figure 33: Usp22 loss leads to increased sporadic intestinal tumor formation. Reduced 
Usp22 expression, especially when combined with an APC mutation, results in increased tumor 
growth in (A) colon and (B) small intestine. (C, D) Partial or complete Usp22 ablation in 
APC1638N/+ background results in the growth of bigger tumor lesions compared to Usp22 wild 
type animals. Mean ± SEM, Student's t-test, n-numbers indicated in Table 17. 
 
Tumor location was documented and similar to the DSS-treated animals there was an 
accumulation of tumors in the proximal region of the small intestine in APC1638N/+, Usp22-/- mice. 
However, while tumors were mainly detected in the proximal section in the DSS-cohort, tumor 
growth was extended to the medial segment in case of the Tam cohort (Figure 34). In Usp22 
heterozygous mice, the tumor distribution was comparable to Usp22-/- littermates. 
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Figure 34: Sporadic CRC lesions accumulate in the proximal and medial SI region in 
APC1638N/+, Usp22-/- mice. Relative tumor sites from five mice per genotype with representable 
tumor burden were depicted. Tumors were clustered in the proximal and medial segments of 
the small intestine of APC1638N/+, Usp22+/- and Usp22-/- animals. 
 
Finally, we assessed on H&E-stained colon section whether Usp22 ablation alone resulted in 
inflammation. Indeed, we observed several areas displaying lymphocyte infiltration and 
damaged epithelial sections in Usp22-/- mice (Figure 35A). Accordingly, the H-score was 
elevated in these animals (Figure 35B) due to a higher percentage of inflammation-associated 
epithelial damage (Figure 35C). 
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Figure 35: Usp22 loss causes mild spontaneous inflammation. (A) Intestinal Usp22 
knockout without additional DSS treatment results in mild intestinal inflammation as revealed 
by H&E staining on colon sections. Scale bar: 100 µm. (B) H-scores of Usp22-/- animals were 
slightly increased due to (C) more epithelial regions affected by inflammation-associated 
damage. Mean ± SEM, Student's t-test, n-numbers indicated in Table 17. 
 
Altogether, we could demonstrate that in APC1638N/+, Usp22-/- mice, the survival is significantly 
decreased and tumor burden increased in a sporadic model for CRC. Moreover, Usp22 loss 
alone was sufficient to induce mild spontaneous inflammation.  
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3.2.4 Intestinal Usp22 deletion prior to colitis results in the worse prognosis 
After these insightful in vivo approaches, the effect of Usp22 loss in the three different treatment 
set-ups was to be determined in order to investigate the different aspects of the role of Usp22 
in tumorigenesis. First, we investigated how a loss of Usp22 affects colitis and intestinal 
tumorigenesis (Tam-DSS). In the second cohort we avoided the possibility that mice with 
different genotypes exert differential inflammatory responses to DSS treatment, which may 
affect the tumor formation rate (DSS-Tam). In addition the effects of Usp22 loss alone were 
tested (Tam) in a model for sporadic CRC. Survival rates of Usp22 wild type, heterozygous 
and knockout animals were analyzed separately to emphasize the consequences of treatment 
options and APC status. 
In mice with USP22 and APC wild type status, the survival remained mainly unaffected 
independent of the treatment (Figure 36A). In contrast, the truncated APC1638N/+ protein resulted 
in early lethality in all mice. While life expectancies between the Tam and DSS-Tam cohorts 
did not differ from each other, Tamoxifen injections prior to colitis (Tam-DSS) resulted in 
significantly shorter survival in APC1638N/+, Usp22+/+ mice compared to the other APC1638N 
animals. 
In Usp22 heterozygous animals, outcomes were similar, i.e. decreased life span due to APC 
mutation (Figure 36B). However, there was no significant difference when comparing treatment 
options in APC1638N mice.  
In general, Usp22 knockout mice showed increased lethality compared to the other genotypes, 
irrespective of the treatment (Figure 36C). Interestingly, in APC1638N mice, there was hardly any 
difference between the Tam and DSS-Tam groups. However, compared to these two cohorts, 
the survival was significantly decreased in Tam-DSS mice.  
In summary, in Usp22 wild type, heterozygous and knockout animals with an APC1638N 
background the Tam-DSS treatment resulted in the shortest life expectancy. The other two 
treatment types (Tam and DSS-Tam) led to outcomes similar to each other. 
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Figure 36: Survival curve analysis among treatment groups. Life expectancy of Usp22+/+, 
Usp22+/- and Usp22-/- animals was compared among the different treatment cohorts. (A) In all 
three groups (Tam-DSS, DSS-Tam, Tam) survival of Usp22 and APC wild type was hardly 
impaired. In Usp22+/+, APC1638N/+ mice the Tam-DSS group was characterized by the shortest 
life span. (B) In Usp22+/- animals the results were similar to the outcome of Usp22 wild type 
mice and no significant difference was detected among treatment groups. (C) In APC1638N/+, 
Usp22-/- mice with Tam-DSS treatment the survival was significantly shorter than in the other 
cohorts.  
 
In addition to the survival analyses the tumor numbers among the three treatment groups were 
compared.  As expected, due to the induction of colitis the oncogenic growth in the colon was 
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elevated in the two DSS-treated cohorts compared to the Tam group (Figure 37A, B). Notably, 
the Tam-DSS group possessed most tumors and their burden was on average 2 to 3-fold 
higher than in DSS-Tam mice. In contrast, oncogenic growth in colons of Tam animals was 
lowest; however, tumor numbers did not differ significantly from the DSS-Tam cohort (Figure 
37C, D). Surprisingly, when observing tumor growth in the small intestine, we observed that 
the majority of Tam animals possessed even more tumors than the Tam-DSS animals. In this 
comparison several key observations were made. Firstly, when deleting Usp22 prior to inducing 
colitis (Tam-DSS), the tumor burden was significantly higher than when performing the 
knockout after DSS treatment (DSS-Tam). Second, in the Tam group the loss of Usp22 alone 
was sufficient to result in tumor formation, especially in the background of an APC mutation. 
Finally, as expected (Adams and Bornemann, 2013), DSS treatment promoted tumor formation 
exclusively in the colon while the small intestine was not or only marginally affected by colitis. 
Together, our in vivo experiments to investigate the role of Usp22 loss in intestinal 
tumorigenesis revealed that surprisingly, Usp22 loss decreased survival and increased tumor 
number. Moreover, oncogenic burden was highest in the Tam-DSS cohort suggesting the 
interplay of Usp22 ablation and inflammatory processes within the intestine. 
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Figure 37: Comparison of tumor burden among treatment groups. Tumor numbers in 
colon and small intestine were compared in Usp22+/+, Usp22+/- and Usp22-/- among the different 
treatment cohorts. (A, B) In the colon the Tam-DSS group was, irrespective of the genotype, 
characterized by a significantly higher tumor burden than the other two cohorts. Differences 
between Tam and DSS-Tam groups were only marginal in the colon. (C, D) In the small 
intestine, Tam mice possessed most tumors; only APC+/+, Usp22-/- mice were affected more 
severely by Tam-DSS. Mean ± SEM, Student's t-test, n-numbers indicated in Table 17. 
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3.3 Intestinal Usp22 loss elevates acute colitis burden resulting in bone fragility 
In our previous DSS experiments we could observe severe inflammatory reactions in Usp22-/- 
animals even several weeks after the end of the treatment. Moreover, our results indicated a 
potential interplay between ablated Usp22 levels, increased inflammation and therefore 
elevated intestinal tumorigenesis. Since there were still inflammatory reactions long time after 
terminating DSS treatment, we assumed that these symptoms are even stronger when the 
colitis is highly acute. Thus, we aimed to observe the consequences of Usp22 during the acute 
phase of intestinal inflammation. For this purpose, we induced colitis in small mouse cohorts 
(Table 18) and sacrificed these animals two days after terminating the DSS treatment. To 
determine the disease activity index, stool consistency, Guaiac score and body weight were 
recorded daily. We could observe diarrhea and the presence of occult blood more frequently 
after the loss of Usp22 than in wild type animals (Figure 38A, B). Moreover, these parameters 
were also worsened in APC mutant compared to APC+/+ mice. While the weight loss was not 
significantly changed among the groups (data not shown), clear differences were detected in 
the DAI (Figure 38C, D). The disease activity index increased in a similar rate in all groups, 
however, the burden was highest in APC1638N/+, Usp22-/- animals.  
 
Table 18: Sizes of the experimental mouse cohorts in which the effects of Usp22 ablation 
was observed during acute colitis. 
 
 APC+/+ APC1638N/+ 
 Usp22+/+ Usp22-/- Usp22+/+ Usp22-/- 
Acute colitis 6 4 3 3 
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Figure 38: Acute colitis is correlated with increased DAI in Usp22-/- mice. During DSS 
administration (A) stool consistency and (B) bleeding intensity were recorded to determine the 
disease activity index. Stool was softer and bloodier in Usp22-/- mice. (C) The daily calculated 
disease activity index rose similarly in all mice (D) but the average values of the entire time 
period was highest in APC1638N/+, Usp22-/- animals. Mean ± SEM, Student's t-test, n-numbers 
indicated in Table 18. 
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After sacrificing animals, blood was extracted and inner organs were isolated. A striking 
difference was observed while comparing APC wild type and mutant mice to each other. When 
extracting blood we noticed that it was paler in APC1638N/+ mice. Thus, we determined the ratio 
between hematocrit and serum. In APC wild types we could measure between 55-60% 
hematocrit in a total blood sample while the ratio was approximately 48% in APC1638N/+, 
Usp22+/+ and 38% in APC1638N/+, Usp22-/- mice (Figure 39A). Accordingly, kidneys (Figure 39B) 
and livers (Figure 39C) were extremely pale in these animals.  
 
Figure 39: The anemic effect of an APC mutation is slightly aggravated by Usp22 loss. 
The relative amount of hematocrit was lower in blood samples of APC1638N/+ mice, especially 
after Usp22 loss. (B) Livers and (C) kidneys were pale in APC mutated animals while (D, E) 
their spleen was enlarged and heavier. Mean ± SEM, Student's t-test, n-numbers indicated in 
Table 18. 
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In accordance with Qadri and colleagues (Qadri et al., 2012) spleens were enlarged in mice 
carrying a heterozygous mutation in the APC gene (Figure 39D, E). Interestingly, spleens of 
APC1638N/+ animals were, although not significant, even bigger after the loss of Usp22. 
As expected, the acute inflammatory reaction had an effect on the length of the intestinal 
organs. While the colon length was similar for the majority of animals, APC1638N/+, Usp22-/- mice 
were characterized by shorter colons (Figure 40A, B). In the small intestine only mild effects 
were observed. On average, SIs of APC1638N/+, Usp22-/- were slightly shorter; however, this 
difference was not significant (Figure 40C). 
 
Figure 40: Acute colitis results in decreased colon lengths in APC1638N/+, Usp22-/- animals. 
(A, B) Colons and (C) small intestines were measured after sacrificing animals. Colons were 
slightly shorter in APC1638N/+, Usp22-/- mice while the small intestines were largely unaffected. 
Mean ± SEM, Student's t-test, n-numbers indicated in Table 18. 
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Colons were stained with H&E to assess the overall organ morphology and the inflammation 
burden. As expected, acute colitis led to inflammation-associated epithelial damage in all 
animals (Figure 41A).  
 
Figure 41: Intestinal loss of Usp22 increases burden during acute colitis. (A) Two days 
after terminating the DSS administration, mice were dissected and colons were stained with 
H&E. While in all animals epithelial integrity was disturbed, in Usp22-/- mice more colon 
segments were characterized by a complete absence of crypt structures. Scale bar: 100 µm. 
(B) The average H-score was elevated upon the loss of Usp22 and accordingly (C) more colon 
segments were affected by severe inflammation-induced epithelial damage in these mice. 
Mean ± SEM, Student's t-test, n-numbers indicated in Table 18. 
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In Usp22+/+ mice several organ regions were detected in which the integrity of the epithelium 
was disturbed. However, in the majority of colon regions only mild signs of inflammation were 
observed. In contrast, Usp22-/- animals were characterized by severe epithelial damage and in 
large segments of the organ no crypt structures were detected at all. In the minority of tissue, 
normal crypts could be found. Accordingly, the average H-score (Figure 41B) and the 
percentage of severely damaged tissue was elevated upon the loss of Usp22 (Figure 41C). 
These findings were independent from the APC status of experimental animals. 
 
Figure 42: Acute colitis results in increased bone fragility in APC+/+, Usp22-/- mice. (A, B) 
To determine bone fragility, femora were placed into a Zwick device which applied pressure 
onto the bone leading to fracture. The loss of Usp22 did not show any effect in APC1638N/+ mice 
with regards to (C) yield load, (D) Fmax, (E) failure load and (F) stiffness. However, these 
parameters revealed that bones of APC+/+, Usp22-/- mice are significantly more fragile than 
femora of Usp22 wild types. Mean ± SEM, Student's t-test, n-numbers indicated in Table 18. 
 
Generally, it was observed in IBD patients that intestinal inflammation correlated with 
decreased bone mineral density and increased fracture risk (Ali et al., 2009; Bernstein et al., 
2000). To determine whether the loss of Usp22 and acute colitis have an impact on bones, we 
observed the bone fragility. Using a Zwick device (Figure 42A, B), the biomechanical properties 
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of femora were measured in cooperation with Dr. med. Dominik Saul (Department of Trauma, 
Orthopedics and Reconstructive Surgery, UMG). With these analyses the applied strength 
during bone deformation (Figure 42C; yield load) and bone fracture (Figure 42D; Fmax) was 
determined. Moreover, the maximum forces applied before breaking the femora (Figure 42E; 
failure load) and the bone stiffness (Figure 42F) were quantified. In APC1638N/+ mice, no 
significant difference was detected between Usp22+/+ and Usp22-/- animals. Interestingly, the 
bone stiffness was significantly decreased in APC+/+, Usp22-/- mice compared to their Usp22 
wild type littermates. Interestingly, inflammatory reactions were sufficient to show an effect on 
bone fragility in APC+/+ but not APC1638N/+ animals with a homozygous Usp22 deletion. In 
summary, these data reveal that effects of acute colitis are aggravated in Usp22-/- mice.  
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3.4 Heterogeneous USP22 expression levels in CRC patients and cell lines 
Previous studies on human material described that high USP22 expression correlates with 
increased oncogenic growth, distant metastasis and poor prognosis (Melo-Cardenas et al., 
2016). Unexpectedly, we showed that abolishing Usp22 expression in the context of 
inflammation-induced and sporadic colorectal cancer in vivo resulted in highly increased tumor 
numbers with an aggressive phenotype. In order to obtain insights into the mechanisms 
responsible for these phenomena, we performed several in vitro and in silico experimental 
approaches. We started our investigations with the analysis of publically available cancer 
databases. Using the IST Online® database possessing expression data from cancer patients 
we observed that a high fraction of CRC patients has low USP22 levels (Figure 43A). Moreover, 
there was no clear correlation between survival rates of patients with low or high USP22 
expression, respectively. This finding was surprising since it contradicted most published 
reports. However, these data reflected the situation for colorectal cancer in general, thus, more 
detailed records were obtained from the OncomineTM platform (TCGA Colorectal Statistics, 
reporter AB028986_1_4358). These data enabled us to identify USP22 mRNA levels in 
different types of cancer in cecum, colon or rectum as well as in normal control samples. 
Notably, mean expression values of all depicted cancer types were lower than in the control 
(Figure 43B).  
To investigate the molecular aspects underlying the effects of USP22 in tumorigenesis we 
planned to perform experiments in vitro. For this purpose protein lysates were isolated from 
several human colorectal cancer cell lines. Afterwards, global USP22 protein levels were 
determined in these rectal adenocarcinoma, colorectal adenocarcinoma and carcinoma cells 
by western blot. As expected, USP22 levels were as diverse as seen in CRC patient data 
obtained from the databases (Figure 43C). While USP22 was detected in all cell lines, only 
faint protein bands were detected in NCI-H508 and T84 cells. Protein amounts were highest in 
COLO320DM, RKO, SW48 and SW480 cells.  
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Figure 43: USP22 expression is heterogeneous in CRC patient samples. (A) USP22 
expression is not only upregulated as reported in literature but was found to be downregulated 
in approximately 50% of CRC patients (obtained from the IST Online® database). (B) 
OncomineTM data (TCGA Colorectal Statistics, reporter AB028986_1_4358) reveal reduced 
USP22 mRNA levels in cecal and several colon- and rectum-associated cancers. (C) USP22 
protein levels are highly diverse in the twelve tested colorectal cancer cell lines.  
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In summary, in CRC patients USP22 mRNA expression levels were not as “black and white” 
as described in the literature. In fact, a high fraction of colorectal cancer patients is 
characterized by low USP22 levels resembling our in vivo results well. This heterogeneity could 
also be confirmed on protein levels in diverse human CRC cell lines we tested by western blot. 
Since to our surprise USP22 expression was seen to be highly diverse in human CRC samples, 
we aimed to further analyze the incidence of patients with low USP22 levels. For this purpose 
patients with heterozygous deletions of the USP22 gene were identified using the cBioPortal 
for Cancer Genomics. Astonishingly, in some cancer types, the majority of patients are 
affected. In fact, approximately 45-50% of colorectal cancer patients have heterozygous 
USP22 deletions (Figure 44A). This finding underlines the relevance of elucidating the 
consequences of USP22 loss in colorectal cancer. Therefore, we decided to perform in vitro 
analyses with a siRNA-mediated loss of USP22. SW480 CRC cells were transfected with four 
individual siRNAs targeting USP22 (siUsp22) and with a smart pool (SP) containing a 
combination of these siRNAs. A non-targeting siRNA (siControl) was used as a control. All 
transfections resulted in a significant decrease of USP22 mRNA levels (Figure 44B). After 
verifying its efficiency on protein level (Figure 44C) we decided to use the smart pool (SP) for 
all subsequent in vitro experiments.  
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Figure 44: Heterozygous USP22 deletions occur frequently in CRC patients and can be 
simulated by siRNA treatment in vitro. (A) Data obtained from the cBioPortal for Cancer 
Genomics website reveal that a big percentage of cancer patients is characterized by a 
heterozygous deletion of USP22 (red: CRC data sets; HETLOSS function). (B) To simulate the 
loss of USP22 in vitro, different individual siRNAs targeting USP22 (siUsp22) and a smart pool 
(SP) were tested for their knockdown efficiency on mRNA level in SW480 cells. Expression 
values were normalized to a non-targeting control siRNA (siControl). Mean ± SD, Student's t-
test, n=3. (C) The smart pool results in a strong reduction of USP22 on protein level in SW480 
cells. 
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Since altered USP22 expression levels were described to affect tumorigenesis, we expected 
that USP22 would have an effect on the morphology or growth rate of human colorectal cancer 
cells. We knocked down USP22 in nine CRC cell lines and observed their morphology after 72 
hours. No striking differences were detected when comparing USP22 knockdown and control 
cells with regards to cell size, shape, number of nuclei etc. (Figure 45). 
 
Figure 45: Knockdown of USP22 marginally affects the morphology of human CRC cell 
lines. 72 hours after the siRNA-mediated loss of USP22, the morphology was assessed in nine 
cell lines. No or only marginal effects were observed. Scale bar: 1,000 µm. 
 
Next, we compared the proliferation rates of these cell lines upon siRNA-mediated USP22 
knockdown over a time period of one week using the Celigo® device. We could observe that 
the loss of USP22, depending on the cell line, can have varying effects on cell growth (Figure 
46). While no difference was detected in NCI-H508, SW480 and SW837 cells, proliferation 
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levels were reduced upon USP22 knockdown in the majority of cells, i.e. COLO201, 
COLO320DM, DLD1, RKO and SW48. Interestingly, cell growth was significantly increased in 
HCT116 cells.  
 
Figure 46: USP22 loss can have differential effects on proliferation of CRC cell lines. 
Two days after knockdown, the proliferation of nine CRC cell lines was measured every 24 h 
using a Celigo® device. The growth rates of some cell lines was not or only marginally affected 
by USP22 knockdown (NCI-H508, SW480, SW837), while in most cell lines a growth 
advantage was observed in siControl cells (COLO201, COLO320DM, DLD1, RKO, SW48). 
HCT116 siUsp22 cells showed increased proliferation.  Mean ± SD, Student's t-test, n=3. 
Proliferation effects could neither be correlated with cell line characteristics such as MSI, CIMP 
and CIN status nor with certain genetic mutations (Table 19). We decided to mainly use 
HCT116 cells for our future experiments since they resemble the in vivo situation best, i.e. 
increased growth of colorectal cancer cells upon USP22 loss. 
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Table 19: Growth characteristics upon USP22 loss do not correlate with MSI, CIN or 
CIMP status of CRC cell lines.  
 
 MSI CIN CIMP Usp22 protein levels 
Growth after USP22 
loss 
COLO201 MSS + + +++ Down 
COLO320DM MSS + - ++++ Down 
DLD1 MSI - + +++ Down 
HCT116 MSI - + ++ Up 
NCI-H508 MSS + - + Unaffected 
RKO MSI - + ++++ Down 
SW48 MSI - + +++ Down 
SW480 MSS + - +++ Unaffected 
SW837 MSS + + ++ Unaffected 
 
It was reported that USP22 and its homolog USP27X can have similar functions (Atanassov et 
al., 2016). To test their effect on CRC cell morphology and proliferation, both peptidases were 
knocked down. Moreover, when performing siRNA-mediated knockdowns, the specificity of the 
siRNA should be confirmed. In this case we aimed to verify whether the effects on proliferation 
are mediated by the loss of USP22 alone or whether the highly homologous USP27X was also 
targeted by the USP22-siRNA. For this purpose, two cell lines with opposing consequences of 
USP22 loss were selected, i.e. SW48 in which USP22 knockdown decreased cell growth and 
HCT116 where proliferation was increased. Cells were transfected with siRNAs targeting 
USP22 and USP27X for single and double knockdowns. The cell morphology was not affected 
by silencing USP22, USP27X or both genes simultaneously (Figure 47A). 
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Figure 47: USP22 and USP27X can have opposing effects on CRC cell proliferation. 
Effects of the loss of USP22, USP27X and both peptidases on morphology and proliferation 
were evaluated. (A) No morphological effect was observed upon siRNA-mediated knockdown. 
Scale bar: 500 µm. (B) While in SW48 cells the loss of USP22 and USP27X had similar 
consequences, in (C) HCT116 opposing effects of these two peptidases was observed by 
Celigo® measurement. After the dual knockdown in HCT116 cells, the anti-proliferative effect 
of USP27X loss was rescued by the additional depletion of USP22. Mean ± SD, Student's t-
test, n=3. 
 
Cell proliferation was assessed by Celigo® measurement and as expected, loss of USP22 
decreased proliferation levels in SW48 (Figure 47B) and increased them in HCT116 cells 
(Figure 47C). Notably, also the knockdown of USP27X had opposing effects in the two tested 
cell lines. SW48 cells grew slightly faster than after loss USP2. In contrast, USP27X reduction 
significantly decreased proliferation in HCT116 cells. Interestingly, in HCT116 cells the 
simultaneous knockdown of USP22 and USP27X could rescue the severe deceleration in 
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growth after siUSP27X treatment. Thus, the possibility that the growth rates after USP22 
knockdown were affected by USP27X-related off-target effects was ruled out. Moreover, 
despite their high homology, USP22 and USP27X can have opposing effects on the 
proliferation of CRC cells. 
For further characterizations we selected four cell lines which reacted differently to the loss of 
USP22 expression. In SW480 and SW837 cells we could not observe any effects upon the 
siRNA-mediated knockdown. In contrast, reduced USP22 levels resulted in a proliferation 
advantage in HCT116 and disadvantage in SW48 cells. The effects on growth behavior 
obtained by Celigo® measurement (Figure 46) were confirmed in a crystal violet-based 
proliferation assay (Figure 48A). We postulated that these proliferative effects were 
translatable to the migratory properties of the cells upon USP22 loss. Indeed, upon knocking 
down USP22, HCT116 cells were characterized by increased migration potential while the 
opposite was observed in SW48 cells (Figure 48B). Interestingly, USP22-depleted HCT116 
cells formed more colonies (Figure 48C) and grew better in an anchorage-independent manner 
(Figure 48D) compared to cells treated with the control siRNA as visualized by crystal violet 
staining. To translate these findings to the observations we made in our in vivo experiments in 
which the APC protein was mutated in some mouse cohorts, we aimed to observe the Wnt 
signaling pathway activity in CRC cells. In addition, increased Wnt activity is a common 
occurrence in human CRCs. For this purpose we have performed a luciferase assay. Briefly, 
reporter plasmids containing a luciferase reporter gene under the control of TCF/LEF response 
elements were introduced into cells. Once, the canonical Wnt signaling is active and luciferase 
substrates are added, fluorescent signal can be measured. A knockdown of β-catenin (siβ-
catenin) was used as a negative control. Characterization of HCT116 cells revealed slightly 
decreased Wnt signaling activity after the loss of USP22 (Figure 48E). In SW480 cells which 
were used as a control, the same outcome was obtained. In summary, HCT116 cells were 
characterized by increased proliferation and migration rates upon USP22 ablation. Moreover, 
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they were able to grow better in anchorage-independent manner. Using a luciferase assay, we 
demonstrated that these properties were not driven by increased Wnt pathway activity. 
 
Figure 48: USP22 is involved in regulation of migration potential, anchorage-
independent growth and Wnt signaling pathway activity. (A) As observed in the Celigo® 
measurements, USP22 depletion can have differential effects on proliferation as shown by this 
crystal violet-based proliferation assay 48 h after knockdown. (B) 24 h after siRNA transfection, 
cells were seeded into trans-well migration inserts. After 48 h cells were stained with crystal 
violet. USP22 loss resulted in increased migration potential in HCT116 cells while the opposite 
was observed in SW48 cells. Scale bar: 500 µm (C) Knockdown enhanced colony formation 
after 4-5 days (D) and cell growth in anchorage-independent manner after 2 weeks. (E) A 
luciferase reporter assay demonstrated decreased Wnt pathway activity in siUsp22 cells, in 
both HCT116 and SW480 cells. Mean ± SD, Student's t-test, n=3. 
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3.5 USP22 regulates proliferation and differentiation processes in CRC cells 
To determine the effect of USP22 loss on global gene expression and to potentially identify the 
mechanism underlying the previous results, we pursued our investigations with transcriptome‐
wide gene expression analyses using mRNA‐sequencing. For this purpose, we selected 
SW837 and SW480 cells and treated them with control- and USP22-siRNA. We decided to use 
SW480 and SW837 for this approach since their gross phenotype was not or only minimally 
affected by USP22 loss and therefore of secondary effects, e.g. due to dramatic changes in 
cell phenotype, were expected to be low. After RNA isolation and quality control using RNA gel 
electrophoresis, libraries were generated and sequencing reactions were performed at the 
TAL. 
Per cell line and condition (siControl and siUsp22) we have analyzed four replicates. The 
sample variance and data quality was assessed by hierarchical clustering and principal 
component analysis. There was a clustering of replicates verifying minimal deviations between 
these samples (Figure 49A). As expected, the difference between the two cell lines was 
immense. In addition, a variation between siControl and siUsp22 was detected as revealed by 
PCA plot (Figure 49B). However, the loss of USP22 seemed to have a higher impact on gene 
expression in SW837 than in SW480 cells. In addition, we compared the replicate variance in 
genes with high fold changes (log2fold change value ± 1, padj ≤0.05). As visualized in these 
heatmaps using the Morpheus tool, replicates show a high similarity (Figure 49C). 
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Figure 49: Quality control of SW480 and SW837 replicates used for mRNA-seq analysis. 
(A) Hierarchical clustering and (B) PCA plot indicate a high similarity between replicates (n=4). 
There is a significant difference between the two cell lines, SW480 and SW837. (C) Highly 
regulated genes (log2fold change value ± 1, padj ≤0.05) and their expression in all replicates 
are shown in SW837 and SW480 cells using the Morpheus tool. Variations among the 
replicates are marginal. The color code indicates the relative minimum (min) and maximum 
(max) expression value per gene. 
 
  
Results 
141 
 
Initially, we decided to examine genes which are differentially expressed in SW837, SW480 
cells and MEFs (see section 3.1). Since these cells are highly different from each other, we 
expected that we would find only few overlapping genes but that these would be of high 
significance since they were affected by USP22 loss in different biological systems. For this 
purpose, genes with a log2 fold change of at least 0.8 in all three cell types were selected. 
These genes were divided into down- (Figure 50A) and upregulated (Figure 50B) genes. 
Outcomes obtained from SW837 cells were shown in the left, from SW480 in the middle and 
from MEFs in the right column. Moreover, the heatmaps were subdivided into four segments 
in which genes strongly regulated in all three cell types (segment on the top), in SW837 (second 
segment), SW480 cells (third segment) and MEFs (bottom) were depicted. Each line 
represents one gene and expression changes can be compared among SW837, SW480 cells 
and MEFs by comparing the three columns. Genes which were not expressed in all cell types 
were excluded from the analyses. While SW837 and SW480 showed similar tendencies, the 
results obtained from MEFs were highly heterogeneous. Approximately half of the genes 
upregulated in the human cell lines were also upregulated in MEFs. In the downregulated 
genes, the overlap between human and murine samples was on average 60%. When focusing 
on genes differentially regulated in Usp22lacZ/lacZ MEFs, there is only low accordance with the 
human cells. In addition, many genes which were differentially regulated in the human cell lines 
were not detected in MEFs and were therefore excluded from the analyses. Due to the low 
accordance between human and murine samples, we decided to no longer take the MEFs into 
account but instead focus on the human cell lines. 
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Figure 50: Moderate consistency of differentially expressed genes after USP22 depletion 
in SW480, SW837 cells and MEFs. mRNA-seq and microarray outcomes were compared by 
displaying differentially regulated genes (log2fold change value ± 0.8, padj ≤0.05) in SW837, 
SW480 and MEFs in a heatmap. Highly (A) down- or (B) upregulated genes of each cell type 
were indicated with the corresponding expression values of the other conditions. The four 
segments indicate genes strongly regulated in all three cell types (top segment), in SW837 
(second segment), SW480 cells (third segment) and MEFs (bottom). Due to low agreement 
with human CRC cells, MEFs were excluded from subsequent analyses.  
 
To obtain an overview on the genes differentially regulated upon USP22 knockdown in SW837 
and SW480 cells, new heat maps were generated. Similar to the previous heatmap, genes with 
a log2 fold change of at least 0.8 in both cell lines were depicted and divided into down- (Figure 
51A) and upregulated (Figure 51B) genes. Results obtained from SW837 cells were visualized 
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in the left column while outcomes from SW480 were shown in the right column. The three 
segments indicate genes differentially regulated in both cell lines (segment on the top), in 
SW837 (middle) and SW480 cells (bottom). Despite the heterogeneity expected when 
comparing two cell lines, several differentially regulated genes could be identified showing the 
same tendency in both, SW480 and SW837.  
 
Figure 51: Comparison of differentially expressed genes after USP22 depletion in SW837 
and SW480 cells. Significantly (A) down- or (B) upregulated genes (log2fold change value ± 
0.8, padj ≤0.05) revealed by mRNA-seq using SW837 and SW480 cells have been depicted in 
a heatmap. Highly affected genes per cell line are shown with the corresponding expression 
values (color key). The three segments indicate genes differentially regulated in both cell lines 
(first segment), in SW837 (second segment), SW480 cells (third segment). 
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By means of the Gene Ontology visualization tool REViGO (Supek et al., 2011), biological and 
cellular processes associated with USP22 loss in SW837 and SW480 cells were depicted. 
Previously, using Usp22lacZ/lacZ MEFs, we detected the enrichment of several proliferation and 
development-related pathways. Indeed, GO analysis of SW837 (Figure 52A, Table 20) and 
SW480 cells (Figure 52B, Table 21) revealed similar outcomes. Mainly, terms associated with 
development and proliferation, as well as cell communication were enriched in both cell types. 
In addition, GO terms revealed that USP22 is associated with the regulation of signaling 
processes and cell communication which could be associated with extracellular stimuli. 
Together, analysis of our mRNA-seq analysis revealed that there is only a low agreement 
between MEFs we have analyzed earlier and CRC cells. The expression of numerous genes 
was affected by USP22 depletion and besides an involvement in proliferation- and 
differentiation-related processes, GO analysis indicated a potential role of USP22 in the 
response to extracellular stimuli. 
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Figure 52: Gene Ontology terms enriched after USP22 loss in SW837 and SW480 cells. 
REViGO analysis revealed enriched cellular processes upon USP22 knockdown in (A) SW837 
and (B) SW480 cells. In both cell lines mainly GO terms associated with development, 
proliferation and cell communication were affected.  
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Table 20: GO terms enriched in siUsp22 SW837 cells as revealed by GOTermFinder. 
Term ID Gene Ontology term 
Cluster 
frequency 
Corrected 
p-value 
FDR 
GO:0032502 Developmental process 24.3% 0.00336 0 
GO:0048583 Regulation of response to stimulus 18.1% 0.00432 0 
GO:0010646 Regulation of cell communication 16.0% 0.00098 0 
GO:0023051 Regulation of signaling 16.0% 0.00174 0 
GO:0009893 Positive regulation of metabolic process 14.9% 0.00121 0 
GO:0009966 Regulation of signal transduction 14.2% 0.0054 0 
GO:0032879 Regulation of localization 12.8% 0.00736 0 
GO:0042127 Regulation of cell proliferation 9.7% 0.00243 0 
GO:0072359 Circulatory system development 8.0% 0.00025 0 
GO:0009725 Response to hormone 7.3% 0.00104 0 
GO:0051270 
Regulation of cellular component 
movement 
6.6% 0.00219 0 
GO:0072358 Cardiovascular system development 6.2% 0.00055 0 
GO:0001568 Blood vessel development 5.9% 0.00142 0 
GO:0001944 Vasculature development 5.9% 0.00223 0 
GO:0045765 Regulation of angiogenesis 3.5% 0.00731 0 
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Table 21: GO terms enriched in siUsp22 SW480 cells as revealed by GOTermFinder. 
Term ID Gene Ontology term 
Cluster 
frequency 
Corrected 
p-value 
FDR 
GO:0019222 Regulation of metabolic process 35.4% 0.00121 0 
GO:0016043 Cellular component organization 31.7% 0.00381 0 
GO:0032502 Developmental process 30.5% 0.0000551 0 
GO:0030154 Cell differentiation 20.7% 0.0009 0 
GO:0048513 Animal organ development 20.1% 0.0000467 0 
GO:0009653 Anatomical structure morphogenesis 19.5% 0.00000422 0 
GO:0010646 Regulation of cell communication 19.5% 0.00046 0 
GO:0023051 Regulation of signaling 19.5% 0.00073 0 
GO:0009888 Tissue development 18.9% 3.04E-10 0 
GO:0010647 Positive regulation of cell communication 12.2% 0.0014 0 
GO:0048729 Tissue morphogenesis 8.5% 0.0000702 0 
GO:0001568 Blood vessel development 7.9% 0.00083 0 
GO:0072358 Cardiovascular system development 7.9% 0.00135 0 
GO:0030198 Extracellular matrix organization 6.7% 0.0000584 0 
GO:0045861 Negative regulation of proteolysis 6.1% 0.00212 0 
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3.6 USP22 regulates the stability of heat shock proteins 
GO analysis revealed that USP22-regulated genes are involved in the response to stimuli. As 
reviewed by Shim and Karin, mRNA expression can be affected by stimuli such as 
developmental, nutritional and pharmacological alterations, however, also by environmental 
factors such as temperature changes (Shim and Karin, 2002). Interestingly, mRNA-seq data 
indicated that levels of heat shock proteins were decreased by reduced USP22 expression in 
both, SW837 and SW480 cells. Generally, there are two HSP90 isoforms present in the 
cytoplasm: the stress-inducible HSP90α and the constitutively expressed HSP90β (Mimnaugh 
et al., 1996; Whitesell and Lindquist, 2005). Notably, our mRNA-seq results only indicated 
altered expression of constitutively active family members. 
To verify this outcome we performed siRNA-mediated knockdown of USP22 in SW837, 
SW480, HCT116 and SW48 cells and determined Heat Shock Protein 90 Alpha Family Class 
B Member 1 (HSP90AB1) mRNA levels. Indeed, we confirmed in all four cell lines that 
HSP90AB1 expression levels were decreased by approximately 50% in siUsp22 cells (Figure 
53A). This phenomenon was observed on protein level as well as shown for HCT116 cells 
(Figure 53B). Since heat shock proteins play a crucial role in the cells’ adaptation to 
environmental changes, we speculated that reduced HSP90AB1 levels can sensitize siUsp22 
cells to high temperatures. For this purpose, we subjected HCT116 cells to heat shocks 48 h 
after USP22 knockdown. As incubation at 42°C only yielded minimal differences (data not 
shown), cells were incubated at 50°C for 1h. As expected, siUsp22 HCT116 control cells grown 
at 37°C grew faster than the wild types (Figure 53C). Comparing this growth rate to the cell 
number after incubation at 50°C, the cell number was reduced by 17% in siControl and by 24% 
in siUsp22 cells. In summary, we could not only detect a decrease of HSP90AB1 on mRNA 
and protein level in siUsp22 cells, but also observed high temperature sensitivity in these cells. 
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Figure 53: The expression of the heat shock protein HSP90AB1 is reduced following 
USP22 depletion leading to increased cell sensitivity. (A) A reduction of HSP90AB1 mRNA 
levels was detected by qRT-PCR upon USP22 knockdown in four cell lines (SW837, SW480, 
HCT116, SW48). Mean ± SD, Student's t-test, n=3. (B) In HCT116 cells this decrease was 
confirmed on protein level. (C) 48 h after siRNA transfection, HCT116 USP22 wild type and 
knockdown cells were incubated either at 37°C or 50°C for 1 h. Compared to the normal growth 
rates at 37°C, incubation at 50°C decreased cell numbers in siControl cells by 17% and in 
siUsp22 cells by 24%. Mean ± SD, Student's t-test, n=4. 
 
To obtain insights into the mechanisms responsible for USP22-mediated regulation of HSP90 
levels, we decided to investigate the functional interaction between USP22 and HSP90AB1 by 
Co-IP. For this purpose, we conjugated protein G sepharose (PGS) beads with antibodies 
targeting either USP22 or HSP90. These beads have been incubated with HCT116 protein 
lysate to precipitate potential USP22-HSP90AB1 protein complexes. As expected, in the 
control conditions (PGS and IgG) neither USP22 nor HSP90AB1 were present while all IgG-
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bands were visible, confirming absence of unspecific USP22- and HSP90-binding to the beads 
or IgG. By using antibodies directed against either USP22 or HSP90, we were able to 
precipitate USP22-HSP90AB1 complexes (Figure 54A) implying direct interaction of these two 
proteins. Furthermore, we investigated whether the ability of USP22 to deubiquitinate proteins 
is associated with the regulation of HSP90 levels. We aimed to determine whether the 
reduction of HSP90AB1 is due to ubiquitination and whether this loss can be prevented by 
inhibiting the proteasome. Moreover, we tested whether this phenomenon is USP22-
dependent. For this purpose, we have added the proteasome inhibitor MG-132 to siControl and 
siUsp22 cells. As expected, loss of USP22 resulted in decreased HSP90AB1 levels (Figure 
54B). However, when the proteasome inhibitor was added, HSP90AB1 amounts remained 
nearly unchanged. This outcome suggested that the reduced HSP90AB1 levels were caused 
by proteasomal degradation due to ubiquitination. 
 
Figure 54: HSP90AB1 interacts with USP22 and is targeted by proteasomal degradation 
in the absence of USP22. (A) Co-IP was performed to investigate the direct interaction 
between USP22 and HSP90AB1. USP22-HSP90AB1 complexes were precipitated with both, 
anti-USP22- and anti-HSP90AB1-conjugated beads. (B) Under normal conditions HSP90 
levels decreased in siUsp22 cells. When the proteasome is inhibited by MG-132 this 
degradation was prevented. 
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3.7 Induction of synthetic lethality in USP22-deficient CRC cells 
Based on these findings we assumed that the residual HSP90 levels are essential for the 
survival and stress-resistance of siUsp22 cells. We therefore hypothesized that diminishing 
HSP90 completely would result in decreased cell survival. Moreover, since targeting USP22 
directly could have tumor-promoting outcomes, our proposed strategy would reflect an 
attractive targeting approach based on the concept of synthetic lethality. Thus, HCT116 cells 
were treated with the HSP90 inhibitor Ganetespib under wild type and USP22 knockdown 
conditions 48 h after siRNA transfection. To determine the general sensitivity towards this 
inhibitor, cells were treated with increasing Ganetespib concentrations for 48 h.  
 
Figure 55: USP22-depleted cells are more sensitive to the HSP90 inhibitor Ganetespib. 
48 h after siRNA transfection, siControl and siUsp22 HCT116 cells were treated with increasing 
concentrations of the HSP90 inhibitor Ganetespib for 48 h. Surviving cells were visualized by 
crystal violet staining. USP22-depleted cells showed increased sensitivity towards this drug. 
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Subsequently, surviving cells were stained with crystal violet. Indeed, we observed that USP22-
depleted cells were more sensitive towards this inhibitor (Figure 55). While only few siUsp22 
cells could withstand treatment with 333 nM Ganetespib, siControl cells could tolerate 10-fold 
higher concentrations. 
Consequently, we aimed to confirm our findings by testing for apoptosis markers on protein 
levels upon USP22 loss and/or HSP90 inhibition. USP22 wild type and -depleted cells were 
treated with 100 nM Ganetespib or DMSO for 48 h. Protein lysates were subjected to western 
blot analysis. In conformity with our hypothesis, in siUsp22 cells treated with Ganetespib 
increased levels of the apoptosis markers cleaved PARP and BIM were observed (Figure 56). 
In summary, these findings strongly support the potential of USP22-deficient cells to be 
targeted by HSP90 inhibitors based on the concept of synthetic lethality. 
 
Figure 56: Ganetespib treatment increases apoptosis levels in USP22-depleted cells. 48 
h after knockdown, HCT116 cells (siControl and siUsp22) have been treated either with DMSO 
or 100 nM Ganetespib for 48 h. Protein lysates were evaluated by western blot in triplicates. 
USP22-depleted cells show an increased abundance of the apoptosis markers cleaved PARP 
(lower PARP band) and BIM upon treatment with the HSP90 inhibitor Ganetespib. 
 
We further assumed that HSP90 inhibition interferes with its function in facilitating P-TEFb 
complex formation which therefore cannot be recruited by BRD4 to phosphorylate the RNA Pol 
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II. To target another player in this process we treated cells with the BET inhibitor JQ1 which 
targets among others BRD4. Similar to the previous approach, 48 h after siRNA transfection, 
we treated siControl and siUsp22 HCT116 cells with increasing concentrations of the inhibitor 
for 48 h. Indeed, control cells could tolerate 250 nM JQ1 while most of the USP22-depleted 
cells could maximally survive a dose of 100 nM (Figure 57A).  
 
Figure 57: Loss of USP22 elevates sensitivity of CRC cells towards JQ1. 48 h after 
HCT116 cells were transfected with control or anti-USP22 siRNAs, cells were treated with 
increasing concentrations of JQ1 for 48 h. (A) A crystal violet-based assay revealed increased 
sensitivity towards JQ1 upon knockdown of USP22. (B) Using the Celigo® device the IC50 was 
determined in these cells. USP22-depleted cells were characterized by a lower IC50 (47 nM) 
than the controls (224 nM). 
To obtain further insights into the sensitivity of siUsp22 cells towards JQ1 treatment, we 
calculated the IC50 based on Celigo® proliferation measurements. This experiment revealed 
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that the IC50 of cells with USP22 wild type levels was 224 nM and of USP22-depleted cells only 
47 nM (Figure 57B). Taken together, CRC cells with low USP22 levels can be specifically 
targeted by treatment with Ganetespib or the BET inhibitor JQ1. 
 
In our aforementioned approaches, we tested the effects of transient USP22 loss in vitro in 
several human CRC cell lines by siRNA-mediated knockdown. However, this silencing is only 
transient and therefore only insufficiently reflects the in vivo situation of USP22 depletion. Thus, 
we decided to take advantage of the CRISPR/Cas9 gene editing technology to permanently 
delete the USP22 gene in HTC116 cells. The use of this construct allowed expression of a 
sgRNA sequence by the U6-promoter and at the same time expression of the Cas9 enzyme 
necessary for gene editing. For rapid selection of positively transfected cells, the plasmid 
contained a coding sequence for the Green Fluorescent Protein (GFP).We simultaneously 
transfected HCT116 cells with two constructs targeting intronic sequences flanking exon 3 to 
exon 5 of USP22, thereby allowing the excision of this segment. This generated a frameshift 
with as consequence deletion of functional USP22 gene (Figure 58).  
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Figure 58: CRISPR/Cas9 
approach to 
permanently deplete 
USP22 in HCT116 cells. 
HCT116 cells were 
transfected with two 
sgRNAs targeting USP22 
(sgRNA “C” and “G”) in a 
Cas9- and GFP-
containing vector. To allow 
selection, this construct 
contains a GFP-reporter. 
These sgRNAs target 
intronic regions upstream 
of exon 3 and downstream 
of exon 5 of the USP22 
gene and generate a 
frameshift.  
 
After 48 h, we evaluated the transfection efficiency by detecting GFP-mediated fluorescence 
emitted by positively transfected cells (Figure 59A). We selected GFP-positive cells by 
fluorescence activated cell sorting (FACS) with the help of Sabrina Becker (Cell-sorting 
technology platform, Department of Haematology and Medical Oncology, UMG). Remarkably, 
with 32% fluorescent and 3% highly fluorescent cells, the transfection efficiency of HTC116 
cells was relatively high (Figure 59B). We decided to culture only highly GFP-positive cells 
(channel P4) as single cells in 96-well plates.  
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Figure 59: Fluorescent cells indicate the presence of the GFP-containing CRISPR/Cas9 
constructs targeting USP22. (A) 48 hours after transfection GFP-positive cells were detected. 
Scale bar: 1,000 µm. (B) Highly fluorescent cells (gate P4) were sorted as single cells by FACS. 
 
After approximately four weeks of culturing and propagating single cells, several clones were 
tested for their USP22 levels. Two cell clones (#1, #2) did not show any residual USP22 protein 
(Figure 60A). As observed after siRNA-mediated knockdown, the loss of USP22 did not result 
in morphological alterations in HCT116 cells (Figure 60B). In addition, proliferation rates were 
assessed and again we could confirm previously obtained results in which reduced USP22 
expression leads to accelerated cell growth in HCT116 cells (Figure 60C). Finally, we 
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confirmed the sensitivity of USP22-depleted cells towards the HSP90 inhibitor Ganetespib 
(Figure 60D). Together, the effects of USP22 loss were reproduced in another cell system 
which represents a powerful tool to further investigate the consequences of a permanent 
USP22 depletion in human CRC cells. 
 
Figure 60: CRISPR/Cas9-mediated USP22 knockout leads to increased proliferation in 
HCT116 cells. (A) The loss of USP22 on protein level was confirmed in CRISPR/Cas9 clones 
#1 and #2. (B) As observed after siRNA-mediated knockdown the loss of USP22 does not 
affect the morphology of HCT116 cells. Scale bar: 100 µm. (C) Reduced USP22 expression 
results in increased proliferation compared to USP22 wild type levels (parental and 
CRISPR/Cas9 clone #3 cells). Mean ± SD, Student's t-test, n=3. (D) The sensitivity towards 
Ganetespib was confirmed in these USP22-depleted cells.  
 
Together, in this project we demonstrated higher inflammation and tumor burden in mice with 
an intestinal deletion of Usp22. These findings were supported by data available in public 
databases in which a heterogeneous expression of USP22 was revealed in CRC patients. 
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Accordingly, human CRC cell lines showed heterogeneous USP22 levels and reacted 
differently after USP22 knockdown with regards to proliferation and migration properties. 
mRNA-seq analyses indicated an involvement of USP22-regulated genes in proliferation- and 
differentiation-related processes as well as response to extracellular stimuli. Accordingly, we 
detected the downregulation of the heat shock protein HSP90AB1 upon USP22 depletion in 
vitro. Interestingly, these cells showed increased sensitivity towards temperature changes and 
could be targeted by HSP90 and BET inhibitors based in the concept of synthetic lethality. 
Moreover, CRISPR/Cas9 cells with a USP22 knockout were generated which displayed high 
sensitivity towards HSP90 inhibition as well. These findings suggest a tumor suppressive 
function of USP22 and that low USP22 levels in CRC cells could be exploited by targeting 
these cells with specific inhibitors. 
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4. DISCUSSION 
 
4.1 USP22 is involved in differentiation and developmental processes in vivo 
Colorectal cancer is a global issue due to its high incidence and mortality rates. Thus, 
researchers worldwide aim to unravel underlying molecular signatures of this disease in order 
to generate and uncover more effective therapies. Despite USP22 overexpression was 
described in a number of human malignancies, its exact functions under physiological and 
pathological conditions remain unclear. In the current project we sought to investigate how 
USP22 functions in organ maintenance and colorectal tumorigenesis. To date, several studies 
on USP22 have been performed in vitro; however, in vivo data are limited. Interestingly, it was 
described by Lin et al. that the complete ablation of Usp22 expression results in early 
embryonic lethality at E10.5 of the post-implantation stage in mice (Lin et al., 2012). The mouse 
line Usp22lacZ utilized in our studies displayed expression of approximately 3% of the correctly 
spliced Usp22 mRNA and can thereby be considered as a hypomorph. Due to the poor quality 
of commercially available antibodies, we were not able to establish immunohistochemical or 
immunofluorescent stainings to visualize reduced USP22 abundance on tissue sections. In 
addition, we repeatedly attempted to stain for Usp22 by in situ hybridization; however, no 
positive result was obtained. In future experiments utilization of the RNAscope® Technology, 
an in situ hybridization-based commercial assay, could help to confirm the reduction of Usp22 
on tissue sections. 
Using Usp22lacZ animals we were able to visualize sites of Usp22 expression by making use of 
the LacZ reporter cassette. Notably, we could detect ubiquitous expression in the majority of 
tissues in embryos at E15.5. Its presence in the majority of tissues and its high abundance 
during embryonic development could explain why a complete loss of Usp22 has systemic 
consequences. In fact, we observed global growth retardation in adult Usp22lacZ/lacZ mice which 
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weighed approximately 40% less than their wild type littermates. Previously, we were able to 
show that Usp22lacZ/lacZ mice were characterized by a differentiation shift in the small intestine, 
i.e. the number of Oflm4-positive stem cells and therefore the rate of differentiated Goblet, 
enteroendocrine and Paneth cells was increased (Kosinsky, 2013; Kosinsky et al., 2015). 
Accordingly, we detected similar differentiation shifts in the brain in which the number of 
precursor cells was decreased. These results suggest that differentiation processes in the 
intestinal epithelium and the cerebral cortex are partially regulated by USP22. Notably, while 
the gross morphology of the small intestine was not affected, the neuronal density within the 
cortex was decreased in Usp22lacZ/lacZ animals. Therefore, we hypothesize that global 
differentiation and lineage specification, at least in some organs, are USP22-dependent. 
However, depending on tissue-specific cofactors, the consequences of Usp22 loss could vary. 
In order to investigate the alterations underlying the effects upon Usp22 reduction, we analyzed 
gene expression changes in mouse embryonic fibroblasts. Subsequent gene ontology analysis 
revealed an association of USP22 and differentiation-/proliferation-associated processes. 
Previously published data in murine embryonic stem cells (ESCs) support our findings since 
Usp22 expression was shown to be induced during ESC differentiation and to be required for 
proper differentiation into all three germ layers. The authors postulated that this function was 
mediated by USP22-associated H2B deubiquitination which controls transcription of the 
repressing factor Sex-Determining Region Y-Box 2 (SOX2) (Sussman et al., 2013). 
Consistently, our group demonstrated an increase of H2Bub1 levels during the differentiation 
of human mesenchymal stem cells (Karpiuk et al., 2012). However, in the present study, 
immunohistochemical stainings for H2Bub1 in the small intestine suggest that the effects of 
USP22 on differentiation are independent from its ability to deubiquitinate histone H2B since 
global H2Bub1 levels were unaffected by USP22 loss. Notably, a recent report from Atanassov 
and co-workers also revealed that global H2Bub1 levels were not elevated upon USP22 
depletion but rather remain unchanged (Atanassov et al., 2016). Therefore, it would be possible 
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that, depending on tissue-specific cofactors, USP22 exerts its function via H2B deubiquitination 
or that USP22 and H2Bub1 affect differentiation independent from one another. To address 
this question, studies in several tissues and cellular differentiation systems would be 
necessary. Taken together, the Usp22lacZ mouse line enabled us to uncover a role of USP22 
in cell differentiation and lineage specification in diverse organ systems. This observation was 
confirmed by microarray studies using MEFs from the same mouse line. Interestingly, these 
findings on differentiation may also be relevant in cancer since so-called cancer stem cells 
represent a subpopulation within a tumor and have been proposed to be able to self-renew and 
give rise to cells with divergent phenotypes. Thereby they can contribute to intratumoral cell 
heterogeneity and can be responsible for cancer initiation, progression and/or recurrence 
(Dawood et al., 2014; Zhang et al., 2015). Notably, in previous studies Glinsky described 
USP22 as a component of the 11-gene signature and speculated that this expression profile 
identifies lesions with cancer stem cell properties (Glinsky, 2005; Glinsky, 2006). Therefore, 
USP22 has been designated as a “putative cancer stem cell marker” in previous reports (Li et 
al., 2014b; Zhang et al., 2008b; Zhang et al., 2008a). Indeed, our data imply that USP22 could 
influence tumorigenesis by affecting differentiation properties of cells, possibly also affecting 
cancer stem cells. This hypothesis was supported by the mRNA-seq approach and subsequent 
GO analyses in human CRC cells which supported a function of USP22 in controlling 
differentiation-related genes in SW837 and SW480 cells.  
 
4.2 Intestinal Usp22 deletion causes mild spontaneous intestinal inflammation 
To evaluate the role of USP22 in intestinal tumorigenesis, we generated mice with a conditional 
intestine-specific ablation of Usp22. An additional APC truncation (APC1638N) and/or DSS-
mediated colitis were utilized to promote tumorigenesis in these animals. To investigate the 
role of Usp22 in intestinal cancer formation in more detail, we made use of three different 
treatment options. There were two models for inflammation-induced CRC in which mice were 
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treated with the chemical agent DSS to induce colitis. Experimental mice in the first cohort 
(Tam-DSS) were injected with Tamoxifen to induce the intestinal ablation of Usp22 and 
afterwards DSS was administered. This cohort allowed us to observe the consequences of 
Usp22 loss on colitis burden and subsequently on the formation of inflammation-induced 
tumors. In contrast, the DSS-Tam animals were treated with DSS first, and four weeks later, 
Usp22 was deleted. In this cohort we could ensure that the colitis burden is comparable in all 
animals and that inflammation intensity was not affected by an intestinal-specific Usp22 loss. 
Finally, we determined the effect of Usp22 ablation in a model for sporadic colorectal cancer 
formation. For this purpose, mice were injected with Tamoxifen, but were not treated with DSS 
(Tam cohort). 
Health parameters were checked on a regular basis, including body weight, stool consistency 
and intestinal bleedings. In the majority of mice, DSS treatment resulted in weight loss, diarrhea 
and bleedings. Especially in the Tam-DSS cohort, APC1638N/+, Usp22-/- mice displayed an 
increased burden. It should be mentioned that also in wild type mice not treated with DSS (Tam 
cohort) intestinal bleedings were detected according to the Guaiac test results. It has been 
reported that the risk of false-positive outcomes is high using this method (Roslani et al., 2012). 
However, even when considering this false-positive “background”, APC1638N/+, Usp22-/- animals 
showed increased bleeding intensities, including bloody anuses. Mice with this genotype were 
frequently affected by increased loss of body weight. Moreover, we detected that the colons in 
APC1638N/+, Usp22-/- animals were shorter than in wild type littermates. In a study on 
inflammatory bowel disease patients it was detected that individuals with ulcerative colitis had 
significantly shorter intestines compared to the healthy control group (Nordgren et al., 1997). 
Therefore, the decreased colon length in APC1638N/+, Usp22-/- mice is likely indicative of severe 
inflammatory burden. In previous studies it was reported that depending on the mouse strain, 
recovery and complete disappearance of symptoms was observed approximately 4-5 weeks 
after DSS administration (Chassaing et al., 2014). In both cohorts used for inflammation-
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induced CRC (Tam-DSS and DSS-Tam) the DSS treatment was terminated when animals 
were 12 weeks old. Interestingly, APC1638N/+, Usp22-/- animals mice had to be sacrificed at an 
age of 12-20 weeks in the Tam-DSS and 18-40 weeks in the DSS-Tam cohort. Therefore, we 
can postulate that several APC1638N/+, Usp22-/- mice in the Tam-DSS group may have still been 
affected by the acute inflammation when they died. However, some mice with this genotype 
died when the symptoms of colitis should have disappeared. Surprisingly, in the histological 
assessment of APC1638N/+, Usp22-/- colons, all mice were affected by similar rates of 
inflammation regardless of whether they died during the acute phase of colitis or when 
symptoms should have already disappeared. Morphological observations made in all these 
mice (i.e. shortening of colons) supported the conclusion that the inflammation was not 
resolved in these animals. In addition, we detected severe lymphocyte accumulation upon the 
loss of Usp22. In fact, large mucosal segments were infiltrated by immune cells resulting in 
increased H-scores. Remarkably, even mice not treated with DSS at all (Tam cohort) were 
characterized by mild inflammatory symptoms upon Usp22 knockout. These findings suggest 
that an intestinal knockout of Usp22 results in prolonged inflammatory reactions upon DSS 
treatment and/or a slowed recovery from inflammation.  Moreover, we assume that the loss of 
Usp22 maintains a latent inflammatory environment in general, even without DSS treatment. 
As a consequence, upon additional induction of colitis, an excessive immune response is 
triggered which is further maintained in Usp22-/- animals even after symptoms have 
disappeared in wild type mice. This may not only happen due to an excessive immune 
response but may also be the result of attenuated feedback mechanisms 
controlling/terminating the inflammatory reaction. Generally, delayed resolution of inflammation 
was associated with, for instance, increased immune cell infiltration, reduced stimulation of 
tissue repair or inefficient efferocytosis (Ortega-Gomez et al., 2013). However, whether one of 
these processes underlies the elevated inflammatory response in Usp22-/- mice is not yet clear 
and should be addressed in future studies. 
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As a consequence of intestinal inflammation, the crypt integrity is compromised which 
interferes with the normal colonic functions including nutrient absorption (Xavier and Podolsky, 
2007). Notably, it was demonstrated that children suffering from inflammatory bowel diseases 
commonly exhibit growth defects due to chronic inflammation and resultant malnutrition 
(Sanderson, 2014). This epiphenomenon of latent inflammation could, besides the role of 
USP22 in differentiation, explain the phenotype of Usp22lacZ/lacZ mice which were characterized 
by growth retardation. Whether Usp22lacZ/lacZ mice were affected by mild intestinal inflammation 
was not tested in those studies and remains to be elucidated. 
To obtain more insights into the impact of Usp22 loss in inflammation, we performed in vivo 
analyses using an acute colitis model. Two days after terminating the DSS treatment, thus 
during the acute phase of colitis, mice were sacrificed. As expected, the disease activity index 
(DAI) including weight loss, stool consistency and intestinal bleedings was elevated in Usp22-
/- animals. It was previously described that a heterozygous APC mutation leads to anemia and 
increased spleen size (Qadri et al., 2012). Consistently, the ratio of hematocrit in blood samples 
was decreased in APC1638N/+ animals. Moreover, these mice possessed pale livers, kidneys as 
well as bigger and heavier spleens. Notably, this phenomenon was slightly aggravated by the 
loss of Usp22. Importantly, strong inflammatory reactions were described to modulate bone 
mineral density and increase fracture risk (Ali et al., 2009; Bernstein et al., 2000). Thus, we 
measured biomechanical properties of bones and observed more fragile bones in APC+/+, 
Usp22-/- animals. Previously, it was shown that APC mutations increase bone mineral density 
(Miclea et al., 2010). However, we could not detect any differences in bone strength between 
APC wild type and APC1638N/+ animals with USP22 wild type status. In fact, the majority of mice 
had similar bone strengths except for APC+/+, Usp22-/- animals. It is not clear why the knockout 
of Usp22 alters bone characteristics only in APC+/+ but not APC1638N/+ mice. To verify these 
findings and to obtain further insights into the role of Usp22 in inflammation-induced bone 
fragility, mouse cohorts with increased n-numbers and a control group which is not treated with 
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DSS are necessary. In addition, computed tomography scans should be performed to obtain 
further insights into bone structure and properties. Together, our results reveal that intestinal 
Usp22 loss enhances inflammation burden in DSS-treated mice, and, remarkably, can even 
cause spontaneous inflammation. Notably, the colitis burden was sufficient to induce 
inflammation-associated bone fragility in Usp22-/- mice. The latent inflammatory environment 
in Usp22-/- animals could be involved in growth retardations in Usp22lacZ/lacZ animals and favor 
colorectal tumor formation.  
To reduce burden, IBD patients are frequently treated with anti-inflammatory drugs such as 
aminosalicylates and corticosteroids or immunosuppressant drugs including azathioprine, 
cyclosporine and TNFα inhibitors (e.g. Infliximab) (Baumgart and Sandborn, 2007). The 
efficacy of several of these drugs was also demonstrated in DSS-induced colitis in mice (Fukata 
et al., 2011; Kim et al., 2010; Myrelid et al., 2015; Sann et al., 2013). However, long-term usage 
of these drugs can have adverse effects, for instance on the intestinal microbiota (Rogers and 
Aronoff, 2016), an aspect of intestinal inflammation which has not been considered in this 
project. As mentioned before, dysbiosis is associated with colitis (Rehman et al., 2010). Initially, 
to test whether the microbiota is involved in the intestinal tumor development, it would be 
possible to treat the mice with antibiotics. As demonstrated by Peuker and colleagues, 
changing the composition of the microbiota by antibiotic treatment can inhibit the intestinal 
tumor growth in Apcmin/+ mice (Peuker et al., 2016). Moreover, identifying and comparing the 
composition of the microbiota in Usp22 wild type and knockout animals could be informative 
and could potentially be correlated to the inflammation intensity in these animals. This 
identification could, for instance, be implemented by 18S rRNA sequencing of the microbiome 
(Dollive et al., 2012). Moreover, Souza and co-workers demonstrated elegantly how the 
supplementation of certain microorganisms can alleviate the effect of colitis in mice (Souza et 
al., 2016). Initially, they induced colitis in animals and observed that upon administration of the 
Escherichia coli strain Nissle 1917 (EcN), the colitis burden was decreased. Afterwards, they 
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applied the fecal content of EcN-treated animals to germ-free mice which were subsequently 
subjected to colitis. Indeed, these mice were protected from colitis-induced symptoms 
indicating to what extent bacteria can influence susceptibility to IBDs. Studies like this suggest 
that fecal microbiota transplantations (FMTs) present promising treatments for IBD patients. In 
a recent meta-analysis, it was demonstrated that FMTs lead to clinical remission in 22% of UC 
and 60.5% of CD patients (Colman and Rubin, 2014). To what extent anti-inflammatory drugs 
or FMTs could ameliorate the effects of Usp22 loss-induced inflammation and therefore lead 
to a lower tumor burden would be an interesting research question remaining to be elucidated. 
 
4.4 Intestinal Usp22 loss promotes inflammation-induced and sporadic CRC 
After measuring the colon length, the number of intestinal tumors was counted and the location 
of cancer lesions was determined. To our surprise, Usp22-/- mice were characterized by an 
elevated tumor burden in both the small intestine and colon. Notably, the observation that 
Usp22 promotes intestinal tumor formation was made in all three experimental cohorts, i.e. 
Tam-DSS, DSS-Tam and Tam. This finding emphasizes the need to compare the three 
experimental cohorts in more detail to determine the impact of Usp22 in inflammation-induced 
(via DSS treatment) and sporadic CRC. When comparing the two groups for inflammation-
induced CRC, it is clear that the Tam-DSS treatment caused more tumors in all genotypes in 
both the small intestine and colon. In fact, the tumor incidence almost doubled in this group. 
As mentioned before, Usp22 loss alone (Tam cohort) resulted in mild latent inflammation, which 
could be the underlying reason for the exacerbated inflammatory processes in Tam-DSS mice. 
In contrast, DSS-Tam mice did not experience the early loss of Usp22. Instead, the burden of 
colitis was similar in all animals and Usp22 was inactivated during or shortly after the process 
of epithelial healing. In other words, after Usp22 knockout, inflammatory processes were 
initiated in Tam-DSS animals and exacerbated during colitis while DSS-Tam mice did not 
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develop this latent inflammation before DSS treatment. Consequently, Tam-DSS animals 
developed more intestinal tumors than DSS-Tam mice.  
As expected, mice only treated with Tamoxifen (Tam cohort) had the lowest tumor burden in 
the colon probably because they did not undergo colitis. Interestingly, Usp22-/- mice in the Tam 
group showed the highest abundance of tumors in the small intestine. Moreover, several 
tumors were detected in the colons of these animals. These findings were surprising since they 
indicate that the loss of Usp22 alone is sufficient to trigger sporadic tumor formation; mainly in 
the small intestine. This observation supports our hypothesis that the loss of Usp22 triggers a 
latent inflammation in the intestinal system which consequently promotes tumorigenesis. 
Therefore, one should keep in mind that, if Usp22 loss alone can maintain a mild latent 
inflammation, the tumor formation in our “sporadic” Tam cohort is most likely, at least to some 
extent, also inflammation-induced. 
Interestingly, the three experimental cohorts showed varying tendencies when evaluating the 
tumor burden in the different intestinal segments. As mentioned before, Tam-DSS was 
associated with the highest tumor number in the colon. In contrast, in the small intestine, Tam 
mice were characterized by the most severe tumor burden, especially in APC1638N/+ mice. 
Generally, colitis exerts strongest effects in the colon (Adams and Bornemann, 2013) which 
could explain why the Tam-DSS group shows most cancer lesions in the colon. However, it is 
challenging to clarify why the tumor burden in the small intestine is highest in the Tam cohort. 
One possible explanation is based on the assumption that Usp22 loss alone results in a latent 
inflammatory environment which finally leads to tumorigenesis. When we expect that the APC 
mutation is mainly correlated with tumor growth in the proximal region, it is likely that immune 
cells migrate to the sites of oncogenic growth in the proximal intestinal regions (Fodde et al., 
1994). This lymphocyte infiltration in turn can promote tumorigenesis in these segments. 
Indeed, it was reported that immune cells are recruited to cancer lesions where they produce 
cytokines and chemokines and thereby accelerate oncogenic growth (Klampfer, 2011). 
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Assuming that intestinal Usp22 loss promotes latent inflammation, it can be expected that the 
rate of infiltrating lymphocytes is increased in Usp22-/- animals, which causes an elevated tumor 
burden in the small intestine. In contrast, if APC1638N/+, Usp22-/- mice are subjected to DSS 
treatment there will be lymphocyte accumulations at the site of acute inflammation, i.e. the 
colon, but a portion of lymphocytes will still migrate to the site of APC1638N-associated 
tumorigenesis, i.e. the proximal SI. This hypothesis would explain the accumulation of tumors 
in the proximal/medial small intestine segments and the colon of APC1638N/+, Usp22-/- mice.  
The phenomenon that there was an accumulation of tumors in the proximal and medial 
segments of the small intestine could be explained by further scenarios. First, the 
aforementioned abundance of the APC mutated tumors in the proximal intestinal region (Fodde 
et al., 1994) could have been augmented by the additional loss of Usp22. Thus, the interplay 
between APC mutation and Usp22 ablation would be the driving factor here. Moreover, the 
Villin promoter is highly active in the upper intestine. Thus, it is possible that the cells in this 
region were strongly affected by the Usp22 loss and therefore, the rate of Usp22 loss-related 
tumorigenesis was increased independent of APC mutation. Here, it would be imaginable that 
this phenomenon is HSP90-dependent. In our in vitro studies we noticed increased 
temperature sensitivity of USP22 knockdown cells, possibly due to the USP22 loss-related 
degradation of the heat shock protein HSP90AB1. Assuming that HSP90AB1 levels are also 
decreased in intestinal epithelial cells in Usp22-/- animals, these cells would display a higher 
sensitivity towards inflammation-induced stress. Thus, these cells would be prone to stress-
related apoptosis or necrosis, which favors and exacerbates inflammation (Davidovich et al., 
2014) and therefore promotes tumorigenesis, for instance, by the production of reactive oxygen 
and nitrogen species (Meira et al., 2008) as mentioned in section 1.5. Since the activity of the 
Villin promoter is highest in the proximal SI region, cells located there are strongly affected by 
USP22 loss and HSP90AB1 reduction. This would potentially explain the increased tumor 
abundancy in the upper SI segment. 
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Importantly, the tumors in Usp22-deficient mice were shown to be more aggressive. Invasive 
tumors could exclusively be found in Usp22-/- animals, independent from the APC status. 
Notably, this increases the risk of metastasis and is therefore associated with a significantly 
poorer prognosis (O'Connell et al., 2004). However, we could not detect any metastases in our 
experimental mice which, nonetheless, could still mean that microinvasion has taken place. In 
addition to invasive adenocarcinomas, we made another interesting observation. The loss of 
Usp22 was correlated with the presence of intramural mucus accumulations and remarkably, 
tumors with a mucinous appearance. Interestingly, patients with colitis-associated CRC 
frequently display mucinous lesions (Higashi et al., 2011) regularly due to a high abundance of 
the mucin components MUC1, MUC2 and MUC5AC (Slotkin and Seidler, 1975). Notably, 
Usp22lacZ/lacZ mice were characterized by an increased abundance of MUC2-positive Goblet 
cells. Therefore, it is likely that APC1638N/+, Usp22-/- mice show a similar increase in Goblet cells; 
however, this still needs to be verified by IHC. As mentioned before, mucinous presentation is 
generally correlated with a poor prognosis compared to normal adenocarcinomas (Verhulst et 
al., 2012). Since mucinous carcinomas are frequently microsatellite instable, a PCR-based MSI 
analysis would have been interesting to obtain further insight into the pathology of tumors 
formed upon the loss of Usp22. The detection of MSI in murine samples based on PCR and 
capillary electrophoresis has already been described (Bacher et al., 2005; Kabbarah et al., 
2003) and would be an appropriate approach to detect the rate of mono- or dinucleotide repeats 
upon Usp22 loss. Together, we could demonstrate that the loss of Usp22 promotes sporadic 
and inflammation-induced colorectal tumorigenesis; however, further analyses are needed to 
reveal tumor characteristics. 
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4.5 Intestinal Usp22 deletion in APC1638N/+ animals decreases life span 
One of the key observations made in this project was the short life span of Usp22-deleted mice. 
Already during the first DSS treatments which we performed (Tam-DSS cohort), we could 
measure severe weight loss and intestinal bleedings in APC1638N/+, Usp22-/- mice. This 
observation was confirmed in DSS-Tam animals. In particular, shortly before the mice needed 
to be sacrificed we noticed worsening of the health status, i.e. swollen abdomen, high weight 
loss, pale extremities, rough fur and limited movements. When APC1638N/+, Usp22-/- mice were 
sacrificed due to their physical condition we regularly detected intussusceptions and rectal 
prolapses. Generally, an intussusception reflects a condition in which a proximal intestinal part 
invaginates into a distal segment. This phenomenon can be observed when the peristaltic 
movement is disturbed, for instance, due to a large tumor (Honjo et al., 2015), and can result 
in an acute intestinal obstruction (Tan et al., 2003). Similarly, a rectal prolapse describes an 
intussusception of the rectal segment through the anus (Hatch and Steele, 2013). In patients, 
late diagnosis can lead to intestinal perforation with consequent peritonitis and eventually 
sepsis, which results in an increased mortality risk (Udo et al., 2016).  
In our study, the detection of intussusceptions and prolapses already indicated the presence 
of tumors in Usp22-/- animals. After sacrificing mice, intussusceptions were predominantly 
found in the proximal region of APC1638N/+ animals, where the frequency of tumors in proximal 
intestinal segments has been described before (Fodde et al., 1994). Indeed, within SI regions 
affected by intussusceptions, large tumors were found.  
Regarding survival and tumor burden in the SI, similar observations were made in mice which 
were not treated with DSS (Tam group), however, lethality was clearly accelerated by colitis. 
In general, the survival rates of APC+/+ animals were nearly unaffected and animal mortality 
was infrequent. Moreover, outcomes of Usp22 wild type and heterozygous animals were similar 
in all three treatment cohorts and no statistically significant variations between these two 
genotypes were observed. Notably, the Tam-DSS group was associated with the shortest 
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survival of APC1638N/+, Usp22-/- mice while only marginal differences were detected between the 
DSS-Tam and Tam mice.  
Our data imply that an intestinal loss of Usp22 causes a latent inflammation in the small 
intestine and colon. This inflammatory state likely accelerates tumorigenesis, which 
subsequently induces early lethality in APC1638N/+, Usp22-/- mice, frequently due to 
intussusceptions or prolapses. Therefore, we hypothesize that treating these animals with anti-
inflammatory drugs or antibiotics could lower inflammation and tumor burden. Even though 
CRC-related death could not be prevented completely due to the APC mutation, this measure 
would be likely to extend survival rates. 
 
4.6 The heterogeneity of USP22 expression in colorectal cancer  
In recent years a significant amount of gene expression and mutation data has become 
publically available. Analyses of these data provide an excellent source of information on gene 
expression profiles, mutation occurrences and patient survival in the field of cancer research. 
In this study, we took advantage of several databases, i.e. OncomineTM, cBioPortal, and the 
IST Online® database, to evaluate USP22 expression levels in colorectal cancer patient 
samples. Based on previously published studies in which USP22 overexpression was detected 
in several cancer types (Melo-Cardenas et al., 2016), we expected to detect elevated USP22 
levels in CRC patients using these online tools. Remarkably, analyses of all databases led to 
the conclusion that USP22 expression is not as ‘black and white’ as described in previous 
studies. In fact, approximately half of listed CRC patients displayed decreased expression of 
USP22. Consistently, USP22 mRNA levels were found to be decreased in several subgroups 
of cecal, colonic or rectal cancer in another database. Interestingly, some CRC datasets 
available on cBioPortal revealed a heterozygous deletion of the USP22 gene in 44-49% of all 
colorectal cancer patients. In comparison, the well-known tumor suppressor TP53 was 
heterozygously deleted in 51-57% and APC in 19-25% of the patients. This underlines the 
Discussion 
172 
 
possibility that USP22 may serve as a tumor suppressor depending on the biological context. 
Accordingly, USP22 protein levels were highly variable in a panel of colorectal cancer cell lines. 
These cells were subsequently transfected with siRNAs targeting USP22 in order to test the 
effect on morphology and proliferation after depletion. While some cell lines were not affected 
by the loss of USP22, in most cells the knockdown resulted in decreased proliferation. 
Interestingly, growth was enhanced in HCT116 cells, which may therefore more closely reflect 
the condition observed in our in vivo approaches, i.e. aggressive growth of colorectal cancer 
cells upon USP22 depletion. In contrast, Xu and co-workers reported decreased cell 
proliferation following USP22 knockdown in HCT116 cells (Xu et al., 2012). Since we could 
reproduce our findings numerous times, we considered our findings as being reliable. After 
these Celigo® measurements, cell line characteristics such as MSI/CIN/CIMP status, were 
evaluated in order to elucidate whether they could be correlated with the proliferation pattern 
of siUsp22 cells. Since we did not detect any correlations, we also considered mutation profiles 
of the cell lines, however, no connection could be made. This heterogeneity was further 
confirmed when testing the migration potential upon USP22 knockdown. While the migration 
potential was inhibited in SW48 cells, we observed the opposite effect in HCT116 cells. 
Meanwhile we aimed to verify that the effects we observed were mediated by a reduction of 
USP22 alone and not by siRNA-associated off-target effects in which the homolog USP27X is 
targeted. For this purpose, we performed individual knockdowns of USP22, USP27X as well 
as both USPs simultaneously in HCT116 and SW48 cells. While none of the conditions showed 
an effect on cell morphology, as expected, USP22 reduction resulted in decreased cell growth 
in SW48 cells. Moreover, in this cell line USP27X loss and the dual knockdown showed similar 
effects to USP22 ablation. In contrast, in HCT116 cells USP22 loss enhances proliferation 
while siUsp27x cells displayed severely impaired proliferation. Notably, the dual knockdown 
could rescue the devastating effect of USP27X on cell growth. Since the siRNAs targeting 
USP22 and USP27X, respectively, had highly different effects on proliferation, we could rule 
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out the possibility that the USP22-siRNAs show off-target effects by modulating USP27X 
levels. Interestingly, our proliferation measurements suggest that if loss of USP27X 
decelerates the growth of CRC cells, it functions as an oncogene. In contrast, the additional 
loss of USP22 rescues this effect, implying that it serves as a tumor suppressor in this context. 
This assumption is supported by a recent report in which the shRNA-mediated loss of USP27X 
resulted in decreased growth of breast cancer cells in a xenograft approach (Atanassov et al., 
2016). In contrast, in non‐small cell lung cancer cells, USP27X was described to act as a tumor 
suppressor in vitro (Weber et al., 2016). Thus, the effects which we have observed in HCT116 
may be cell line-specific and possibly, the role of USP27X is just as context-specific as the 
function of USP22 in tumorigenesis. 
 
4.7 The interaction between USP22 and HSP90AB1  
To obtain further insights into the mechanisms underlying the effect of USP22 in CRC cells, 
we performed mRNA-seq in SW837 and SW480 cells. These cell lines were selected since 
they underwent only marginal changes upon USP22 knockdown. Therefore, we expected that 
the secondary effects caused, for instance, by dramatic changes in cell phenotype, would be 
minimal and negatively influence results. We were able to confirm that HSP90AB1 is 
downregulated in siUsp22 cells. Generally, HSP90 family members are involved in cellular 
adaptation to stress (Whitesell and Lindquist, 2005). While the stress-inducible HSP90α 
isoforms were not affected by USP22 depletion, the constitutively expressed HSP90β member 
HSP90AB1 was downregulated. Consistently, when we performed heat shock assays, we 
demonstrated that siUsp22 cells possessing decreased HSP90AB1 levels are characterized 
by elevated temperature sensitivity. Generally, increased expression of HSP90 family 
members correlated with human malignancies (McDowell et al., 2009) and a variety of HSP90 
inhibitors has been tested in clinical trials (Solarova et al., 2015). Surprisingly, when analyzing 
the frequency of heterozygous deletions using cBioPortal it was determined that HSP90AB1 is 
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affected in 3-8% of CRC patients and in up to 30% of individuals suffering from other cancers. 
Thus, similar to USP22, the levels of HSP90AB1 in CRC can be heterogeneous. When 
correlating these findings to our in vivo results indicating that Usp22 deletion contributes to 
intestinal tumorigenesis, there are three possible scenarios. First, it would be imaginable that 
the tumor-promoting effect of USP22 ablation is in part mediated by the resultant HSP90AB1 
reduction. Second, it is imaginable that the reduction of HSP90AB1 via USP22 ablation does 
not only sensitize cells to elevated temperatures but also to inflammatory signaling which can 
also be considered as stress. This scenario would support our hypothesis based on our in vivo 
approaches in which Usp22 loss was associated with increased inflammation. If USP22 has a 
general role in protecting the cell from stress-induced factors, Usp22 knockout mice could be 
affected by increased inflammation burden. Consequently, the risk of developing tumors would 
increase in these animals. While several studies published so far show that the inhibition of 
HSP90 suppresses inflammation-associated processes (Lilja et al., 2015; Zhao et al., 2013), a 
dual role of HSP90, protective and cytotoxic, was observed as well (Paepe et al., 2009). In 
order to confirm this assumption the HSP90AB1 levels should be determined in mouse tissue, 
i.e. by western blot, qRT-PCR and IHC. A third possibility is that the reduction of HSP90AB1 
in our in vitro experiments is a bystander effect and is not responsible for the effects we observe 
following USP22 loss. Instead, another unknown factor may be associated with the tumor 
suppressor activity of USP22. 
Subsequent analysis of the functional interaction by Co-IP revealed that USP22 and 
HSP90AB1 form a complex. Our finding was supported by a proteomics-based study in which 
several heat shock protein 70 members were identified as USP22 interaction partners (Sowa 
et al., 2009). Afterwards, by evaluating HSP90AB1 levels upon treatment with the proteasome 
inhibitor MG-132, we could demonstrate that decreased HSP90 amounts in siUsp22 cells are 
dependent upon proteasomal degradation of this protein. Due to the physical interaction and 
the temperature sensitivity of siUsp22 cells we speculated that cancer cells with low USP22 
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levels are highly dependent on the residual HSP90 expression. Consequently, we aimed to 
take advantage of low HSP90 levels created by USP22 loss to induce synthetic lethality with 
the help of the HSP90 inhibitor Ganetespib. Indeed, we could observe that cells with a siRNA- 
and CRISPR/Cas9-mediated depletion of USP22 are more sensitive to Ganetespib. Based on 
this finding we hypothesize that under physiological conditions, USP22 deubiquitinates HSP90 
family members and thereby stabilizes them (Figure 61). Subsequently, HSP90 can facilitate 
the formation of the P-TEFb complex which will be recruited by BRD4 to phosphorylate the 
RNA Pol II. In contrast, the loss of USP22 leads to the poly-ubiquitination of its substrate 
HSP90, resulting in its proteasomal degradation. Consequently, formation rates of the P-TEFb 
complex would be decreased. Thus, P-TEFb binding rates to BRD4 and therefore RNA Pol II 
phosphorylation-associated transcriptional elongation would be reduced. In turn, transcription 
levels of HSP90 and further genes potentially preventing tumorigenesis would be reduced. 
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Figure 61: Proposed model of the effect of USP22 loss on HSP90 levels. (A) Under normal 
conditions, HSP90 facilitates the formation of the P-TEFb complex. Upon recognition of 
acetylated marks, BRD4 recruits P-TEFb and CDK9 phosphorylates the RNA Pol II. Thereby 
promoter proximal pausing is released and transcription, e.g. of HSP90AB1, is promoted. (B) 
In the absence of USP22, polyubiquitination rates of HSP90 increase, resulting in its 
proteasomal degradation. As a consequence, the P-TEFb complex formation is diminished, 
leading to lower RNA Pol II phosphorylation and decreased transcriptional elongation. 
Reduced HSP90 levels elevate the cells’ sensitivity towards stress stimuli and therefore, cells 
are highly dependent on the residual HSP90 rates. 
 
Based on this potential model, we tested the effect of the BET inhibitor JQ1. Normally, HSP90 
facilitates the assembly of the P-TEFb complex which is subsequently recruited by the BET 
protein BRD4. We proposed that after the Ganetespib-mediated inhibition of HSP90, the PTEF-
b stability and therefore its binding to BRD4 is reduced. Consequently, by inhibiting BRD4 using 
JQ1 and thus preventing the recruitment of PTEF-b to chromatin, we expected to observe 
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similar effects in siUsp22 cells as after Ganetespib treatment. Interestingly, BRD4 has also 
been identified as a HSP90 client which is stabilized by this heat shock protein (Zhou et al., 
2015). Indeed, following JQ1 treatment we could detect increased sensitivity of siUsp22 cells 
towards this small molecule inhibitor. While it is not completely clear why synthetic lethality was 
induced using JQ1, there are two possible scenarios. First, it is imaginable that, similar to 
HSP90, BRD4 is normally deubiquitinated by USP22 and that siUsp22 cells are dependent on 
the residual BRD4 levels. Moreover, this stabilization could be mediated by HSP90 as 
previously described (Zhou et al., 2015) and therefore indirectly by USP22. Indeed, we could 
detect sporadic BRD4 reduction upon depletion of USP22. However, this effect was highly 
variable. Another possibility could be that by the inhibition of BRD4, the transcription patterns 
of several genes are affected and that, among others, HSP90 expression is further decreased. 
The reduction of HSP90 can then result in decreased P-TEFb complex assembly which leads 
to reduced phosphorylation of RNA Pol II. Thus, the release of promoter proximal pausing was 
decreased which can affect a variety of genes. Taken together, we speculate that siUsp22 cells 
are dependent on their low HSP90 and possibly BRD4 levels and a further decrease by 
Ganetespib or JQ1 is lethal for the cells. In future experiments this could be verified by testing 
BRD4 protein levels upon Ganetespib treatment. Alternatively, gene expression profiles after 
JQ1 and Ganetespib treatment as well as USP22 knockdown could be identified by mRNA-
seq and subsequently compared to evaluate the overlap of affected genes between these 
conditions. In summary, even if the reduction of HSP90AB1 is only a bystander effect after 
USP22 ablation, these outcomes demonstrate that it is possible to exploit USP22/HSP90AB1 
reduction in CRC cells and to target them based on this characteristic making use of the 
concept of synthetic lethality.  
 
 
Discussion 
178 
 
4.8 USP22: oncogene or tumor suppressor? 
One striking outcome of this project is the discrepancy when comparing our data to previously 
published reports. To date, several studies described that USP22 overexpression promotes 
tumor development or progression suggesting an oncogenic role of USP22. Most studies 
demonstrating elevated USP22 levels in cancer patient samples were based either on 
microarray data or immunohistochemical stainings. However, some of the antibodies used for 
the IHC approaches showed two or more bands when we tested them in western blot analyses. 
Thus, the specificity for USP22 of these antibodies is questionable and it would be possible 
that USP51 and/or USP27X which have a structure highly similar to USP22, were detected by 
these antibodies as well. As mentioned before, we could not find a commercially available 
antibody which specifically stains USP22 on tissue sections. Intriguingly, in the current study 
we could demonstrate in vivo and in vitro that USP22 loss can elevate tumor burden. Therefore, 
our results imply a rather tumor suppressive function of USP22. This is a novel finding which 
questions the universality of most previous studies focusing on the role of USP22 in cancer. 
Thus, we do not hypothesize that only one aspect can be true: that USP22 expression is either 
elevated or reduced in malignancies. Instead, it is well accepted that cancer reflects a highly 
heterogeneous group of diseases and the molecular signatures can be vastly diverse 
(Budinska et al., 2013). In our study, the heterogeneity of USP22 expression could be 
demonstrated in a number of experiments. First, when investigating USP22 expression levels 
in databases we observed that a high fraction of CRC patients were characterized by 
decreased USP22 expression levels. Second, heterozygous USP22 deletions were verified in 
approximately half of CRC patients. Accordingly, USP22 protein levels were shown to be highly 
heterogeneous in a panel of CRC cell lines and the knockdown of USP22 had diverse effects 
on the proliferation of these cells. Indeed, in most tested cell lines, USP22 ablation slowed the 
growth of CRC cells. However, some cell lines were not affected at all, while in HCT116 cells, 
proliferation was elevated upon the loss of USP22. It is challenging to find out which factors 
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determine whether high or low USP22 levels promote tumorigenesis. In general, tumor biology 
is an extremely complex field since it can be influenced by several factors such as the site of 
the tumor, and therefore tissue-specific determinants, tumor subtype and genetic signature. 
Therefore, it is possible that USP22 loss only favors growth and progression of certain CRC 
subtypes. As mentioned in our results, Usp22-/- animals were characterized by the presence of 
mucus accumulations as well as tumors with a mucinous presentation. Moreover, we 
demonstrated that oncogenic growth was accelerated in an inflammatory environment when 
Usp22 levels were low. Therefore, this could mean that USP22 only acts as a tumor suppressor 
in cancer lesions with a mucinous appearance or under inflammatory circumstances while it 
otherwise functions as an oncogenic factor. 
Moreover, it would be imaginable that the function of USP22 in tumorigenesis is indeed 
dependent on H2Bub1 levels. As mentioned before, H2Bub1 was described as a tumor 
suppressive mark (Cole et al., 2015; Melling et al., 2016) and under normal conditions, USP22 
deubiquitinates the core histone H2B, thus, it mediates the decrease of H2Bub1 levels (Zhang 
et al., 2008b). Even though we could not observe any changes in H2Bub1 levels upon USP22 
loss in our studies, depending on the tissue and tumor subtypes, USP22 could exert its cancer-
related effects via H2B deubiquitination. Thus, it would be possible that in some tissue types, 
overexpression of USP22 and the resultant decrease in H2Bub1 can be directly correlated to 
increased tumorigenesis. This could be the case in the previously published studies in which 
authors have described that increased USP22 expression leads to high oncogenic growth.  
However, counterintuitively, tumorigenesis could also be mediated by decreased H2Bub1 
levels due to decreased HSP90 expression caused by USP22 ablation. This could occur if 
USP22 loss decreases HSP90 levels, PTEF-b complex assembly efficiency decreases and 
therefore the phosphorylation rates of the RNA Pol II are reduced. The same is true for BRD4 
inhibition due to which PTEF-b can no longer be recruited by BRD4 and therefore RNA Pol II 
phosphorylation is impaired. Both scenarios can result in the condition that the adapter protein 
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WAC is no longer recruited by RNA Pol II, the RNF20/RNF40 complex is not bound and 
therefore H2B is not ubiquitinated. Consequently, the loss of H2Bub1 could be correlated to 
increased tumor formation rates. In order to test these hypotheses, tissue microarrays 
generated from several cancer types could be tested for their H2Bub1 levels by IHC and for 
USP22 levels using an in situ hybridization-based approach. It would be of great value to 
determine whether H2Bub1 loss is specific to certain cancer subtypes and whether these 
findings correlate with USP22 levels. 
Moreover, in future projects it would be interesting to elucidate whether USP22 can also act 
independently from the SAGA complex as has been demonstrated for USP51 and USP27X 
(Atanassov et al., 2016). To precipitate USP22 present in the SAGA complex, one could tag 
one SAGA-member and purify this protein including the USP22 bound to it. Using the same 
protein lysate the total USP22 amount can then be detected which allows the estimation of the 
abundance of “free”, unbound USP22. Moreover, USP22 targets and interaction partners could 
be identified in a mass spectrometry-based approach. Whether USP22 functions via these 
targets could subsequently be determined by assessing the consequences after depleting 
these proteins. Together, while USP22 was described as an oncogene in literature, it displayed 
tumor suppressive properties in our experimental setup. However, further research is 
necessary to determine whether USP22 functions within or independent of the SAGA complex 
in tumorigenesis and whether this function is associated with H2B monoubiquitination.  
 
4.9 USP22 as a target in colorectal cancer therapy? 
As recently discussed in a review by Melo-Cardenas et al., based on the literature USP22 
would represent an attractive target in cancer therapy. In fact, they reported that there is 
ongoing research to generate and optimize USP22 inhibitors (Melo-Cardenas et al., 2016). 
However, as shown in the current project, inhibiting USP22 could have devastating effects on 
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colorectal cancer patients since it could even accelerate tumor growth and lead to the formation 
of invasive carcinomas. Therefore, it is essential to further elucidate the mechanisms 
underlying the aggressive oncogenic growth due to reduced USP22 levels. It would be 
important to know, for instance, if a certain tumor subtype such as mucinous carcinomas is 
linked to low USP22 levels. Using tumor biopsies, USP22 levels and tumor characteristics 
could be determined and, according to the outcome of these analyses, therapy options can be 
defined. With this approach it could be prevented that a protein is inhibited which, in fact, acts 
as a tumor suppressor in several patients. However, it would be challenging to unravel all 
aspects underlying the heterogeneity of USP22 expression in CRC and, therefore, even after 
patient stratification, there remains a risk of selecting a suboptimal therapy option. With this 
consideration in mind, it would be a safer option to exploit the fact that some CRC patients are 
characterized by low USP22 expression and treat them with drugs that are already approved 
due to their high tolerance and anti-tumor efficacy. In our project, we were able to successfully 
induce synthetic lethality by treating CRC cells with USP22 reduction either with Ganetespib 
or JQ1. Ganetespib, a small molecule inhibitor of HSP90, is a promising agent tested in a 
variety of cancer types (Proia and Bates, 2014). Moreover, its advantage is its low toxicity as, 
among others, shown in colorectal cancer patients (Cercek et al., 2014). Comparatively, BET 
inhibitors are well-tolerable and currently used in several clinical studies testing its efficacy in 
various types of malignancies and further diseases (Ferri et al., 2016). Therefore, after 
determining the genetic profile of CRC patients, treatment with Ganetespib or BET inhibitors 
could be promising in individuals with low USP22 expression levels. Moreover, as described 
before, the potency of a number of (epigenetic) inhibitors could be further improved by 
combining them with other therapeutics. For instance, combinations with BRAF and MEK 
inhibitors were shown to overcome drug resistance and enhance the efficacy of Ganetespib 
(Acquaviva et al., 2014). Similarly, in previous studies, synergistic effects could be observed 
after combining JQ1 with the mTOR inhibitor rapamycin (Lee et al., 2015) as well as histone 
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deacetylase inhibitors (Shahbazi et al., 2016) and CDK inhibitors (Baker et al., 2015). 
Afterwards, it would be desirable to transplant our USP22-deficient CRISPR/Cas9 cells into 
immunodeficient mice via xenograft and test the effect of inhibition. Finally, we could create a 
new cohort of Usp22loxP Tam-DSS mice and directly treat them with the respective inhibitors 
after the knockout of Usp22. It would be particularly interesting from a clinical perspective if, 
indeed, the tumor burden in Usp22-/- animals could be reduced or even eliminated by the 
inhibitor treatment. 
 
4.10 Concluding remarks 
To date, several studies identified a number of substrates deubiquitinated by USP22 and have 
reported USP22 overexpression in diverse cancer types. However, the exact physiological 
function of USP22 and the mechanisms underlying its involvement in oncogenic growth needed 
to be elucidated and were addressed in the current study. For this purpose, we performed in 
vivo, in vitro and in silico analyses. By analyzing genetic mouse models, consequences of a 
global reduction (Usp22lacZ mice) and intestine-specific deletion (Usp22loxP mice) of Usp22 were 
detected in vivo, while human CRC cell lines and public databases were used for our in vitro 
and in silico studies, respectively. 
By analyzing Usp22lacZ animals we discovered that Usp22 is ubiquitously expressed throughout 
the majority of tissues in the developing embryo. The involvement of USP22 in developmental 
processes in vivo was demonstrated by the growth retardation in Usp22-hypomorphic mice. 
Moreover, differentiation and lineage specification in murine tissues are dependent on the 
presence of USP22. Finally, microarray analysis using MEFs underlined the relevance of 
USP22 during development and proliferation and confirmed our in vivo results. The most 
striking finding of this study was that USP22, in contrast to previously published reports, can 
also act as a tumor suppressor. When analyzing expression profiles of CRC patients using 
publically available databases, we could demonstrate that USP22 expression during colorectal 
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carcinogenesis is not as ‘black and white’ as described in the literature. Indeed, almost half of 
CRC patients displayed decreased USP22 expression or even heterozygous deletions. 
Interestingly, our in vivo approaches suggest inflammation-promoting effects of Usp22 
ablation. In fact, inflammation intensity upon Usp22 ablation was severe enough to induce 
colitis-induced bone fragility. Intriguingly, simultaneous loss of APC and USP22 resulted in 
decreased survival and increased intestinal tumor burden in sporadic and inflammation-
induced CRC. Moreover, APC1638N/+, Usp22-/- mice even developed invasive carcinomas. 
Therefore, USP22 should not be exclusively considered as an oncogene since it can clearly 
function as a tumor suppressor, at least in some contexts. Importantly, the generation and 
application of USP22 inhibitors could display a high risk for CRC patients characterized by 
increased or normal USP22 expression since they could increase tumor burden by artificially 
causing decreased USP22 activity. In addition, these inhibitors could induce chronic 
inflammation. Instead, it would be a safe alternative to exploit USP22-deficiency in CRC cells 
by targeting HSP90AB1, a novel USP22 interaction partner identified in this project. The 
application of the HSP90 inhibitor Ganetespib as well as the epigenetic drug JQ1 induced 
synthetic lethality in CRC cells with low USP22 levels. In future experiments, the interaction of 
USP22 and HSP90AB1 should be studied in detail and the efficacy of Ganetespib and JQ1 
tested in vivo. Taken together, in the current study we were able to demonstrate that USP22 is 
crucial for cell differentiation processes and has an unexpected tumor suppressor function in 
colorectal cancer. 
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